<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74062</article-id><article-id pub-id-type="doi">10.7554/eLife.74062</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group><subj-group subj-group-type="heading"><subject>Physics of Living Systems</subject></subj-group></article-categories><title-group><article-title>Fast bacterial growth reduces antibiotic accumulation and efficacy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-170047"><name><surname>Łapińska</surname><given-names>Urszula</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3593-9248</contrib-id><email>U.Lapinska@exeter.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-168797"><name><surname>Voliotis</surname><given-names>Margaritis</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6488-7198</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256580"><name><surname>Lee</surname><given-names>Ka Kiu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256581"><name><surname>Campey</surname><given-names>Adrian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256582"><name><surname>Stone</surname><given-names>M Rhia L</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270354"><name><surname>Tuck</surname><given-names>Brandon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256583"><name><surname>Phetsang</surname><given-names>Wanida</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-256584"><name><surname>Zhang</surname><given-names>Bing</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107746"><name><surname>Tsaneva-Atanasova</surname><given-names>Krasimira</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6294-7051</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-256585"><name><surname>Blaskovich</surname><given-names>Mark AT</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-168802"><name><surname>Pagliara</surname><given-names>Stefano</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9796-1956</contrib-id><email>s.pagliara@exeter.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Living Systems Institute, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Biosciences, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Department of Mathematics, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rqy9422</institution-id><institution>Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland</institution></institution-wrap><addr-line><named-content content-type="city">Brisbane</named-content></addr-line><country>Australia</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vt9qd57</institution-id><institution>Department of Chemistry and Chemical Biology, Rutgers, the State University of New Jersey</institution></institution-wrap><addr-line><named-content content-type="city">Piscataway</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>EPSRC Hub for Quantitative Modelling in Healthcare, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01x8hew03</institution-id><institution>Department of Bioinformatics and Mathematical Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Sofia</named-content></addr-line><country>Bulgaria</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cooper</surname><given-names>Vaughn S</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>University of Pittsburgh</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Storz</surname><given-names>Gisela</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04byxyr05</institution-id><institution>National Institute of Child Health and Human Development</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>07</day><month>06</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e74062</elocation-id><history><date date-type="received" iso-8601-date="2021-09-20"><day>20</day><month>09</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-05-08"><day>08</day><month>05</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-10-19"><day>19</day><month>10</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.10.18.464851"/></event></pub-history><permissions><copyright-statement>© 2022, Łapińska et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Łapińska et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74062-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74062-figures-v1.pdf"/><abstract><p>Phenotypic variations between individual microbial cells play a key role in the resistance of microbial pathogens to pharmacotherapies. Nevertheless, little is known about cell individuality in antibiotic accumulation. Here, we hypothesise that phenotypic diversification can be driven by fundamental cell-to-cell differences in drug transport rates. To test this hypothesis, we employed microfluidics-based single-cell microscopy, libraries of fluorescent antibiotic probes and mathematical modelling. This approach allowed us to rapidly identify phenotypic variants that avoid antibiotic accumulation within populations of <italic>Escherichia coli</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Burkholderia cenocepacia,</italic> and <italic>Staphylococcus aureus</italic>. Crucially, we found that fast growing phenotypic variants avoid macrolide accumulation and survive treatment without genetic mutations. These findings are in contrast with the current consensus that cellular dormancy and slow metabolism underlie bacterial survival to antibiotics. Our results also show that fast growing variants display significantly higher expression of ribosomal promoters before drug treatment compared to slow growing variants. Drug-free active ribosomes facilitate essential cellular processes in these fast-growing variants, including efflux that can reduce macrolide accumulation. We used this new knowledge to eradicate variants that displayed low antibiotic accumulation through the chemical manipulation of their outer membrane inspiring new avenues to overcome current antibiotic treatment failures.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Bacteria can cause an array of diseases ranging from mildly inconvenient to deadly. In fact, every year around the world, five million people succumb to a bacterial infection. Antibiotics can kill bacteria or stop their growth, but many bacterial species are now able to evade these drugs.</p><p>To be efficient, most antibiotics first need to get inside a bacterium; there, they accumulate until they reach the concentration they need to act. Often, the drugs make their way through channel-like structures (‘pores’) studded through the external membranes of bacteria and which control the passage of molecules in and out of cells.</p><p>Resistance usually emerges when genetic changes provide the microorganism with an advantage against antibiotics, or when the microorganism performs the biochemical reactions necessary for life at a slower pace.</p><p>In contrast, Łapińska, Pagliara et al. decided to examine how genetically similar <italic>Escherichia coli</italic> bacteria which differed in their growth rate would fare against antibiotics. The drug targeted ribosomes, the machinery that produces proteins in a cell. A combination of techniques was used to follow individual cells, revealing that fast-growing variants better managed to survive. A closer look showed that bacteria which were growing quickly had a surplus of ribosomes, which then produced more pores that could pump the antibiotic out the cell. Next, Łapińska, Pagliara et al. exposed the bacteria to both the antibiotic and a compound that weakens bacterial membrane; this erased the advantage shown by the fast-growing variants. Overall, this work gives a finer understanding of the mechanisms that underlie antibiotic resistance, which could help pave the way to new strategies to combat harmful bacteria.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>membrane transport</kwd><kwd>antibiotics</kwd><kwd>single-cell analysis</kwd><kwd>antibiotic resistance</kwd><kwd>phenotypic heterogeneity</kwd><kwd>antibiotic uptake</kwd><kwd>efflux</kwd><kwd>microfluidics</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>Escherichia coli</italic></kwd><kwd>Pseudomonas aeruginosa</kwd><kwd>Staphylococcus aureus</kwd><kwd>Burkholderia cenocepacia</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/V008021/1</award-id><principal-award-recipient><name><surname>Łapińska</surname><given-names>Urszula</given-names></name><name><surname>Pagliara</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MCPC17189</award-id><principal-award-recipient><name><surname>Łapińska</surname><given-names>Urszula</given-names></name><name><surname>Pagliara</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000936</institution-id><institution>Gordon and Betty Moore Foundation</institution></institution-wrap></funding-source><award-id>GBMF5514</award-id><principal-award-recipient><name><surname>Pagliara</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000266</institution-id><institution>Engineering and Physical Sciences Research Council</institution></institution-wrap></funding-source><award-id>EP/T017856/1</award-id><principal-award-recipient><name><surname>Voliotis</surname><given-names>Margaritis</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>Krasimira</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000266</institution-id><institution>Engineering and Physical Sciences Research Council</institution></institution-wrap></funding-source><award-id>EP/M506527/1</award-id><principal-award-recipient><name><surname>Campey</surname><given-names>Adrian</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>WT1104797/Z/14/Z</award-id><principal-award-recipient><name><surname>AT Blaskovich</surname><given-names>Mark</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000288</institution-id><institution>Royal Society</institution></institution-wrap></funding-source><award-id>RG180007</award-id><principal-award-recipient><name><surname>Pagliara</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>H2020 Marie Skłodowska-Curie Actions</institution></institution-wrap></funding-source><award-id>H2020-MSCA-ITN-2015-675752</award-id><principal-award-recipient><name><surname>Pagliara</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Phenotypic variants that avoid antibiotic accumulation within clonal bacterial populations are a significant contributor to antibiotic treatment failure and can rely on previously unrecognised survival strategies such as fast growth during drug treatment.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Phenotypic heterogeneity between genetically identical cells has been observed across all three domains of life (<xref ref-type="bibr" rid="bib79">Richards et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Ackermann, 2015</xref>). This heterogeneity is characterised by individual cells that display differing phenotypic traits (<xref ref-type="bibr" rid="bib36">Golding et al., 2005</xref>; <xref ref-type="bibr" rid="bib56">Lidstrom and Konopka, 2010</xref>) and permit genotypes to persist in fluctuating environments (<xref ref-type="bibr" rid="bib1">Ackermann, 2015</xref>). Phenotypic heterogeneity in the bacterial response to antibiotics contributes to antimicrobial resistance (<xref ref-type="bibr" rid="bib110">Windels et al., 2019b</xref>; <xref ref-type="bibr" rid="bib54">Levin-Reisman et al., 2019</xref>; <xref ref-type="bibr" rid="bib16">Brauner et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Bamford et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Goode et al., 2021a</xref>; <xref ref-type="bibr" rid="bib40">Goormaghtigh and Van Melderen, 2019</xref>; <xref ref-type="bibr" rid="bib39">Goode et al., 2021b</xref>) and the failure to effectively treat bacterial infections (<xref ref-type="bibr" rid="bib60">Mulcahy et al., 2010</xref>; <xref ref-type="bibr" rid="bib44">Helaine et al., 2014</xref>; <xref ref-type="bibr" rid="bib89">Stapels et al., 2018</xref>). Therefore, it is imperative to develop new diagnostics capable of rapidly identifying phenotypic variants that survive antibiotic treatment (<xref ref-type="bibr" rid="bib9">Baltekin et al., 2017</xref>) and develop new antibiotic therapies against such phenotypic variants (<xref ref-type="bibr" rid="bib83">Shatalin et al., 2021</xref>).</p><p>Here we hypothesise that this phenotypic diversification is driven by fundamental cell-to-cell differences in membrane transport mechanisms and their underpinning regulatory networks. In order for an antibiotic to be effective, it needs to reach its cellular target at a concentration that is inhibitory for micro-organism growth (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>). In gram-negative bacteria, intracellular antibiotic accumulation (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>; <xref ref-type="bibr" rid="bib101">Van Bambeke et al., 2006</xref>; <xref ref-type="bibr" rid="bib86">Six et al., 2018</xref>) is a complex biophysical phenomenon involving different physicochemical pathways and a combination of exquisitely regulated active and passive transport processes (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>; <xref ref-type="bibr" rid="bib113">Zgurskaya et al., 2018</xref>). These processes include diffusion through the outer membrane lipid bilayer (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>) and porins (<xref ref-type="bibr" rid="bib67">Pagès et al., 2008</xref>; <xref ref-type="bibr" rid="bib62">Nestorovich et al., 2002</xref>); self-promoted uptake through the outer membrane (<xref ref-type="bibr" rid="bib32">Farmer et al., 1992</xref>); diffusion through the inner membrane lipid bilayer which displays orthogonal selection properties compared to the outer membrane (<xref ref-type="bibr" rid="bib85">Silver, 2016</xref>; <xref ref-type="bibr" rid="bib18">Cama et al., 2019</xref>); active transport via inner membrane transporters (<xref ref-type="bibr" rid="bib85">Silver, 2016</xref>); efflux out of the cell (<xref ref-type="bibr" rid="bib30">Du et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">Blair et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Blair et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Fitzpatrick et al., 2017</xref>); enzymatic modification or degradation (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>); and eventually binding to the intracellular target.</p><p>Learning the rules that permit antibiotics to accumulate in gram-negative bacteria is vitally important in order to combat phenotypic and genotypic resistance to antibiotics (<xref ref-type="bibr" rid="bib85">Silver, 2016</xref>; <xref ref-type="bibr" rid="bib2">Acosta-Gutiérrez et al., 2018</xref>; <xref ref-type="bibr" rid="bib97">Tommasi et al., 2015</xref>). However, most permeability data are sequestered in proprietary databases (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>). Moreover, such experimental datasets have often been generated via cell-free methods that permit the measurement of the diffusion rate of a compound through simplified membrane pathways (<xref ref-type="bibr" rid="bib28">Delcour, 2013</xref>), but care should be taken when projecting these data to the more complex accumulation dynamics in live cells (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>). Live or fixed cell methodologies including radiometric, fluorometric or biochemical assays (<xref ref-type="bibr" rid="bib49">Kojima and Nikaido, 2013</xref>; <xref ref-type="bibr" rid="bib74">Piddock et al., 1999</xref>; <xref ref-type="bibr" rid="bib3">Asuquo and Piddock, 1993</xref>), mass spectrometry (<xref ref-type="bibr" rid="bib114">Zhou et al., 2015</xref>; <xref ref-type="bibr" rid="bib80">Richter et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Davis et al., 2014</xref>; <xref ref-type="bibr" rid="bib76">Prochnow et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Brochado et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Iyer et al., 2018</xref>; <xref ref-type="bibr" rid="bib96">Tian et al., 2017</xref>), Raman spectroscopy (<xref ref-type="bibr" rid="bib43">Heidari-Torkabadi et al., 2015</xref>), microspectroscopy (<xref ref-type="bibr" rid="bib104">Vergalli et al., 2018</xref>; <xref ref-type="bibr" rid="bib103">Vergalli et al., 2017</xref>; <xref ref-type="bibr" rid="bib105">Vergalli et al., 2020</xref>), and fluorescence microscopy (<xref ref-type="bibr" rid="bib78">Reuter et al., 2020</xref>) have also been employed to carry out antibiotic accumulation assays. These techniques generally rely on ensemble measurements that average the results obtained from a large population of micro-organisms, or are derived from examining only a handful of individual bacteria. Therefore, little is known about the variability in individual drug accumulation across many single cells within a clonal population.</p><p>Here, we fill this fundamental gap in our knowledge by harnessing the power of microfluidics-microscopy (<xref ref-type="bibr" rid="bib51">Łapińska et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Cama et al., 2020</xref>) combined with fluorescent antibiotic-derived probes (<xref ref-type="bibr" rid="bib91">Stone et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Lin et al., 2021</xref>; <xref ref-type="bibr" rid="bib15">Blaskovich et al., 2019</xref>) as well as unlabelled antibiotics. This approach allows us to examine the interactions between the major classes of antibiotics and hundreds of live individual bacteria in real-time whilst they are being dosed with the drugs. Combined with mathematical modelling these data allow us to rapidly identify phenotypic variants that avoid antibiotic accumulation and are able to sustain growth in the presence of drugs without acquiring genetic mutations. We show that bacteria close to the antibiotic source accumulate faster membrane-targeting antibiotics but more slowly antibiotics with intracellular targets compared to bacteria further away from the antibiotic source. In contrast with the current consensus that slow cell growth leads to reduced antibiotic efficacy, we discover that fast growing phenotypic variants avoid macrolide accumulation due to a higher abundance of both ribosomes (i.e. the drug target) and efflux pumps. We further demonstrate that chemically manipulating the bacterial outer membrane permits us to eradicate variants that display low antibiotic accumulation. Adopting our novel approach in clinical settings to inform the design of improved drug therapies could aid refining our one health approach to antimicrobial resistance.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Experimental assessment of single-cell real-time drug accumulation dynamics</title><p>We combined our recently developed single-cell microfluidics-microscopy platform (<xref ref-type="bibr" rid="bib51">Łapińska et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Cama et al., 2020</xref>; <xref ref-type="bibr" rid="bib93">Stone et al., 2020</xref>) with a library of fluorescent derivatives representing most major classes of antibiotics, including macrolides (roxithromycin) (<xref ref-type="bibr" rid="bib93">Stone et al., 2020</xref>), oxazolidinones (linezolid) (<xref ref-type="bibr" rid="bib72">Phetsang et al., 2014</xref>), glycopeptides (vancomycin) (<xref ref-type="bibr" rid="bib15">Blaskovich et al., 2019</xref>), fluoroquinolones (ciprofloxacin) (<xref ref-type="bibr" rid="bib92">Stone et al., 2019</xref>), antifolates (trimethoprim) (<xref ref-type="bibr" rid="bib73">Phetsang et al., 2016</xref>), and membrane-targeting lipopeptides/peptides (polymyxin B, octapeptin, and tachyplesin) (<xref ref-type="bibr" rid="bib15">Blaskovich et al., 2019</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Phenotypic heterogeneity in the accumulation of the major classes of antibiotics.</title><p>(<bold>A</bold>) Illustration depicting the eight antibiotics employed in this study alongside their bacterial targets. (<bold>B</bold>) Accumulation of the fluorescent derivative of roxithromycin in 265 individual <italic>E. coli</italic> (continuous lines) after adding the probe at 46 µg mL<sup>–1</sup> extracellular concentration in M9 minimal medium from t=0 onwards. Fluorescence values were background subtracted and normalised first by cell size and then to the maximum value in the dataset (see Methods). The circles and shaded areas represent the mean and SD of the values from 265 bacteria collated from biological triplicate. The squares represent the fluorescent values of a representative bacterium that does not accumulate the fluorescent derivative of roxithromycin, whereas the triangles represent the fluorescent values of a representative bacterium that accumulates the drug. Insets: representative brightfield and fluorescence images after 7000 s incubation in the fluorescent derivative of roxithromycin, the symbols indicate the two representative bacteria above. Scale bar: 5 µm. (<bold>C</bold>) Population average (symbols) and SD (shaded areas) of the accumulation of the fluorescent derivatives of polymyxin B (triangles), trimethoprim (stars), roxithromycin (circles), and vancomycin (squares) probes added at 46 µg mL<sup>–1</sup> extracellular concentration in M9 minimal medium from t=0 onwards. Data are obtained by averaging at least one hundred single-cell values (i.e. N=103, 175, 265, and 236, respectively) collated from biological triplicate. Corresponding single-cell data along with data for the fluorescent derivatives of linezolid, tachyplesin, octapeptin, and ciprofloxacin probes are reported in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Measurements of single-cell drug accumulation, size, elongation rate and doubling time in E. coli, S. aureus, P. aeruginosa and B. cenocepacia.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74062-fig1-data1-v1.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Measurement of single-cell elongation rates.</title><p>Average elongation rate during growth in lysogeny broth (LB) after injection of <italic>E. coli</italic> in the mother machine at t=0. The data are the mean and standard error of the mean calculated over measurements performed on 30 individual bacteria collated from biological triplicate.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Measurement of single-cell drug accumulation.</title><p>Accumulation of the fluorescent derivatives of (<bold>A</bold>) polymyxin B, (<bold>B</bold>) octapeptin, (<bold>C</bold>) tachyplesin, (<bold>D</bold>) linezolid, (<bold>E</bold>) ciprofloxacin, (<bold>F</bold>) trimethoprim, (<bold>G</bold>) roxithromycin, and (<bold>H</bold>) vancomycin in 103, 104, 128, 115, 122, 175, 265, and 236 individual <italic>E. coli</italic>, respectively (continuous lines), after adding each probe at 46 µg mL<sup>–1</sup> extracellular concentration in M9 minimal medium from t=0 onwards. Data were collated from biological triplicate. Fluorescence values were background subtracted and normalised by cell size (see Methods). The symbols and shaded areas represent the mean and SD of the corresponding single-cell values. Insets: representative fluorescence images showing the accumulation of each probe at the specified time point. Scale bar: 5 µm. The vertical dotted lines represent the time point at which the median of each dataset became larger than zero. The median remained zero throughout the entire experiments carried out with vancomycin-NBD, hence the dotted line has been arbitrarily set at 11,500 s in (<bold>H</bold>) for comparison purposes only.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Measurement of normalised single-cell drug accumulation.</title><p>Normalised accumulation of the fluorescent derivatives of (<bold>A</bold>) polymyxin B, (<bold>B</bold>) octapeptin, (<bold>C</bold>) tachyplesin, (<bold>D</bold>) linezolid, (<bold>E</bold>) ciprofloxacin, (<bold>F</bold>) trimethoprim, (<bold>G</bold>) roxithromycin, and (<bold>H</bold>) vancomycin. These data are reproduced from <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> after normalising all fluorescent values to the maximum fluorescence value in each dataset.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Heterogeneity in the accumulation of different antibiotics.</title><p>Population averages (symbols) and SDs (shaded areas) of the accumulation of the fluorescent derivatives of tachyplesin (triangles), octapeptin (crosses), linezolid (hexagons), and ciprofloxacin (diamonds) added at 46 µg mL<sup>–1</sup> extracellular concentration in M9 minimal medium from t=0 onwards. Data were obtained by averaging N=128, 104, 115, and 122 single-cell values, respectively, collated from biological triplicate presented in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Measurement of single-cell doubling times.</title><p>Distribution of single cell doubling times during treatment with roxithromycin dissolved in (<bold>A</bold>) miminal medium M9 and (<bold>B</bold>) lysogeny broth (LB) as a drug milieu against the parental and (<bold>C</bold>) a Δ<italic>tolC</italic> knockout strain. The fluorescent derivative of roxithromycin was delivered at an extracellular concentration of 46 µg mL<sup>–1</sup> at t=0 to N=40, 38, and 46 individual bacteria, respectively. The average doubling time was (75±28), (29±9), and (80±30) min, respectively. The distributions of doubling times in (<bold>A</bold>) and (<bold>C</bold>) were not statistically different (<italic>p</italic>-value =0.51), whereas the distributions in (<bold>A</bold>) and (<bold>B</bold>) were statistically different (****). None of the bacteria reported in (<bold>A</bold>) and (<bold>C</bold>) underwent a full cell cycle from birth to division during treatment, since all the bacteria that divided during treatment were born before treatment started. 65% of the bacteria reported in (<bold>B</bold>) underwent a full cell cycle.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp5-v1.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title>Interdependence between cell size and drug accumulation.</title><p>Absence of correlation between the area of each single bacterium before antibiotic treatment and the kinetic parameters (<bold>A</bold>) <italic>t<sub>0</sub></italic>, (<bold>B</bold>) <italic>k<sub>1</sub></italic> and (<bold>C</bold>) <italic>F<sub>max</sub></italic> describing the onset, uptake rate and level of saturation of the fluorescent derivative of roxithromycin in N=104 <italic>E. coli</italic> after adding the probe at 192 µg mL<sup>–1</sup> extracellular concentration in M9 minimal medium from t=0 onwards. Data were collated from biological triplicate. We also found no correlation between cell area and the three kinetic accumulation parameters above for the other seven antibiotic probes investigated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp6-v1.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 7.</label><caption><title>Staining of bacteria with different antibiotics.</title><p>Temporal dependence of the fraction of <italic>E. coli</italic> stained by fluorescent derivatives of polymyxin B (downwards triangles), tachyplesin (upwards triangles), octapeptin (crosses), linezolid (hexagons), trimethoprim (stars), ciprofloxacin (diamonds), roxithromycin (circles), or vancomycin (squares). The stained fraction at each time point is defined as the ratio of the number of bacteria displaying a fluorescence distinguishable from the background over the total number of bacteria at that time point. Symbols and error bars are the mean and standard error of the mean values calculated by averaging the N=103, 128, 104, 115, 175, 122, 265, and 236 individual bacteria, respectively, from biological triplicate presented in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp7-v1.tif"/></fig><fig id="fig1s8" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 8.</label><caption><title>Comparison of single-cell roxithromycin accumulation in <italic>E. coli</italic> and <italic>S. aureus</italic>.</title><p>Accumulation of the fluorescent derivative of roxithromycin in (<bold>A</bold>) N=265 individual <italic>E. coli</italic> and (<bold>B</bold>) N=195 individual <italic>S. aureus</italic> (continuous lines), after adding the probe at 46 µg mL<sup>–1</sup> extracellular concentration in M9 minimal medium from t=0 onwards. Data were collated from biological triplicate. Fluorescence values were background subtracted and normalised by cell size. The symbols and shaded areas are the mean and SD of the corresponding single-cell values. The measured minimum inhibitory concentration (MIC) of roxithromycin-NBD against <italic>E. coli</italic> and <italic>S. aureus</italic> was 192 and 1 µg mL<sup>–1</sup>, respectively. Insets: representative fluorescence images showing the accumulation of the fluorescent derivative of roxithromycin 3600 s post addition to the bacteria hosting channels. Scale bar: 5 µm. The vertical dotted lines represent the time points at which the median of each dataset became larger than zero.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp8-v1.tif"/></fig><fig id="fig1s9" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 9.</label><caption><title>Comparison of single-cell vancomycin accumulation in <italic>E. coli</italic> and <italic>S. aureus</italic>.</title><p>Accumulation of the fluorescent derivative of vancomycin in (<bold>A</bold>) N=236 individual <italic>E. coli</italic> and (<bold>B</bold>) N=63 individual <italic>S. aureus</italic> (continuous lines) cells, after adding the probe at 46 µg mL<sup>–1</sup> extracellular concentration in M9 minimal medium from t=0 onwards. Data were collated from biological triplicate. Fluorescence values were background subtracted and normalised by cell size. The symbols and shaded areas are the mean and SD of the corresponding single-cell values. The measured minimum inhibitory concentration (MIC) of vancomycin-NBD against <italic>E. coli</italic> and <italic>S. aureus</italic> was &gt;192 and 0.5 µg mL<sup>–1</sup>, respectively. I Insets: representative fluorescence images showing the accumulation of the fluorescent derivative of roxithromycin 1800 s post addition to the bacteria hosting channels. Scale bar: 5 µm. The vertical dotted lines represent the time points at which the median of each dataset became larger than zero.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp9-v1.tif"/></fig><fig id="fig1s10" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 10.</label><caption><title>Comparison of single-cell ciprofloxacin accumulation in <italic>E. coli</italic>, <italic>P. aeruginosa,</italic> and <italic>B. cenocepacia</italic>.</title><p>Accumulation of the fluorescent derivative of ciprofloxacin in (<bold>A</bold>) N=122 individual <italic>E. coli</italic>, (<bold>B</bold>) N=84 individual <italic>P. aeruginosa</italic> and (<bold>C</bold>) N=86 individual <italic>B. cenocepacia</italic> (continuous lines) cells, after adding the probe at 46 µg mL<sup>–1</sup> extracellular concentration in M9 minimal medium from t=0 onwards. Data were collated from biological triplicate. Fluorescence values were background subtracted and normalised by cell size. The symbols and shaded areas are the mean and SD of the corresponding single-cell values. The measured minimum inhibitory concentration (MIC) of ciprofloxacin-NBD against <italic>E. coli</italic>, <italic>P. aeruginosa,</italic> and <italic>S. aureus</italic> was 8, 32, and 32 µg mL<sup>–1</sup>, respectively. The vertical dotted lines represent the time points at which the median of each dataset became larger than zero. As expected ciprofloxacin-NBD accumulated to a significantly lower extent in <italic>P. aeruginosa</italic> since it lacks general porins, thus displaying a lower permeability compared to <italic>E. coli</italic> and <italic>B. cenocepacia</italic> (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp10-v1.tif"/></fig><fig id="fig1s11" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 11.</label><caption><title>Impact of drug milieu and concentration on drug accumulation.</title><p>(<bold>A</bold>) Accumulation of the fluorescent derivative of roxithromycin in lysogeny broth (LB) (circles) or M9 medium (squares) drug milieu delivered to N=46 and 265 individual <italic>E. coli</italic>, respectively, at an extracellular concentration of 46 µg mL<sup>–1</sup>. (<bold>B</bold>) Accumulation of the fluorescent derivative of roxithromycin delivered at a concentration of 192 (upward triangles) and 46 (squares) µg mL<sup>–1</sup> in a M9 medium drug milieu to N=110 and 265 individual <italic>E. coli</italic>, respectively. (<bold>C</bold>) Accumulation of the fluorescent derivative of polymyxin B delivered at a concentration of 46 (diamonds) and 1 (downward triangles) µg mL<sup>–1</sup> in a M9 medium drug milieu to N=101 and 97 individual <italic>E. coli</italic>, respectively. Data were collated from biological triplicate and fluorescence values were background subtracted and normalised by cell size. The symbols and shaded areas represent the mean and SD of the corresponding single-cell values.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp11-v1.tif"/></fig><fig id="fig1s12" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 12.</label><caption><title>Impact of drug labelling on drug accumulation.</title><p>(<bold>A</bold>) Accumulation of unlabelled ciprofloxacin (triangles) and of the fluorescent derivative ciprofloxacin-NBD (diamonds) delivered to N=48 and 122 individual <italic>E. coli</italic>, respectively, at an extracellular concentration of 200 and 46 µg mL<sup>–1</sup> in M9 medium, respectively. It is worth noting that unlabelled ciprofloxacin was not detectable neither extracellularly nor intracellularly at concentrations below 200 µg mL<sup>–1</sup>. (<bold>B</bold>) Accumulation of the fluorescent derivatives roxithromycin-NBD (squares) and roxithromycin-DMACA (hexagons) at an extracellular concentration of 46 µg mL<sup>–1</sup> in a M9 medium drug milieu delivered to N=265 and 77 individual <italic>E. coli</italic>, respectively. In both figures data were collated from biological triplicate and fluorescence values were background subtracted and normalised by cell size. The symbols and shaded areas are the mean and SD of the corresponding single-cell values normalised to the maximum mean fluorescence value in each dataset.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp12-v1.tif"/></fig><fig id="fig1s13" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 13.</label><caption><title>Main single-cell kinetic parameters inferred using our mathematical model.</title><p>Distributions of <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> kinetic parameters describing the accumulation of the fluorescent derivatives of polymyxin B, octapeptin, tachyplesin, linezolid, ciprofloxacin, trimethoprim, and roxithromycin (from top to bottom, respectively). These parameters were inferred by fitting the single-cell data reported in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> using our mathematical model (see Methods). Data for which the fitting algorithm returned divergent transitions were not reported and typically represented less than 1% of the data (compare N here and in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). <italic>t<sub>0</sub></italic> is the inferred accumulation onset, i.e., the time at which each bacterium fluorescence became distinguishable from background fluorescence, <italic>k<sub>1</sub></italic> is the inferred rate of uptake, <italic>F<sub>max</sub></italic> is the inferred fluorescence saturation level at steady-state. CV is the coefficient of variation of the single-cell values in each dataset.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp13-v1.tif"/></fig><fig id="fig1s14" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 14.</label><caption><title>Second order single-cell kinetic parameters inferred using our mathematical model.</title><p>Distributions of <italic>k<sub>2</sub></italic>, <italic>d<sub>r</sub></italic> and <italic>d<sub>c</sub></italic> kinetic parameters describing the accumulation of fluorescent antibiotic derivatives of polymyxin B, octapeptin, tachyplesin, linezolid, ciprofloxacin, trimethoprim, and roxithromycin (from top to bottom, respectively). These parameters were inferred by fitting the single-cell data reported in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> using our mathematical model (see Methods). Data for which the fitting algorithm returned divergent transitions were not reported and typically represented less than 1% of the data (compare N here and in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). <italic>k<sub>2</sub></italic> is the inferred adaptive inhibitory rate constant that describes the dip we observed in some single-cell trajectories in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <italic>d<sub>r</sub></italic> is the drug loss rate constant, <italic>d<sub>c</sub></italic> is the dampening rate constant. CV is the coefficient of variation of the single-cell values in each dataset. Membrane targeting antibiotic probes displayed, on average, a higher adaptive inhibitory rate constant (<italic>k<sub>2</sub></italic>=0.006, 0.007, and 0.006 a.u. s<sup>–2</sup> for tachyplesin, polymyxin B, and octapeptin, respectively) compared to antibiotics with intracellular targets (<italic>k<sub>2</sub></italic>=0.0001, 0.00005, 0.0003, and 0.0001 s for linezolid, trimethoprim, ciprofloxacin, and roxithromycin, respectively). Remarkably, we found notable cell-to-cell differences in <italic>k<sub>2</sub></italic> across all investigated drugs with a maximum CV of 251% for roxithromycin and a minimum CV of 67% for trimethoprim. Membrane targeting antibiotic probes also displayed, on average, a higher drug loss rate constant (<italic>d<sub>r</sub></italic> =0.09, 0.09, and 0.03 s<sup>–1</sup> for tachyplesin, polymyxin B, and octapeptin, respectively) compared to antibiotics with intracellular targets (<italic>d<sub>r</sub></italic> =0.0003, 0.001, 0.0005, and 0.001 s for linezolid, trimethoprim, ciprofloxacin, and roxithromycin, respectively). Remarkably, we found notable cell-to-cell differences in <italic>d<sub>r</sub></italic> across all investigated drugs with a maximum CV of 208% for roxithromycin and a minimum CV of 44% for trimethoprim. Membrane targeting antibiotic probes also displayed, on average, a higher dampening rate constant (<italic>d<sub>c</sub></italic> =0.009, 0.01, and 0.009 s<sup>–1</sup> for tachyplesin, polymyxin B, and octapeptin, respectively) compared to antibiotics with intracellular targets (<italic>d<sub>c</sub></italic> =0.0006, 0.0005, 0.002, and 0.0003 s for linezolid, trimethoprim, ciprofloxacin, and roxithromycin, respectively). Remarkably, we found notable cell-to-cell differences in <italic>d<sub>c</sub></italic> across all investigated drugs with a maximum CV of 187% for tachyplesin and a minimum CV of 28% for linezolid.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp14-v1.tif"/></fig><fig id="fig1s15" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 15.</label><caption><title>Coupling between accumulation parameters.</title><p>Correlation between (<bold>A</bold>) <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic>, (<bold>B</bold>) <italic>t<sub>0</sub></italic> and <italic>F<sub>max</sub></italic>, (<bold>C</bold>) <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> describing the accumulation of the fluorescent derivatives of polymyxin B (downward triangles), tachyplesin (upward triangles), octapeptin (crosses), linezolid (hexagons), trimethoprim (stars), ciprofloxacin (diamonds), or roxithromycin (circles) in N=103, 106, 88, 178, 175, 122, and 265 individual <italic>E. coli</italic>, respectively. Each data point represents the values of two kinetic parameters inferred for an individual bacterium from the data in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> using our mathematical model. Statistical classification of the accumulation of (<bold>D</bold>) membrane-targeting antibiotics (i.e. polymyxin B, tachyplesin, and octapeptin) vs intracellular-targeting antibiotics (i.e. linezolid, trimethoprim, ciprofloxacin, and roxithromycin), (<bold>E</bold>) polymyxin B, (<bold>F</bold>) tachyplesin, or (<bold>G</bold>) octapeptin vs the remaining membrane-targeting antibiotics, (<bold>H</bold>) linezolid, (<bold>I</bold>) trimethoprim, (<bold>J</bold>) ciprofloxacin, or (<bold>K</bold>) roxithromycin vs remaining antibiotics with an intracellular target. These confusion tables are predictions generated using only the two kinetic parameters that can be rapidly measured experimentally, namely <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic>. Similar statistical classifications were obtained when using the full set of kinetic parameters, i.e., <italic>k<sub>2</sub></italic>, <italic>d<sub>r</sub></italic>, and <italic>d<sub>c</sub></italic> in addition to <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig1-figsupp15-v1.tif"/></fig></fig-group><p>Each antibiotic was functionalised at a site that minimises any changes in biological activity, adding a substituent that allows for facile coupling with a small fluorophore, nitrobenzoxadiazole (NBD, <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) as previously reported (<xref ref-type="bibr" rid="bib15">Blaskovich et al., 2019</xref>; <xref ref-type="bibr" rid="bib93">Stone et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Phetsang et al., 2014</xref>; <xref ref-type="bibr" rid="bib92">Stone et al., 2019</xref>; <xref ref-type="bibr" rid="bib73">Phetsang et al., 2016</xref>). Using minimum inhibitory concentration (MIC) assays we found that the fluorescent derivatives of polymyxin B, octapeptin, tachyplesin, vancomycin, and linezolid maintained the antibiotic activity of the parent drug against <italic>E. coli</italic>, whereas the fluorescent derivatives of roxithromycin, trimethoprim, and ciprofloxacin displayed a 3-fold, 64-fold, and 256-fold increase compared to the parent drug, respectively (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). Next we used each probe in our microfluidics-microscopy platform (<xref ref-type="bibr" rid="bib51">Łapińska et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Cama et al., 2020</xref>; <xref ref-type="bibr" rid="bib93">Stone et al., 2020</xref>; <xref ref-type="bibr" rid="bib35">Glover et al., 2022</xref>) to quantify the dynamics of the accumulation of each antibiotic in individual bacteria in real-time (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Briefly, we loaded an aliquot of a stationary phase clonal bacterial culture in a microfluidic device equipped with small parallel channels, each hosting between one and six bacteria (<xref ref-type="bibr" rid="bib51">Łapińska et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Cama et al., 2020</xref>; <xref ref-type="bibr" rid="bib93">Stone et al., 2020</xref>). Then we continuously flowed lysogeny broth (LB) medium into xthe device for 2 hr to stimulate cell growth and reproduction. During this period bacteria displayed an average elongation rate of (5.3±1.2) µm hr<sup>–1</sup>. We also performed separate experiments flowing LB for a longer period of time and found that the elongation rate (averaged across the bacterial population) did not further increase after the first 2 hr exposure to LB (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), corroborating previous bulk data showing that <italic>E. coli</italic> is in exponential phase between 2 and 5 hr after passage in fresh medium (<xref ref-type="bibr" rid="bib87">Smith et al., 2018</xref>). Therefore after 2 hr incubation in LB, we injected one of the antibiotic probes and imaged the real-time intracellular probe accumulation in hundreds of individual live bacteria (<xref ref-type="video" rid="app1video1 app1video2">Appendix 1—Videos 1 and 2</xref>). Typically, upon onset drug accumulation increased until reaching steady-state saturation levels (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) due to probe efflux, compound transformation (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>), or target saturation (<xref ref-type="bibr" rid="bib85">Silver, 2016</xref>), although several bacteria displayed divergent accumulation dynamics (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplements 2</xref> and <xref ref-type="fig" rid="fig1s3">3</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p></sec><sec id="s2-2"><title>Heterogeneity in antibiotic accumulation in gram-negative and gram-positive bacteria</title><p>These single-cell measurements revealed hitherto unrecognised phenotypic heterogeneity in intracellular drug accumulation in clonal populations of <italic>E. coli</italic> as evident from the microscopy images in <xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>. In contrast, standard techniques measure population averages of drug accumulation across thousands or millions of cells (<xref ref-type="bibr" rid="bib86">Six et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Kojima and Nikaido, 2013</xref>; <xref ref-type="bibr" rid="bib3">Asuquo and Piddock, 1993</xref>; <xref ref-type="bibr" rid="bib114">Zhou et al., 2015</xref>; <xref ref-type="bibr" rid="bib80">Richter et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Davis et al., 2014</xref>; <xref ref-type="bibr" rid="bib76">Prochnow et al., 2019</xref>; <xref ref-type="bibr" rid="bib96">Tian et al., 2017</xref>). In our single-cell assay, population averages (circles in <xref ref-type="fig" rid="fig1">Figure 1B</xref>) did not reflect the fact that some phenotypic variants displayed a remarkably delayed onset, slower uptake rate or reduced saturation with respect to other cells (e.g. compare the accumulation trajectories reported by the squares - no accumulation - vs triangles - high accumulation - in <xref ref-type="fig" rid="fig1">Figure 1B</xref>). These phenotypic variants have thus far remained unrecognised in population-based experiments and give rise to large coefficients of variation (CV, the ratio of the SD over the mean) in the accumulation of each of the eight investigated antibiotics (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). In the following, we will, therefore, use CV as a reporter for phenotypic heterogeneity within bacterial populations as previously reported (<xref ref-type="bibr" rid="bib84">Silander et al., 2012</xref>).</p><p>It is worth noting that all bacteria within each experiment were exposed to the same concentration of probe (46 µg mL<sup>–1</sup>) for the same duration and to the same drug milieu, i.e., minimal medium M9 to avoid dilution of probes due to cell growth (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>). As a consequence, during drug treatment bacterial divisions were rare events. For example, during treatment with roxithromycin dissolved in M9, none of the analysed bacteria underwent a full cell cycle from birth to division. Moreover, 15% of the bacteria analysed underwent one division during treatment but were born before drug treatment commenced with an average doubling time of (75±28) min (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). In comparison, during treatment with roxithromycin dissolved in LB, 41% of the analysed bacteria underwent a full cell cycle from birth to division. Furthermore, when including bacteria that underwent one division during treatment but were born before drug treatment, the average doubling time (29±9 min) was significantly shorter compared to that measured for treatment in M9 (****, <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). Moreover, in accordance with previous studies about phenotypic responses to antimicrobials (<xref ref-type="bibr" rid="bib109">Windels et al., 2019a</xref>; <xref ref-type="bibr" rid="bib77">Pu et al., 2016</xref>; <xref ref-type="bibr" rid="bib4">Attrill et al., 2021</xref>), we found that bacterial variants displaying delayed or reduced antibiotic accumulation were genuine phenotypic variants, since DNA sequencing of the device outflow did not reveal any genetic mutations compared to untreated bacteria. Furthermore, these variants did not display significant differences in cell size (<xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>) and we further normalised each single-cell fluorescence value to the corresponding single-cell size (see Methods) (<xref ref-type="bibr" rid="bib95">Taniguchi et al., 2010</xref>).</p><p>Due to the presence of these phenotypic variants, not all the bacteria were stained by each antibiotic probe, thus we found drug-dependent dynamics in the fraction of stained bacteria (<xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7</xref>). The lipopeptide/peptide probes targeting the outer bacterial membrane (polymyxin B, octapeptin, and tachyplesin) stained 90% of the investigated bacteria within 1000 s post-addition to the microfluidic device. At this time, the trimethoprim and ciprofloxacin probes targeting intracellular components had stained only 50% of the bacteria, whereas the number of bacteria stained by roxithromycin and vancomycin probes, with a large molecular weight (1064 and 1650 g mol<sup>–1</sup>, respectively), was close to zero. However, the roxithromycin probe did stain 50 and 90% of the bacteria around 7500 s and 9000 s, respectively, post-addition to the device, by which time only 15% of the bacteria had been stained by vancomycin. The lack of vancomycin staining was expected since vancomycin cannot cross the gram-negative double membrane to access its peptidoglycan target (<xref ref-type="bibr" rid="bib61">Murray, 1995</xref>).</p><p>Next, we verified that this hitherto unrecognised heterogeneity in antibiotic accumulation is not a phenotypic feature exclusive to <italic>E. coli</italic>. When we compared and contrasted roxithromycin-NBD accumulation in <italic>E. coli</italic> against uptake in the gram-positive bacterium <italic>S. aureus</italic>, we found that although the latter displayed more rapid accumulation dynamics (<xref ref-type="fig" rid="fig1s8">Figure 1—figure supplement 8</xref> and ; <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), also <italic>S. aureus</italic> displayed phenotypic variants with delayed or reduced accumulation. In fact, roxithromycin-NBD reached saturation levels 3000 s post-addition in some <italic>S. aureus</italic> cells, whereas other bacteria accumulated the drug at very low levels and only by 5000 s post-addition (with a CV in range 53–372% and 29–73% for <italic>E. coli</italic> and <italic>S. aureus</italic>, respectively). In contrast, the gram-positive targeting vancomycin-NBD readily and homogeneously accumulated in <italic>S. aureus</italic> within 2500 s post-addition (CV in range 12–14%), but did not accumulate in <italic>E. coli</italic> (within this same timeframe, <xref ref-type="fig" rid="fig1s9">Figure 1—figure supplement 9</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Finally, we found phenotypic variants with delayed or reduced accumulation of ciprofloxacin-NBD in three clinically-relevant gram-negative bacteria: <italic>E. coli</italic>, <italic>P. aeruginosa,</italic> and <italic>B. cenocepacia</italic> (CV in range 12–329%, 24–534%, and 31–90%, <xref ref-type="fig" rid="fig1s10">Figure 1—figure supplement 10</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Furthermore, ciprofloxacin-NBD accumulated more slowly and to a lower extent in <italic>P. aeruginosa</italic> compared to <italic>E. coli</italic> and <italic>B. cenocepacia</italic> (<xref ref-type="fig" rid="fig1s10">Figure 1—figure supplement 10</xref>) in accordance with previous measurements at the whole population level (<xref ref-type="bibr" rid="bib3">Asuquo and Piddock, 1993</xref>) and possibly due to the high porin impermeability in <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="bib98">Ude et al., 2021</xref>).</p><p>In order to verify that dilution of the intracellular concentration via bacterial doubling did not play a key role in the observed heterogeneity in antibiotic accumulation, we run separate controls using <italic>E. coli</italic> and roxithromycin-NBD dissolved either in M9 or LB. We found higher roxithromycin-NBD accumulation (<xref ref-type="fig" rid="fig1s11">Figure 1—figure supplement 11</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>) as well as shorter doubling times (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>) when LB was used as drug milieu. We also found similarly large heterogeneity when roxithromycin-NBD was dissolved in M9 or LB (CV in range of 84–372% and 51–428%, respectively). These data demonstrate that heterogeneity in roxithromycin accumulation cannot be explained via dilution due to bacterial doubling. Finally, in order to verify that neither the drug concentration nor the labelling underpin the observed heterogeneity in antibiotic accumulation, we run separate controls using <italic>E. coli</italic> and different concentrations of roxithromycin-NBD and polymyxin B-NBD (<xref ref-type="fig" rid="fig1s11">Figure 1—figure supplement 11</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>), as well as unlabelled ciprofloxacin, ciprofloxacin-NBD, roxithromycin-NBD, and roxithromycin-DMACA (dimethylaminocoumarin-4-acetate, <xref ref-type="fig" rid="fig1s12">Figure 1—figure supplement 12</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). When using the same excitation conditions used for our fluorescent derivatives (0.03 s exposure to the blue excitation band of a broad-spectrum LED operated at 8 mW, see Methods), unlabelled ciprofloxacin autofluorescence detected from the bacteria was not distinguishable from the background (i.e. from empty channels). However, unlabelled ciprofloxacin was distinguishable from the background upon 0.1 s exposure to the UV excitation band of a broad-spectrum LED operated at 40 mW. In all cases we identified phenotypic variants with delayed or reduced antibiotic accumulation, leading to large CVs as shown in <xref ref-type="fig" rid="fig1s11">Figure 1—figure supplements 11</xref> and <xref ref-type="fig" rid="fig1s12">12</xref>. We can also exclude possible effects of variations in magnesium availability (<xref ref-type="bibr" rid="bib32">Farmer et al., 1992</xref>; <xref ref-type="bibr" rid="bib70">Peterson et al., 1987</xref>) on the measured heterogeneity in antibiotic accumulation since all bacteria were exposed to the same medium within the microfluidic device.</p></sec><sec id="s2-3"><title>Single-cell coupling between kinetic accumulation parameters</title><p>Prompted by these novel findings, we moved on to an in-depth examination of antibiotic accumulation dynamics and the underlying cellular and molecular mechanisms. First, we developed and implemented a mathematical model to capture the phenomenology of drug accumulation in our experiments, for example in terms of the measured lag in drug uptake and the time-varying uptake rate, without making assumptions regarding underlying biological mechanisms (e.g. positive feedback). Briefly, this model describes drug accumulation based on two coupled ordinary differential equations. The first equation describes drug accumulation in terms of uptake, which proceeds at a time-varying rate, and drug loss (due to efflux or degradation or dilution via growth [<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>]), which we assume to be a first order reaction with rate constant <italic>d<sub>c</sub></italic>. The second equation describes how the drug uptake rate changes over time to take into account that the experimentally measured drug uptake is not always constant. Here we assume a state of uptake (parameter <italic>k<sub>1</sub>,</italic> which switches on with a time delay; parameter <italic>t<sub>0</sub></italic>); a linear decay term (parameter <italic>d<sub>r</sub></italic>); as well as an adaptive inhibitory effect (parameter <italic>k<sub>2</sub></italic>) of the intracellular drug concentration on the uptake rate (allowing us to capture the dip we observe in some single-cell trajectories in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). We used this model to fit our single-cell <italic>E. coli</italic> data on the accumulation of all the above investigated drugs apart from vancomycin. This allowed us to compare and contrast the accumulation kinetic parameters above for the different antibiotics, since we used the same probe concentration for each drug (46 µg mL<sup>–1</sup>) and all drugs were tested against the same clonal <italic>E. coli</italic> population. For vancomycin we found poor fitting for the majority of cells (195 out of 241 cells), as the fluorescent signal remained indistinguishable from the background, due to low cellular uptake (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2H</xref>).</p><p>Membrane targeting antibiotic probes displayed on average faster accumulation onset (<italic>t<sub>0</sub></italic>=306, 364, and 571 s for tachyplesin, polymyxin B, and octapeptin, respectively) compared to antibiotics with an intracellular target (<italic>t<sub>0</sub></italic>=437, 2525, 3608, and 6,614 s for linezolid, trimethoprim, ciprofloxacin, and roxithromycin, respectively, <xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Remarkably, we found notable cell-to-cell differences in <italic>t<sub>0</sub></italic> across all investigated drugs with a maximum CV of 209% for polymyxin B, and a minimum CV of 25% for roxithromycin (<xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref>), further confirming the presence of phenotypic variants with delayed antibiotic accumulation. It is also worth noting that linezolid displayed an accumulation onset value closer to the one recorded for antibiotics with a membrane target compared to the one measured for antibiotics with an intracellular target. However, when considering the other five accumulation parameters linezolid displayed values in line with those measured for antibiotics with an intracellular target (see below).</p><p>Membrane targeting antibiotic probes also displayed, on average, steeper rates of uptake (<italic>k<sub>1</sub></italic>=260, 229, and 93 a.u. s<sup>–2</sup> for tachyplesin, polymyxin B, and octapeptin, respectively) compared to antibiotics with an intracellular target (<italic>k<sub>1</sub></italic>=4.4, 1.6, 0.9, and 0.3 a.u. s<sup>–2</sup> for roxithromycin, linezolid, ciprofloxacin, and trimethoprim, respectively, <xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Also, <italic>k<sub>1</sub></italic> was heterogeneous across all drugs investigated with a maximum CV of 124% for roxithromycin and a minimum CV of 37% for trimethoprim (<xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref>), further confirming the presence of phenotypic variants with slow antibiotic uptake.</p><p>Membrane targeting antibiotic probes also displayed, on average, higher steady-state saturation levels (<italic>F<sub>max</sub></italic> =2,597, 2,357, and 2,264 a.u. for tachyplesin, octapeptin, and polymyxin B, respectively) compared to antibiotics with an intracellular target (<italic>F<sub>max</sub></italic> =1,034, 512, 253, and 180 a.u. for roxithromycin, linezolid, trimethoprim, and ciprofloxacin, respectively, <xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). <italic>F<sub>max</sub></italic> was also heterogeneous with a maximum CV of 55% for roxithromycin and a minimum CV of 9% for octapeptin (<xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref>) further confirming the presence of phenotypic variants with reduced antibiotic accumulation. For brevity, the second order kinetic parameters <italic>k<sub>2</sub></italic>, <italic>d<sub>r</sub></italic>, and <italic>d<sub>c</sub></italic> are reported and discussed only in <xref ref-type="fig" rid="fig1s14">Figure 1—figure supplement 14</xref> and in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p><p>The finding that accumulation of membrane targeting probes happens earlier, faster and to a greater extent than probes with an intracellular target can be easily rationalised considering that the latter probes need to cross the gram-negative double membrane. This represents a very good validation of our combined experimental and theoretical approach. However, the large heterogeneity in the kinetic parameters describing the accumulation of all probes, due to phenotypic variants with delayed or reduced accumulation, was instead unexpected. Additionally, the finding that roxithromycin simultaneously displayed the most delayed accumulation onset but also the steepest rate of uptake and highest steady-state saturation levels, across antibiotic probes with intracellular targets, was also unexpected. These data corroborate the hypothesis that multiple mechanisms must be involved in intracellular antibiotic accumulation at the level of the individual cell (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>), a point which we expand on below.</p><p>Next, we used the inferred accumulation kinetic parameters to test the hypothesis that phenotypic variants within a clonal population specialise to reduce antibiotic accumulation. When we pooled together the data for all the antibiotics tested against <italic>E. coli</italic>, we found a strong negative correlation between <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic> and <italic>t<sub>0</sub></italic> and <italic>F<sub>max</sub></italic>, but a strong positive correlation between <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> (<xref ref-type="fig" rid="fig1s15">Figure 1—figure supplement 15A-C</xref>, Pearson coefficients <italic>r</italic>=–0.40,–0.27, and 0.65, respectively, p&lt;0.0001). The negative correlations between <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic> and <italic>t<sub>0</sub></italic> and <italic>F<sub>max</sub></italic> across the bacterial population were not due to negative correlations for each individual cell. In fact, we found that for 86 and 79% of cells across all antibiotic treatments there was a positive correlation between <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic> and between <italic>t<sub>0</sub></italic> and <italic>F<sub>max</sub></italic>. In contrast, at the population level we found a significantly negative correlation between <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic> for the accumulation of polymyxin B, octapeptin, and roxithromycin probes and a significantly negative correlation between <italic>t<sub>0</sub></italic> and <italic>F<sub>max</sub></italic> for the accumulation of polymyxin B, octapeptin, linezolid, and trimethoprim probes. Finally, we found a significantly positive correlation between <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> for the accumulation of polymyxin B, ciprofloxacin, and roxithromycin probes (<xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). The latter correlation was partially imposed by the definition of <italic>F<sub>max</sub></italic> in the model. In fact, we found that 78% of the cells displayed a positive correlation between these two parameters at the single-cell level. These strong correlations show that the bacteria, which start accumulating drugs later also display, slow uptake and low saturation levels. This statistical analysis also reveals that it is possible to rapidly identify phenotypic variants displaying reduced antibiotic accumulation by inferring the whole set of kinetic parameters from a smaller subset (e.g. by inferring <italic>F<sub>max</sub></italic> from <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic>, the latter two can be measured significantly faster).</p><p>Furthermore, we also used our mathematical framework to test the hypothesis that treatment with each antibiotic gives rise to a unique accumulation profile. Using statistical classification with only two kinetic parameters (<italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic>, i.e. the two parameters that can be rapidly measured experimentally), we found that treatment with membrane targeting probes is correctly classified against treatment with intracellular targeting probes with 99% accuracy (1075 cells analysed, <xref ref-type="fig" rid="fig1s15">Figure 1—figure supplement 15D</xref>). Moreover, treatment with polymyxin B, tachyplesin, or octapeptin was correctly classified among treatments with the other two membrane targeting probes with 77, 76, and 64%, respectively (<xref ref-type="fig" rid="fig1s15">Figure 1—figure supplement 15E-G</xref>). Finally, treatment with linezolid, trimethoprim, ciprofloxacin, or roxithromycin was correctly classified among treatments with the other three intracellular targeting probes with 97, 84, 64, and 86% accuracy, respectively (<xref ref-type="fig" rid="fig1s15">Figure 1—figure supplement 15H-K</xref>). It is worth noting that we obtained similar levels of accuracy when we run such statistical classifications using the full set of kinetic accumulation parameters (i.e. <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic>, <italic>k<sub>2</sub></italic>, <italic>d<sub>r</sub></italic>, and <italic>d<sub>c</sub></italic>), further demonstrating that measuring only <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic> provides a good description of the antibiotic accumulation process.</p><p>Taken together, these data suggest the existence of a unique accumulation pattern for the specific antibiotic in use and could be employed in combination with existing single-cell microfluidic platforms to rapidly phenotype drug sensitivity (<xref ref-type="bibr" rid="bib9">Baltekin et al., 2017</xref>; <xref ref-type="bibr" rid="bib5">Bakshi et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Bergmiller et al., 2017</xref>), ultimately in clinical antibiotic testing.</p></sec><sec id="s2-4"><title>Phenotypic variants with reduced antibiotic accumulation survive antibiotic treatment</title><p>Next, we hypothesised that phenotypic variants displaying reduced antibiotic accumulation also better survive antibiotic treatment, the correlation between antibiotic uptake and efficacy remaining poorly investigated (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>). We decided to focus on the macrolide roxithromycin since a large number of phenotypic variants displayed reduced roxithromycin accumulation (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). When we measured the elongation rate of individual cells while they were being dosed with roxithromycin-NBD dissolved in LB, we found two distinct cellular responses. While the majority of cells stopped growing during drug exposure, some phenotypic variants within the same clonal <italic>E. coli</italic> population continued elongating for the entire duration of drug treatment (see representative trajectories in <xref ref-type="fig" rid="fig2">Figure 2A and B</xref> and in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Correlation between antibiotic efficacy and antibiotic accumulation.</title><p>Temporal patterns of elongation rate during exposure to the fluorescent derivative of roxithromycin for (<bold>A</bold>) five representative <italic>E. coli</italic> bacteria that accumulated the drug and (<bold>B</bold>) five representative <italic>E. coli</italic> bacteria that did not accumulate the drug. The fluorescent derivative of roxithromycin was delivered at t=0 at a concentration of 46 µg mL<sup>–1</sup> and was dissolved in lysogeny broth (LB), circles and arrows indicate <italic>t<sub>0</sub></italic>, the time point at which each bacterium started to accumulate the drug (i.e. bacterial fluorescence signal became distinguishable from the background). (<bold>C</bold>) Correlation between each bacterium <italic>t<sub>0</sub></italic> and its average elongation rate throughout exposure to the fluorescent derivative of roxithromycin (i.e. 0&lt;t&lt; 8100 s). r is the Pearson coefficient quantifying the correlation above, ***: p-value&lt;0.001, N=52 bacteria. (<bold>D</bold>) Average elongation rates for bacteria that had not yet started (before uptake) or had started (after uptake) accumulating the fluorescent derivative of roxithromycin, as well as for bacteria that did not accumulate the drug (no uptake). The red dashed and blue dotted lines within each violin plot represent the median and quartiles of each data set, respectively. Paired <italic>t</italic>-test between elongation rates before and after onset in accumulation: ****: p-value&lt;0.0001, N=36 pairs. Unpaired <italic>t</italic>-test between the elongation rates of bacteria that did not take up the drug compared to the elongation rate of bacteria that had not yet started taking up the drug: not significant, p-value=0.07, N=13 and 36 bacteria, respectively. Unpaired <italic>t</italic>-test between the elongation rates of bacteria that did not take up the drug compared to the elongation rate of bacteria that had started taking up the drug: ****: p-value&lt;0.0001, N=13 and 36 bacteria, respectively.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Single-cell elongation rates during roxithromycin treatment.</title><p>Temporal patterns of elongation rate during exposure to the fluorescent derivative of roxithromycin for five representative <italic>E. coli</italic> bacteria that accumulated the drug and five representative <italic>E. coli</italic> bacteria that did not accumulate the drug. The fluorescent derivative of roxithromycin was delivered at t=0 at a concentration of 46 µg mL<sup>–1</sup> and was dissolved in lysogeny broth (LB).</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig2-data1-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Correlation between drug accumulation and efficacy.</title><p>Correlation between each bacterium <italic>t<sub>0</sub></italic> and its average elongation rate throughout exposure to the fluorescent derivative of roxithromycin.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig2-data2-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Average elongation rates for bacteria that had not yet started ccumulating the fluorescent derivative of roxithromycin.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig2-data3-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><caption><title>Average elongation rates for bacteria that had started accumulating the fluorescent derivative of roxithromycin.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig2-data4-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig2sdata5"><label>Figure 2—source data 5.</label><caption><title>Average elongation rates for bacteria that did not accumulate the fluorescent derivative of roxithromycin.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig2-data5-v1.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Interdependence between single-cell elongation rate before treatment and single-cell elongation rate during exposure to (<bold>A</bold>) roxithromycin-NBD and (<bold>B</bold>) unlabelled roxithromycin.</title><p>r is the Pearson correlation coefficient, *: p-value&lt;0.05, ***: p-value&lt;0.001. N=46 and 51 individual <italic>E. coli</italic> investigated and collated from biological triplicate. In each experiment <italic>E. coli</italic> was grown for 2 hr in the microfluidic device with continuous supply of fresh lysogeny broth (LB). During this 2 hr growth period the elongation rate of each bacterium was measured between consecutive time points and the average elongation rate for each bacterium was calculated. At the end of this 2 hr growth period, 46 µg mL<sup>–1</sup> roxithromycin-NBD or unlabelled roxithromycin dissolved in LB was continuously delivered for a 4 hr treatment period in the microfluidic device. During this 4 hr treatment period the elongation rate of each bacterium was measured as indicated above. The data in (A) are reproduced from <xref ref-type="fig" rid="fig2">Figures 2C</xref> and <xref ref-type="fig" rid="fig4">4A</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Furthermore, there were significant cell-to-cell differences in the time at which cells stopped growing (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Notably, this time coincided with the onset in roxithromycin-NBD accumulation (<italic>t<sub>0</sub></italic>, indicated by circles and arrows in <xref ref-type="fig" rid="fig2">Figure 2A</xref>), suggesting a link between lag in drug uptake and lag in cell growth. However, other mechanisms might contribute to lag in drug uptake including a positive feedback loop in drug binding or positive feedback between efflux and drug accumulation (<xref ref-type="bibr" rid="bib52">Le et al., 2021</xref>). Phenotypic variants that continued growing instead did not accumulate roxithromycin-NBD for the entire duration of the treatment (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). When we formally analysed the entire dataset, we found a strong positive correlation between the onset of roxithromycin-NBD accumulation and the average elongation rate during exposure to roxithromycin-NBD (<italic>r</italic>=0.49, ***, <xref ref-type="fig" rid="fig2">Figure 2C</xref>, and <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). Moreover, bacteria that accumulated roxithromycin-NBD displayed a drastically reduced elongation rate after roxithromycin-NBD accumulation started compared to their elongation rate before uptake (**** paired <italic>t</italic>-test, <xref ref-type="fig" rid="fig2">Figure 2D</xref>, and <xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>). Phenotypic variants that did not accumulate roxithromycin-NBD instead displayed an elongation rate that was not significantly different compared to the elongation rate of bacteria that had not yet started taking up roxithromycin-NBD (ns unpaired <italic>t</italic>-test, <xref ref-type="fig" rid="fig2">Figure 2D</xref>). Finally, phenotypic variants that did not accumulate roxithromycin-NBD displayed an elongation rate that was significantly higher compared to the elongation rate of bacteria that had started taking up roxithromycin-NBD (**** unpaired <italic>t</italic>-test, <xref ref-type="fig" rid="fig2">Figure 2D</xref>). Moreover, we also found a significantly positive correlation between single-cell elongation rate before treatment and single-cell elongation rate during treatment (<italic>r</italic>=0.34, *, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), although, as expected, the average elongation rate significantly decreased after roxithromycin-NBD addition (5.2±2.9 µm h<sup>–1</sup> vs 3.7±2.3 µm h<sup>–1</sup>, before and after drug addition, respectively, ****, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, and <xref ref-type="supplementary-material" rid="fig2sdata4">Figure 2—source data 4</xref>). Finally, to further verify that these findings were not due to drug labelling, we performed these experiments with unlabelled roxithromycin. We found that the drug autofluorescence detected from the bacteria was not distinguishable from the background (i.e. the fluorescence detected from channels that did not contain bacteria). We confirmed a significantly positive correlation between single-cell elongation rate before treatment and single-cell elongation rate during treatment (<italic>r</italic>=0.47, ***, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref> and <xref ref-type="supplementary-material" rid="fig2sdata5">Figure 2—source data 5</xref>, a point on which we expand below). We also found large single cell growth variability in the presence of labelled and unlabelled roxithromycin (CV of 59 and 44%, respectively).</p><p>Taken together these data demonstrate that cell-to-cell differences in drug accumulation are strongly linked with heterogeneity in antibiotic efficacy, prompting us to investigate the mechanisms underlying phenotypic variants with delayed or reduced antibiotic accumulation.</p></sec><sec id="s2-5"><title>The microcolony architecture affects heterogeneity in antibiotic accumulation</title><p>First, we tested the hypothesis that these phenotypic variants reduced antibiotic accumulation because of the presence of other bacteria (i.e. screening cells) between them and the main microfluidic chamber, where the drug is injected. To test this hypothesis, we classified our data in subpopulations of bacteria that had 0, 1, 2, 3, or 4 screening cells between themselves and the main microfluidic chamber (see Inset in <xref ref-type="fig" rid="fig3">Figure 3E</xref> where the drug diffuses from left to right).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Effect of the presence of screening cells on the accumulation of antibiotics in single cells.</title><p>Dependence of the kinetic parameters <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic>, and <italic>F<sub>max</sub></italic> for the accumulation of fluorescent derivatives of polymyxin B (<bold>A–C</bold>) and roxithromycin (<bold>D–F</bold>) on the number of screening cells between the bacterium under investigation and the main microfluidic chamber where the drug is continuously injected. Each data point is the value of a kinetic parameter inferred for an individual bacterium from the data in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> using our mathematical model, N=103 and 265 for polymyxin B and roxithromycin, respectively. The red dashed and blue dotted lines within each violin plot represent the median and quartiles of each data set, respectively. r is the Pearson coefficient quantifying the correlation between each inferred kinetic parameter and the number of screening cells in front of each bacterium. ns: not significant correlation, *: p-value&lt;0.05, **: p-value&lt;0.01, ***: p-value&lt;0.001, ****: p-value&lt;0.0001. Inset: representative brightfield and fluorescence images illustrating, from left to right, a bacterium screened by 0, 1, 2, 3, and 4 cells, respectively; roxithromycin-NBD was injected in the main microfluidic chamber in the left-hand side of the image and diffused from left to right. The fluorescence image shows early roxithromycin-NBD accumulation in the bacterium screened by the highest number of cells.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Impact of microcolony architecture on drug accumulation.</title><p>Dependence of the kinetic parameters <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic>, and <italic>F<sub>max</sub></italic> for the accumulation of fluorescent derivatives of polymyxin B and roxithromycin on the number of screening cells between the bacterium under investigation and the main microfluidic chamber where the drug is continuously injected.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig3-data1-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Simulations of antibiotic diffusion and absorption.</title><p>Antibiotic concentrations at the bacterial surface for bacteria with 0, 1, 2, 3 or 4 screening cells between themselves and the open end of the channel with an absorption rate of 0.2 mol m<sup>–2</sup> s<sup>–1</sup> or 0.002 mol m<sup>–2</sup> s<sup>–1</sup>.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig3-data2-v1.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Simulations of antibiotic diffusion and absorption.</title><p>Numerical simulations of antibiotic diffusion in microfluidic channels hosting a single file of five bacteria with an absorption rate of (<bold>A</bold>) 0.2 mol m<sup>–2</sup> s<sup>–1</sup> or (<bold>B</bold>) 0.002 mol m<sup>–2</sup> s<sup>–1</sup>. Antibiotic was added at t=0 and the extracellular antibiotic concentration at the open end of the channel (at the bottom of maps) was kept constant at 7×10<sup>4</sup> mol m<sup>–3</sup>. (<bold>C</bold>) and (<bold>D</bold>) corresponding antibiotic concentrations at the bacterial surface for bacteria with 0, 1, 2, 3 or 4 screening cells between themselves and the open end of the channel (black circles, blue squares, red triangles, green diamonds, and magenta hexagons, respectively).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig3-figsupp1-v1.tif"/></fig></fig-group><p>For polymyxin B we observed that increasing the number of screening cells increased <italic>t<sub>0</sub></italic> while reducing <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> (Pearson correlation coefficient <italic>r</italic>=0.50,–0.48, and –0.40,****, **** and ***, respectively, <xref ref-type="fig" rid="fig3">Figure 3A–C</xref> and <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>). Moreover, octapeptin and tachyplesin displayed strong negative correlation between <italic>k<sub>1</sub></italic> and the number of screening cells (<italic>r</italic>=–0.63 and –0.67, respectively, ****); octapeptin also displayed a strong positive correlation between <italic>t<sub>0</sub></italic> and the number of screens (<italic>r</italic>=0.71, ****). These data were in accordance with our hypothesis that screening cells transiently decrease the pool of drug molecules available for screened cells until the bacteria closer to the main chamber reach antibiotic accumulation saturation levels. These data could explain the large heterogeneity in <italic>t<sub>0</sub></italic> measured for such membrane-targeting probes (<xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref>). In contrast with our hypothesis, for roxithromycin we found that increasing the number of screens in front of a cell reduced <italic>t<sub>0</sub></italic> and increased <italic>F<sub>max</sub></italic> (<italic>r</italic>=–0.16 and 0.15, **, and *, respectively, <xref ref-type="fig" rid="fig3">Figure 3D–F</xref> and <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>). Moreover, both ciprofloxacin and linezolid displayed a strong negative correlation between <italic>t<sub>0</sub></italic> and the number of screens (<italic>r</italic>=–0.53 and –0.28, **** and ***, respectively); ciprofloxacin also displayed a strong positive correlation between <italic>k<sub>1</sub></italic> and the number of screens (<italic>r</italic>=0.32, ***).</p><p>Delayed accumulation of membrane targeting drugs in bacteria screened by other cells could be explained by a transient reduction in the extracellular drug concentration around these bacteria (compared to the concentration in the main microfluidic chamber) due to rapid drug binding to the membranes of screening cells. In accordance with this hypothesis, when we run 2D numerical simulations of drug diffusion in channels hosting bacteria with a high drug absorption rate (<italic>γ</italic>=0.2 mol m<sup>–2</sup> s<sup>–1</sup>, see Methods), we found a gradient in extracellular drug concentration along the channel length: for the first 90 min post drug addition, the concentration was highest around the bacterium without screens and lowest around the bacterium with four screens (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). On the contrary, in the presence of bacteria with a low absorption rate (<italic>γ</italic>=0.002 mol m<sup>–2</sup> s<sup>–1</sup>), the extracellular drug concentration equilibrated along the channel length within 2 min post drug addition to the device (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Accordingly, in the presence of bacteria with high absorption rate, the intracellular drug concentration (that we simply modelled as concentration at the bacterial surface) reached saturation levels in the bacterium without screens within minutes post drug addition, whereas the bacterium with 4 screens reached saturation levels 90 min post drug addition (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref> and <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>). Conversely, bacteria with low absorption rate accumulated the drug independently on the number of screens (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). Therefore, according to these simplified 2D transport simulations (i.e. we do not take into account neither efflux nor transport across the gram-negative double barrier), delayed accumulation of membrane targeting drugs in bacteria screened by other cells is due to a transient reduction in the extracellular drug concentration around these bacteria, whereas other mechanisms must underpin increased roxithromycin accumulation in screened bacteria and this phenomenon should be investigated further in future studies. It is worth noting that these findings were not dictated by oxygen limitation or low metabolic activity as in the case of biofilms (<xref ref-type="bibr" rid="bib106">Walters III et al., 2003</xref>). In fact, we (<xref ref-type="bibr" rid="bib51">Łapińska et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Glover et al., 2022</xref>) and others (<xref ref-type="bibr" rid="bib107">Wang et al., 2010</xref>) have previously demonstrated that nutrients, including oxygen and metabolites, uniformly distribute across the whole length of bacteria hosting channels in our microfluidic device.</p><p>It is also worth noting that mechanisms other than the microcolony architecture must underlie phenotypic variants with reduced antibiotic accumulation. In fact, we registered significant cell-to-cell differences in antibiotic accumulation even within the same subpopulation of bacteria with the same number of screening cells; these differences were more pronounced for antibiotic with intracellular targets compared to membrane targeting antibiotics (e.g. roxithromycin and polymyxin B, respectively, in <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec id="s2-6"><title>Cell-to-cell differences in growth rate before treatment contribute to heterogeneity in antibiotic accumulation</title><p>In order to further dissect the mechanisms underlying phenotypic variants with reduced antibiotic accumulation, we took advantage of continuous live-cell imaging to track individual bacteria for the 2 hr growth period in LB before incubation in each antibiotic. This permitted us to investigate links between each bacterium’s growth and its capability to avoid or delay antibiotic accumulation. We investigated the correlation between elongation rates before treatment (averaged over all the values obtained during the 2 hr growth period) and the kinetic parameters describing the accumulation of two representative membrane-targeting antibiotics, i.e., octapeptin and tachyplesin, and two representative antibiotics with intracellular targets, i.e., trimethoprim and roxithromycin.</p><p>We did not find any significant correlation between single-cell elongation rate before treatment and any of the kinetic parameters describing the accumulation of octapeptin and trimethoprim (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A-C and 1G-I</xref>, respectively, and <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>; <xref ref-type="supplementary-material" rid="fig4sdata3">Figure 4—source data 3</xref>). However, we found a positive correlation between single-cell elongation rate before treatment and <italic>k<sub>1</sub></italic> for tachyplesin (<italic>r</italic>=0.59, **, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>, and <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>), suggesting that the latter accumulated faster in fast growing cells. On the contrary, for roxithromycin, we found a significantly positive correlation between single-cell elongation rate before treatment and <italic>t<sub>0</sub></italic> and a significantly negative correlation between single-cell elongation rate before treatment and <italic>F<sub>max</sub></italic> (<italic>r</italic>=0.66 and –0.54, **** and ***, respectively, <xref ref-type="fig" rid="fig4">Figure 4A and C</xref>, and <xref ref-type="supplementary-material" rid="fig4sdata4">Figure 4—source data 4</xref>), but no correlation with cell size (<xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref>). These data suggest that roxithromycin accumulated more slowly and to a lesser extent in bacteria that were growing faster prior to antibiotic treatment. The measured variability in the elongation rate before antibiotic treatment was larger compared to that measured in previous reports (<xref ref-type="bibr" rid="bib9">Baltekin et al., 2017</xref>; <xref ref-type="bibr" rid="bib107">Wang et al., 2010</xref>). This discrepancy is due to the fact that we started to measure single-cell elongation rates immediately upon loading an aliquot of stationary phase <italic>E. coli</italic> in the mother machine. In contrast previous studies either did not measure elongation rates of the first 10 generations upon loading <italic>E. coli</italic> in the mother machine (<xref ref-type="bibr" rid="bib107">Wang et al., 2010</xref>) or precultured <italic>E. coli</italic> for 2 hr before loading in the mother machine (<xref ref-type="bibr" rid="bib9">Baltekin et al., 2017</xref>). Therefore, our measurements capture heterogeneous growth resumption from stationary phase (<xref ref-type="bibr" rid="bib53">Levin-Reisman et al., 2010</xref>; <xref ref-type="bibr" rid="bib47">Jõers and Tenson, 2016</xref>), with a minority of bacteria that did not divide in the 2 hr growth prior to antibiotic exposure (i.e. 10%, non dividing subgroup <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A-C</xref>), a few bacteria that divided once (i.e. 30%, slow dividing subgroup, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D-F</xref>), and the majority of bacteria that divided two times (i.e. 60%, fast dividing subgroup, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2G-I</xref>). Elongation rates within bacteria that divided once fell within 1.5 and 5 µm h<sup>–1</sup>, whereas elongation rates within bacteria that divided two times fell within 4 and 12 µm h<sup>–1</sup>, with a within subgroup variation of 3–4 folds in line with previous reports (<xref ref-type="bibr" rid="bib9">Baltekin et al., 2017</xref>; <xref ref-type="bibr" rid="bib107">Wang et al., 2010</xref>). Importantly, cells within both the slow and fast dividing subgroups displayed a significant correlation between elongation rates before treatment and <italic>t<sub>0</sub></italic> or <italic>F<sub>max</sub></italic> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Differential cell growth and expression of key molecular pathways prior antibiotic treatment contributes to heterogeneity in roxithromycin accumulation.</title><p>(<bold>A–C</bold>) Correlation between the single-cell kinetic parameters <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> describing the accumulation of roxithromycin-NBD and the bacterial elongation rate during the 2 hr growth period preceding antibiotic treatment (see Methods). Measurements were carried out on N=50 individual <italic>E. coli</italic>, collated from biological triplicate, before and after exposure to 192 µg mL<sup>–1</sup> roxithromycin-NBD dissolved in M9. (<bold>D–F</bold>) Correlation between single-cell green fluorescent protein (GFP) fluorescence, as a proxy for the expression of <italic>tolC</italic>, <italic>ompC,</italic> and <italic>rrnB</italic> promoters, and single-cell kinetic parameters <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> describing the accumulation of roxithromycin-DMACA (at an extracellular concentration of 192 µg mL<sup>–1</sup>). r is the Pearson coefficient quantifying the correlation between each inferred kinetic parameter and the corresponding elongation rate of each cell. ns: not significant correlation, **: p-value&lt;0.01, ***: p-value&lt;0.001, ****: p-value&lt;0.0001. Dashed lines are linear regressions to the data. Measurements were carried out on N=34, 30, and 33 individual <italic>E. coli</italic> collated from biological triplicate for the <italic>tolC</italic>, <italic>ompC,</italic> and <italic>rrnB</italic> reporter strains, respectively.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Correlation between octapeptin accumulation and cell growth state.</title><p>Interdependence between single-cell elongation rate before treatment and the onset <italic>t<sub>0</sub></italic>, the rate <italic>k<sub>1</sub></italic>, and the saturation <italic>F<sub>max</sub></italic> in the accumulation of the fluorescent derivative of octapeptin.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig4-data1-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Correlation between tachyplesin accumulation and cell growth state.</title><p>Interdependence between single-cell elongation rate before treatment and the onset <italic>t<sub>0</sub></italic>, the rate <italic>k<sub>1</sub></italic>, and the saturation <italic>F<sub>max</sub></italic> in the accumulation of the fluorescent derivative of tachyplesin.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig4-data2-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Correlation between trimethoprim accumulation and cell growth state.</title><p>Interdependence between single-cell elongation rate before treatment and the onset <italic>t<sub>0</sub></italic>, the rate <italic>k<sub>1</sub></italic>, and the saturation <italic>F<sub>max</sub></italic> in the accumulation of the fluorescent derivative of trimethoprim.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig4-data3-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>Correlation between roxithromycin accumulation and cell growth state.</title><p>Interdependence between single-cell elongation rate before treatment and the onset <italic>t<sub>0</sub></italic>, the rate <italic>k<sub>1</sub></italic>, and the saturation <italic>F<sub>max</sub></italic> in the accumulation of the fluorescent derivative of roxithromycin.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig4-data4-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Correlation between the expression of <italic>tolC</italic> and roxithromycin accumulation.</title><p>Correlation between single-cell GFP fluorescence, as a proxy for the expression of <italic>tolC</italic> promoter and the single-cell kinetic parameter <italic>t<sub>0</sub></italic> describing the onset in the accumulation of roxithromycin-DMACA (at an extracellular concentration of 192 µg mL<sup>–1</sup>).</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig4-data5-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>Correlation between the expression of <italic>ompC</italic> and roxithromycin accumulation.</title><p>Correlation between single-cell GFP fluorescence, as a proxy for the expression of <italic>ompC</italic> promoter and the single-cell kinetic parameter <italic>k<sub>1</sub></italic> describing the rate of uptake in the accumulation of roxithromycin-DMACA (at an extracellular concentration of 192 µg mL<sup>–1</sup>).</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig4-data6-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata7"><label>Figure 4—source data 7.</label><caption><title>Correlation between the expression of <italic>rrnB</italic> and roxithromycin accumulation.</title><p>Correlation between single-cell GFP fluorescence, as a proxy for the expression of <italic>rrnB</italic> promoter and the single-cell kinetic parameter <italic>F<sub>max</sub></italic> describing the saturation level in the accumulation of roxithromycin-DMACA (at an extracellular concentration of 192 µg mL<sup>–1</sup>).</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig4-data7-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig4sdata8"><label>Figure 4—source data 8.</label><caption><title>Correlation between the expression of <italic>rrnH</italic> and roxithromycin accumulation.</title><p>Correlation between single-cell GFP fluorescence, as a proxy for the expression of <italic>rrnH</italic> promoter, and the single-cell kinetic parameter <italic>F<sub>max</sub></italic> describing the saturation level in the accumulation of roxithromycin-DMACA (at an extracellular concentration of 192 µg mL–1).</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig4-data8-v1.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Correlation between drug accumulation and cell growth state.</title><p>Interdependence between single-cell elongation rate before treatment and the onset <italic>t<sub>0</sub></italic>, the rate <italic>k<sub>1</sub></italic>, and the saturation <italic>F<sub>max</sub></italic> in the accumulation of fluorescent derivatives of (<bold>A–C</bold>) octapeptin, (<bold>D–F</bold>) tachyplesin, and (<bold>G–I</bold>) trimethoprim, respectively. r is the Pearson correlation coefficient, **: p-value&lt;0.01, ns: not significant, p-value&gt;0.05. N=28, 27, and 61 individual <italic>E. coli</italic> investigated for the accumulation of the fluorescent derivatives of octapeptin, tachyplesin, and trimethoprim, respectively, and collated from biological triplicate. In each experiment <italic>E. coli</italic> were grown for 2 hr in the microfluidic device with continuous supply of fresh lysogeny broth (LB). During this 2 hr growth period the elongation rate of each bacterium was measured between consecutive time points and the average elongation rate for each bacterium was calculated. At the end of this 2 hr growth period, one of the three fluorescent antibiotic derivatives above was continuously delivered for a 4 hr treatment period in the microfluidic device at a concentration of 46 µg mL<sup>–1</sup> in M9 minimal medium. During this 4 hr treatment period single-cell fluorescence data were obtained and dynamic accumulation parameters <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> were inferred by fitting these single-cell data to our mathematical model (see Methods).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Differential cell growth contributes to heterogeneity in roxithromycin accumulation.</title><p>Correlation between the single-cell kinetic parameters <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> describing the accumulation of roxithromycin-NBD and the bacterial elongation rate during the 2 hr growth period preceding antibiotic treatment for (<bold>A–C</bold>) non-dividing bacteria, (<bold>D–F</bold>) bacteria that divided once, (<bold>G–I</bold>) bacteria that divided twice during the 2 hr growth period preceding antibiotic treatment. Data are reproduced from <xref ref-type="fig" rid="fig4">Figure 4A–C</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Distribution of single-cell elongation rates during roxithromycin treatment.</title><p>Circles are single <italic>E. coli</italic> cell elongation rates averaged over the duration of treatment with 192 µg mL<sup>–1</sup> roxithromycin-NBD dissolved in M9. Measurements were carried out on N=50 individual <italic>E. coli</italic>, collated from biological triplicate. The red line and blue dotted lines within each violin plot represent the median and quartiles of each data set, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Negative correlation between ribosomal expression and roxithromycin accumulation.</title><p>Correlation between the single-cell kinetic parameter <italic>F<sub>max</sub></italic> describing the accumulation of roxithromycin-DMACA (at an extracellular concentration of 192 µg mL<sup>–1</sup>) and the single-cell GFP fluorescence as a proxy for the expression of <italic>rrnH</italic> promoter. r is the Pearson coefficient, ****: p-value&lt;0.0001. The dashed line is a linear regression to the data. Measurements were carried out on N=35 individual <italic>E. coli</italic> collated from biological triplicate.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig4-figsupp4-v1.tif"/></fig></fig-group><p>Taken together these data suggest that phenotypic variants displaying delayed or reduced roxithromycin accumulation are bacteria that grow faster before antibiotic treatment starts. These novel findings are surprising considering that phenotypic survival to antibiotics has traditionally been linked to slow growth, low metabolic activity, and bacterial dormancy prior to antibiotic treatment (<xref ref-type="bibr" rid="bib6">Balaban et al., 2004</xref>; <xref ref-type="bibr" rid="bib7">Balaban et al., 2013</xref>; <xref ref-type="bibr" rid="bib55">Lewis, 2007</xref>). In contrast, here we show that fast growth prior to antibiotic treatment facilitates delayed roxithromycin accumulation as well as reducing the amount of macrolide accumulating in individual bacteria at steady state. It is worth noting that growth in cell volume during roxithromycin treatment might help bacteria in diluting the intracellular drug concentration. In fact, we measured a 3-fold variation in elongation rate (and thus in cell volume considering that the other two cell dimensions are physically constrained in all cells due to the device geometry), with the slowest and fastest bacterium displaying an elongation rate of 0.7 and 2.3 µm h<sup>–1</sup>, respectively, during treatment with roxithromycin at a growth inhibitory concentration (i.e. 192 µg mL<sup>–1</sup>, <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Therefore, the measured variation in roxithromycin accumulation is due in part to dilution of the intracellular drug concentration via differential cell growth. This effect is accounted for in our phenomenological mathematical model via the rate constant <italic>d<sub>c</sub></italic>, which describes drug loss through efflux, degradation or dilution via growth. Moreover, other factors must also play a role in the measured cell-to-cell differences in roxithromycin accumulation. In fact, these differences include a 160-fold variation in <italic>t<sub>0</sub></italic> (30 s&lt;<italic>t<sub>0</sub></italic>&lt; 4900 s), a 60-fold variation in <italic>k<sub>1</sub></italic> (0.2 a.u. s<sup>–2</sup> &lt;<italic>k<sub>1</sub></italic>&lt;12 a.u. s<sup>–2</sup>) and a 12-fold variation in <italic>F<sub>max</sub></italic> (250 a.u. &lt;<italic>F<sub>max</sub></italic> &lt; 3000 a.u.) far larger than the measured variation in elongation rate.</p></sec><sec id="s2-7"><title>Single-cell ribosome and efflux pump abundance contributes to heterogeneity in macrolide accumulation</title><p>In order to determine other mechanisms underpinning phenotypic variants with reduced roxithromycin accumulation, we investigated some of the key molecular pathways underlying antibiotic accumulation (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>). We hypothesised that heterogeneity in <italic>t<sub>0</sub></italic> could be linked to cell-to-cell differences in the capability to pump antibiotics out from the cell, thus delaying the onset of accumulation. <italic>tolC</italic>, which encodes the outer membrane channel of the multidrug efflux pump AcrAB-TolC and the macrolide efflux pump MacAB-TolC (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>), was the most highly expressed efflux pump related gene according to our transcriptomic data of <italic>E. coli</italic> cultures growing on LB for a period of 2 hr after dilution of an overnight culture (<xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>; <xref ref-type="bibr" rid="bib87">Smith et al., 2018</xref>). Therefore, we used a <italic>tolC</italic> transcriptional reporter strain (<xref ref-type="bibr" rid="bib10">Bamford et al., 2017</xref>) to establish a link between <italic>t<sub>0</sub></italic> and <italic>tolC</italic> expression during the 2 hr growth period before exposure to roxithromycin. In line with our hypothesis above, we found a positive correlation between the expression of <italic>tolC</italic> and <italic>t<sub>0</sub></italic> (<italic>r</italic>=0.51, **, <xref ref-type="fig" rid="fig4">Figure 4D</xref>, and <xref ref-type="supplementary-material" rid="fig4sdata5">Figure 4—source data 5</xref>).</p><p>Next, we hypothesised that heterogeneity in the rate of drug uptake <italic>k<sub>1</sub></italic> could be ascribed to cell-to-cell differences in the expression of outer membrane porins allowing antibiotic passage across the outer membrane. <italic>ompC</italic>, which encodes the outer membrane protein OmpC facilitating influx of several antibiotics (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">Nikaido, 2003</xref>), was the most highly expressed outer membrane protein encoding gene according to our transcriptomic data at the population level (<xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>, <xref ref-type="bibr" rid="bib87">Smith et al., 2018</xref>). In contrast with our hypothesis, we did not find a significant correlation between <italic>ompC</italic> expression and <italic>k<sub>1</sub></italic> (<italic>r</italic>=0.27, ns, <xref ref-type="fig" rid="fig4">Figure 4E</xref> and <xref ref-type="supplementary-material" rid="fig4sdata6">Figure 4—source data 6</xref>).</p><p>Finally, we hypothesised that saturation levels in roxithromycin accumulation could depend on the ribosomal content (i.e. the drug target) at the single-cell level. Accordingly, we found a strong negative correlation between the expression of the ribosomal promoters <italic>rrnB</italic> and <italic>rrnH</italic> [two ribosomal promoters with different level of expression (<xref ref-type="bibr" rid="bib59">Maeda et al., 2015</xref>) and routinely used as reporters for ribosomal activity (<xref ref-type="bibr" rid="bib69">Panlilio et al., 2021</xref>) and <italic>F<sub>max</sub></italic> (<italic>r</italic>=–0.75 and –0.68, ****, <xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="supplementary-material" rid="fig4sdata7">Figure 4—source data 7</xref>, <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>, and <xref ref-type="supplementary-material" rid="fig4sdata8">Figure 4—source data 8</xref>, respectively).</p><p>Taken together these data shed light on the molecular mechanisms underpinning the observed heterogeneity in the intracellular accumulation of the macrolide roxithromycin: fast growing variants reduce the intracellular accumulation of roxithromycin, and thus better survive treatment with this drug, via elevated ribosomal content and, to a lesser extent, higher expression of efflux pumps. These data suggest that reduced metabolism and dormancy might not always represent the best bacterial strategy for overcoming antibiotic challenge (<xref ref-type="bibr" rid="bib6">Balaban et al., 2004</xref>; <xref ref-type="bibr" rid="bib7">Balaban et al., 2013</xref>; <xref ref-type="bibr" rid="bib55">Lewis, 2007</xref>; <xref ref-type="bibr" rid="bib66">Otto, 2021</xref>).</p></sec><sec id="s2-8"><title>External manipulation of the heterogeneity in antibiotic accumulation</title><p>Building on the molecular understanding gained above, we then set out to establish whether phenotypic variants displaying reduced roxithromycin accumulation could be suppressed via genetic or chemical manipulation. In order to do so, we employed a <italic>ΔtolC</italic> knockout mutant and found that, when investigating roxithromycin accumulation, <italic>t<sub>0</sub></italic> was significantly lower and <italic>k<sub>1</sub></italic> was significantly higher in the <italic>ΔtolC</italic> mutant compared to the parental strain (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>, respectively, and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Genetic and chemical manipulation of heterogeneity in drug accumulation.</title><p>Distributions of single-cell values for the kinetic parameters (<bold>A</bold>) <italic>t<sub>0</sub></italic>, (<bold>B</bold>) <italic>k<sub>1</sub></italic> and (<bold>C</bold>) <italic>F<sub>max</sub></italic> describing the accumulation of the fluorescent derivative of roxithromycin (at 46 µg mL<sup>–1</sup> in M9) in the <italic>E. coli</italic> BW25113 parental strain (PS), the knockout mutant <italic>ΔtolC</italic> and the parental strain co-treated with unlabelled polymyxin B at 1 µg mL<sup>–1</sup> extracellular concentration. The red dashed and blue dotted lines within each violin plot represent the median and quartiles of each data set, respectively. ****: p-value&lt;0.0001. N=262, 241, and 116 individual parental strain <italic>E. coli</italic> treated with the roxithromycin probe, <italic>ΔtolC E. coli</italic> treated with the roxithromycin probe and parental strain <italic>E. coli</italic> co-treated with the roxithromycin probe and 1 µg mL<sup>–1</sup> unlabelled polymyxin B.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Genetic and chemical manipulation of heterogeneity in drug accumulation.</title><p>Distributions of single-cell values for the kinetic parameters <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> describing the accumulation of the fluorescent derivative of roxithromycin (at 46 µg mL<sup>–1</sup> in M9) in the <italic>E. coli</italic> BW25113 parental strain (PS), the knockout mutant <italic>ΔtolC</italic> and the parental strain co-treated with unlabelled polymyxin B at 1 µg mL<sup>–1</sup> extracellular concentration.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig5-data1-v1.csv"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Genetic manipulation of heterogeneity in drug accumulation.</title><p>Distributions of single-cell values for the kinetic parameters <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> describing the accumulation of the fluorescent derivative of roxithromycin (at 46 µg mL<sup>–1</sup> in M9) in the knockout mutant <italic>ΔompC</italic>.</p></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-74062-fig5-data2-v1.csv"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Distributions of single-cell values for the kinetic parameters (<bold>A</bold>) <italic>t<sub>0</sub></italic>, (<bold>B</bold>) <italic>k<sub>1</sub></italic> and (<bold>C</bold>) <italic>F<sub>max</sub></italic> describing the accumulation of the fluorescent derivative of roxithromycin (at 46 µg mL<sup>–1</sup> in M9) in the <italic>E. coli</italic> BW25113 parental strain and the knockout mutant <italic>ΔompC</italic>. The red dashed and blue dotted lines within each violin plot represent the median and quartiles of each data set, respectively. None of the kinetic parameters was significantly different in the knockout mutant <italic>ΔompC</italic> compared to the parental strain, p-values of 0.39, 0.69, and 0.41, respectively. N=262 and 100 individual bacteria for the parental and <italic>ΔompC</italic> strain, respectively.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74062-fig5-figsupp1-v1.tif"/></fig></fig-group><p>However, we also found <italic>ΔtolC</italic> phenotypic variants with reduced roxithromycin accumulation and even higher levels of heterogeneity in the three kinetic parameters for the <italic>ΔtolC</italic> mutant compared to the parental strain (CV of 27 vs 25%, 114 vs 80%, 72 vs 62% for <italic>t<sub>0</sub></italic>, <italic>k<sub>1</sub></italic>, and <italic>F<sub>max</sub></italic>, respectively, <xref ref-type="fig" rid="fig5">Figure 5</xref>). Furthermore, the <italic>ΔtolC</italic> knockout strain did not display a significantly longer average doubling time during roxithromycin treatment compared to the parental strain (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>). Therefore, the measured impact of the absence of <italic>tolC</italic> on roxithromycin accumulation (i.e. significantly shorter <italic>t<sub>0</sub></italic> and larger <italic>k<sub>1</sub></italic>) cannot be ascribed to dilution via cell doubling.</p><p>Next, we employed a <italic>ΔompC</italic> knockout mutant and found that roxithromycin accumulation was not significantly different compared to that measured for the parental strain (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>), thus corroborating the data above obtained using an <italic>ompC</italic> fluorescent reporter strain (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Therefore, we hypothesised that the composition and permeability of the lipid bilayer making up the bacterial outer membrane could underlie heterogeneity in roxithromycin accumulation. If this were true, the heterogeneity in roxithromycin accumulation could be chemically manipulated by using agents that permeabilise the outer membrane, such as polymyxin B (<xref ref-type="bibr" rid="bib99">Vaara, 1992</xref>). Accordingly, when we treated the parental strain with roxithromycin-NBD at 46 µg mL<sup>–1</sup> in combination with unlabelled polymyxin B at 1 µg mL<sup>–1</sup> extracellular concentration, we found a significant decrease in the heterogeneity of <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> compared to roxithromycin-NBD treatment alone (CV of 59 vs 80%, 14 vs 62%, respectively, <xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Additionally, the accumulation dynamics of roxithromycin-NBD in the presence of unlabelled polymyxin B was significantly earlier and faster compared to that measured in the absence of polymyxin B (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Taken together, these data suggest that phenotypic variants displaying reduced roxithromycin accumulation might have a significantly more impermeable outer membrane than phenotypically susceptible bacteria, possibly due to differences in lipid composition and packing and that targeting the outer membrane might be a viable avenue for suppressing variants with reduced intracellular antibiotic accumulation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Bacterial slow growth has often been associated with decreased antibiotic susceptibility (<xref ref-type="bibr" rid="bib6">Balaban et al., 2004</xref>; <xref ref-type="bibr" rid="bib8">Balaban et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Pontes and Groisman, 2020</xref>) with few exceptions (<xref ref-type="bibr" rid="bib65">Orman and Brynildsen, 2013</xref>; <xref ref-type="bibr" rid="bib71">Peyrusson et al., 2020</xref>). Moreover, a recent paper suggested that phenotypic variants accumulate lower levels of phenoxymethylpenicillin while being in a dormant state before treatment (<xref ref-type="bibr" rid="bib77">Pu et al., 2016</xref>). In contrast, our data suggest that fast growth and elevated ribosomal content better prepare phenotypic variants for avoiding the intracellular accumulation of roxithromycin, a finding that could inform the design of antibiotic therapy using macrolides.</p><p>A linear correlation between ribosomal abundance and growth rate has previously been found via ensemble measurements obtained on exponentially growing <italic>E. coli</italic> supplied with nutrients of increasing quality in the absence of antibiotics (<xref ref-type="bibr" rid="bib82">Scott et al., 2010</xref>). Our findings enrich the current understanding of the interdependence of cell growth and ribosomal content demonstrating that this correlation holds within an isogenic population homogeneously exposed to the same medium.</p><p>Previous ensemble measurements have demonstrated that fast growth on high quality nutrients decreases <italic>E. coli</italic> growth inhibition by antibiotics that irreversibly bind to ribosomes (such as roxithromycin [<xref ref-type="bibr" rid="bib29">Dinos et al., 2003</xref>]) compared to slower growth on poor quality nutrients (<xref ref-type="bibr" rid="bib41">Greulich et al., 2015</xref>). Here, we offer a mechanistic understanding of this unexpected finding, showing that reduced growth inhibition in fast growing cells is dictated by growth-dependent transport rates, as fast growing variants displayed reduced macrolide accumulation. Importantly, we demonstrated that this phenotypic response is found not only at the population-level (<xref ref-type="bibr" rid="bib41">Greulich et al., 2015</xref>), but also within an isogenic population.</p><p>These new data can be rationalised by considering that in fast growing variants a fraction of leading actively translating ribosomes (<xref ref-type="bibr" rid="bib24">Dai et al., 2016</xref>) escapes roxithromycin binding, while other ribosomes stall after accumulating roxithromycin. Drug-free active ribosomes continue to facilitate essential cellular processes including efflux that can reduce macrolide accumulation. Accordingly, we found that variants delaying roxithromycin accumulation also displayed a significantly higher expression of the efflux promoter <italic>tolC</italic> compared to bacteria that readily accumulated roxithromycin. Moreover, the deletion knockout Δ<italic>tolC</italic> displayed significantly earlier and faster accumulation of roxithromycin compared to the parental strain, confirming that roxithromycin is a substrate of the AcrAB- and MacAB-TolC efflux pumps (<xref ref-type="bibr" rid="bib85">Silver, 2016</xref>). However, this mutant exhibited accumulation heterogeneity levels comparable to the parental strain. These data suggest that phenotypic variants reduce antibiotic accumulation using processes other than efflux alone, in contrast with previous findings (<xref ref-type="bibr" rid="bib77">Pu et al., 2016</xref>), and in accordance with our data on the key role played by heterogeneity in ribosomal abundance.</p><p>Our data also revealed a strong correlation between the accumulation of roxithromycin and the effect of this antibiotic on cell growth down to the scale of the individual cell. This suggests that phenotypic variants with reduced antibiotic accumulation could be an important factor contributing to phenotypic resistance to antibiotics (<xref ref-type="bibr" rid="bib1">Ackermann, 2015</xref>; <xref ref-type="bibr" rid="bib10">Bamford et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Balaban et al., 2019</xref>; <xref ref-type="bibr" rid="bib108">Wilmaerts et al., 2019</xref>). This new knowledge deepens our understanding of phenotypic resistance to antibiotics that is currently centred around target deactivation or modification (<xref ref-type="bibr" rid="bib8">Balaban et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">Gollan et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Defraine et al., 2018</xref>) with very little known about the correlation between antibiotic accumulation and antibiotic efficacy (<xref ref-type="bibr" rid="bib81">Rybenkov et al., 2021</xref>; <xref ref-type="bibr" rid="bib77">Pu et al., 2016</xref>).</p><p>Experimental evidence suggests that both macrolides and polymyxins use the self-promoted uptake pathway. Moreover, polymyxins have a higher affinity to the lipopolysaccharides (LPS) compared to macrolides and increase the permeability of the outer membrane to other freely diffusing antibiotic molecules (<xref ref-type="bibr" rid="bib32">Farmer et al., 1992</xref>). Accordingly, we observed that OmpC, which is a major route of antibiotic influx via the hydrophilic pathway (<xref ref-type="bibr" rid="bib27">Delcour, 2009</xref>), did not play a role in roxithromycin accumulation. Our data show instead that the phenotypic variants that avoid roxithromycin accumulation can be suppressed by delivering roxithromycin in combination with polymyxin B. Moreover, roxithromycin accumulated at lower saturation levels in the presence of polymyxin B as expected due to competitive binding to the LPS.</p><p>These data suggest that heterogeneity in roxithromycin accumulation could also be due to cell-to-cell differences in LPS composition. It is conceivable that phenotypic variants within the clonal population might have a decreased ethanolamine content. This would result in an increased negative charge of the LPS core and a decreased permeability to roxithromycin but not to polymyxin B (<xref ref-type="bibr" rid="bib23">Clark, 1984</xref>) in accordance with our data. It is also conceivable that phenotypic variants within a clonal population might display esterification of the core-lipid A phosphates (<xref ref-type="bibr" rid="bib70">Peterson et al., 1987</xref>). However, this would result in decreased permeability to both roxithromycin and polymyxin B in contrast with our data showing (i) comparatively smaller cell-to-cell differences in polymyxin B accumulation (beyond the heterogeneity generated by the microcolony architecture) and (ii) that adding polymyxin B suppresses the heterogeneity in roxithromycin accumulation. Finally, it has been suggested that macrolides use the hydrophobic pathway (<xref ref-type="bibr" rid="bib100">Vaara, 1993</xref>). It is conceivable that phenotypic variants within the clonal population might display a higher expression of <italic>lpxA</italic> and thus reduced permeability to roxithromycin; however, this hypothesis remains to be tested.</p><p>We further demonstrate that the presence of phenotypic variants that avoid antibiotic accumulation is not dictated by the microcolony architecture (as represented by bacterial cell position within a microfluidic channel). However, our data are in agreement with previous work in clinical settings suggesting that macrolides, quinolones, and oxazolidinones are more effective within infecting biofilms compared to glycopeptides and polymyxins (<xref ref-type="bibr" rid="bib106">Walters III et al., 2003</xref>; <xref ref-type="bibr" rid="bib111">Wu et al., 2015</xref>). In fact, we demonstrate that antibiotics with intracellular targets accumulate more readily and to higher saturation levels in bacteria within the inner core of the colony. In contrast, membrane targeting drugs accumulate more readily, faster, and at higher saturation levels in bacteria at the outer rim of the colony. This drug-specific effect of colony architecture on drug accumulation must rely on growth-independent mechanism and efflux-independent mechanism. In fact, we did not find significant correlations between the position of a cell within the colony and neither the expression of <italic>tolC</italic>, <italic>ompC,</italic> or <italic>rrnB</italic> nor the bacterial elongation rate (p-value=0.13, 0.13, 0.46, and 0.34, respectively).</p><p>In conclusion, this work reveals hitherto unrecognised phenotypic variants that avoid antibiotic accumulation within bacterial populations. In contrast with the current consensus, we demonstrate that fast growing phenotypic variants avoid macrolide accumulation and survive treatment due to elevated ribosomal content. We further show that it is possible to eradicate phenotypic variants currently avoiding macrolide accumulation by using a roxithromycin-polymyxin combination therapy. These data give strength to recent evidence that administered doses of polymyxins can be lowered in combination therapies (<xref ref-type="bibr" rid="bib17">Brochado et al., 2018</xref>) and demonstrate that roxithromycin could be repurposed against gram-negative bacteria. Finally, our novel single-cell approach reveals that each antibiotic is characterised by a unique accumulation pattern and thus could in future be employed to simultaneously characterise the accumulation and efficacy of new leading antibiotic compounds (<xref ref-type="bibr" rid="bib48">Kepiro et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Hammond et al., 2021</xref>; <xref ref-type="bibr" rid="bib64">Nonejuie et al., 2013</xref>; <xref ref-type="bibr" rid="bib90">Stokes et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Cama et al., 2022</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Chemicals and cell culture</title><p>All chemicals were purchased from Fisher Scientific or Sigma-Aldrich unless otherwise stated. LB medium (10 g L<sup>–1</sup> tryptone, 5 g L<sup>–1</sup>yeast extract, and 0.5 g L<sup>–1</sup> NaCl) and LB agar plates (LB with 15 g L<sup>–1</sup> agar) were used for planktonic growth and setting up overnight cultures. Glucose-free M9-minimal media, used to dissolve fluorescent antibiotic derivatives was prepared using 5×M9 minimal salts (Merck), diluted as appropriate, with additional 2 mM MgSO<sub>4</sub>, 0.1 mM CaCl<sub>2</sub>, 3 µM thiamine HCl in Milli-Q water. Stock solutions of polymyxin B, octapeptin, tachyplesin, vancomycin, linezolid, roxithromycin, and trimethoprim were obtained by dissolving these compounds in dimethyl sulfoxide; ciprofloxacin instead was dissolved in 0.1 M HCl in Milli-Q water. These stock solutions were prepared at a concentration of 640 µg mL<sup>–1</sup>. <italic>E. coli</italic> BW25113 was purchased from Dharmacon (GE Healthcare). <italic>ompC</italic>, <italic>tolC, rrnH</italic> and <italic>rrnB</italic> reporter strains of an <italic>E. coli</italic> K12 MG1655 promoter library (<xref ref-type="bibr" rid="bib112">Zaslaver et al., 2006</xref>) were purchased from Dharmacon . Plasmids were extracted and transformed into chemically competent <italic>E. coli</italic> BW25113 as previously reported (<xref ref-type="bibr" rid="bib45">Henry and Brynildsen, 2016</xref>). Deletion mutants <italic>ΔtolC</italic> and <italic>ΔompC</italic> were also purchased from Dharmacon. <italic>S. aureus</italic> ATCC 25923, <italic>P. aeruginosa</italic> PA14 flgK::Tn5(Tcr) (the deletion of the flagellum FlgK facilitated holding cells in the hosting channel thanks to the reduced bacterial motility) and <italic>B. cenocepacia</italic> K56-2 were kindly provided by A. Brown and S. van Houte. All strains were stored in 50% glycerol stock at –80 °C. Streak plates for each strain were produced by thawing a small aliquot of the corresponding glycerol stock every 2 weeks and plated onto LB agar. Overnight cultures were prepared by picking a single bacterial colony from a streak plate and growing it in 100 mL fresh LB medium on a shaking platform at 200 rpm and 37 °C for 17 hr.</p></sec><sec id="s4-2"><title>Synthesis of fluorescent derivatives of antibiotics</title><p>Fluorescent antibiotic derivatives from trimethoprim (<xref ref-type="bibr" rid="bib73">Phetsang et al., 2016</xref>) (antifolate), linezolid (<xref ref-type="bibr" rid="bib72">Phetsang et al., 2014</xref>) (oxazolidinone), ciprofloxacin (<xref ref-type="bibr" rid="bib92">Stone et al., 2019</xref>) (fluoroquinolone), and roxithromycin (<xref ref-type="bibr" rid="bib93">Stone et al., 2020</xref>) (macrolide) were prepared as previously described. Vancomycin (<xref ref-type="bibr" rid="bib14">Blaskovich et al., 2018</xref>) (glycopeptide), polymyxin (<xref ref-type="bibr" rid="bib34">Gallardo-Godoy et al., 2016</xref>), and octapeptin (<xref ref-type="bibr" rid="bib102">Velkov et al., 2018</xref>) (both lipopeptides) and tachyplesin (<xref ref-type="bibr" rid="bib31">Edwards et al., 2017</xref>) (antimicrobial peptide) analogues were designed and synthesised based on structure-activity-relationship studies and synthetic protocols reported in prior publications, introducing an azidolysine residue for the subsequent ‘click’ reactions with nitrobenzoxadiazole (NBD)-alkyne. Additionally, a fluorescent derivative of roxithromycin using the fluorophore dimethylamino-coumarin-4-acetate (DMACA) was synthesised and used only to determine the impact of labelling on single-cell antibiotic accumulation.</p></sec><sec id="s4-3"><title>Determination of minimum inhibitory concentration</title><p>Single colonies of <italic>E. coli</italic> BW25113 were picked and cultured overnight in cation-adjusted Mueller Hinton broth (CAMHB) at 37 °C, then diluted 40-fold and grown to OD<sub>600</sub>=0.5. 60 µL of each antibiotic or fluorescent antibiotic derivative stocks were added to the first column of a 96-well plate. 40 µL CAMHB was added to the first column, and 30 µL to all other wells. 70 µL solution was then withdrawn from the first column and serially transferred to the next column until 70 µL solution withdrawn from the last column was discharged. The mid-log phase cultures (i.e. OD<sub>600</sub>=0.5) were diluted to 10<sup>6</sup> colony forming units (c.f.u.) ml<sup>–1</sup> and 30 µL was added to each well, to give a final concentration of 5×10<sup>5</sup> c.f.u. ml<sup>–1</sup>. Each plate contained 2 rows of 12 positive control experiments (i.e. bacteria growing in CAMHB without antibiotics) and two rows of 12 negative control experiments (i.e. CAMHB only). Plates were covered with aluminium foil and incubated at 37 °C overnight. The minimum inhibitory concentrations (MICs) of fluorescent derivatives of polymyxin B, octapeptin, tachyplesin, vancomycin, linezolid, roxithromycin, ciprofloxacin, trimethoprim, and each corresponding parental antibiotic against <italic>E. coli</italic> BW25113 were determined visually, with the MIC being the lowest concentration well with no visible growth (compared to the positive control experiments).</p></sec><sec id="s4-4"><title>Fabrication of the microfluidic devices</title><p>The mould for the mother machine microfluidic device was fabricated by Kelvin Nanotechnology using previously established multilevel photolithography processes (<xref ref-type="bibr" rid="bib68">Pagliara et al., 2007</xref>). This mould is equipped with six identical microfluidic networks that can be controlled simultaneously and independently to maximise experimental throughput. Each of these networks is equipped with approximately 6000 lateral microfluidic channels with width and height of 1 μm each and a length of 20 μm. These lateral channels are connected to a main microfluidic chamber that is 25 μm and 100 μm in height and width, respectively. Polydimethylsiloxane (PDMS) replicas of this device were realised as previously described (<xref ref-type="bibr" rid="bib58">Locatelli et al., 2016</xref>). Briefly, a 10:1 (base:curing agent) PDMS mixture was cast on the mould and cured at 70 °C for 120 min in an oven. The cured PDMS was peeled from the epoxy mould and fluidic accesses were created by using a 0.75 mm biopsy punch (Harris Uni-Core, WPI). The PDMS chip was irreversibly sealed on a glass coverslip by exposing both surfaces to oxygen plasma treatment (10 s exposure to 30 W plasma power, Plasma etcher, Diener, Royal Oak, MI, USA). This treatment temporarily rendered the PDMS and glass hydrophilic, so immediately after bonding the chip was filled with 2 μL of a 50 mg/mL bovine serum albumin solution and incubated at 37 °C for 30 min, thus passivating the internal surfaces of the device and preventing subsequent cell adhesion. We have also made available a step-by-step experimental protocol for the fabrication and handling of microfluidic devices for investigating the interactions between antibiotics and individual bacteria (<xref ref-type="bibr" rid="bib20">Cama and Pagliara, 2021</xref>).</p></sec><sec id="s4-5"><title>Imaging single-cell drug accumulation dynamics</title><p>An overnight culture was prepared as described above and typically displayed an optical density at 595 nm (OD<sub>595</sub>) around 5. A 50 mL aliquot of the overnight culture above was centrifuged for 5 min at 4000 rpm and 37 °C. The supernatant was filtered twice (Medical Millex-GS Filter, 0.22 μm, Millipore Corp.) to remove bacterial debris from the solution and used to resuspend the bacteria in their spent LB to an OD<sub>600</sub> of 75. A 2 μL aliquot of this suspension was injected in each of the microfluidic networks above described and incubated at 37 °C. The high bacterial concentration favours bacteria entering the narrow lateral channels from the main microchamber of the mother machine (<xref ref-type="bibr" rid="bib10">Bamford et al., 2017</xref>). We found that an incubation time between 5 and 20 min allowed filling of the lateral channels with, typically, between one and three bacteria per channel. Shorter incubation times were required for motile or small bacteria, such as <italic>P. aeruginosa</italic> and <italic>S. aureus</italic>, respectively. An average of 80% of lateral channels of the mother machine device were filled with bacteria. The microfluidic device was completed by the integration of fluorinated ethylene propylene tubing (1/32&quot;×0.008&quot;). The inlet tubing was connected to the inlet reservoir, which was connected to a computerised pressure-based flow control system (MFCS-4C, Fluigent). This instrumentation was controlled by MAESFLO software (Fluigent). At the end of the 20 min incubation period, the chip was mounted on an inverted microscope (IX73 Olympus, Tokyo, Japan) and the bacteria remaining in the main microchamber of the mother machine were washed into the outlet tubing and into the waste reservoir by flowing LB at 300 μL h<sup>–1</sup> for 8 min and then at 100 μL h<sup>–1</sup> for 2 h. Bright-field images were acquired every 20 min during this 2 hr period of growth in LB. Images were collected via a 60×, 1.2 N.A. objective (UPLSAPO60XW, Olympus) and a sCMOS camera (Zyla 4.2, Andor, Belfast, UK). The region of interest of the camera was adjusted to visualise 23 lateral channels per image and images of 10 different areas of the microfluidic device were acquired at each time point in order to collect data from at least 100 individual bacteria per experiment. The device was moved by two automated stages (M-545.USC and P-545.3C7, Physik Instrumente, Karlsruhe, Germany, for coarse and fine movements, respectively). After this initial 2 hr growth period in LB, the microfluidic environment was changed by flowing minimal medium M9 (unless otherwise stated) with each of the NBD (unless otherwise stated) fluorescent antibiotic derivatives at a concentration of 46 μg mL<sup>–1</sup> (unless otherwise stated, also unlabelled ciprofloxacin was delivered at 200 µg mL<sup>–1</sup>) at 300 μL h<sup>–1</sup> for 8 min and then at 100 μL h<sup>–1</sup> for 4 h. During this 4 hr period of exposure to the fluorescent antibiotic derivative in use, upon acquiring each bright-field image the microscope was switched to fluorescent mode and FITC filter using Labview. A fluorescence image was acquired by exposing the bacteria for 0.03 s to the blue excitation band of a broad-spectrum LED (CoolLED pE300white, maximal power =200 mW Andover, UK) at 20% of its intensity (with a power associated with the beam light of 8 mW at the sample plane). In the case of unlabelled ciprofloxacin the UV excitation band of such LED was used at 100% of its intensity. These parameters were adjusted in order to maximise the signal to noise ratio. Bright-field and fluorescence imaging during this period was carried out every 5 min. The entire assay was carried out at 37 °C in an environmental chamber (Solent Scientific, Portsmouth, UK) surrounding the microscope and microfluidics equipment.</p></sec><sec id="s4-6"><title>Image and data analysis</title><p>Images were processed using ImageJ software as previously described (<xref ref-type="bibr" rid="bib51">Łapińska et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Blaskovich et al., 2019</xref>; <xref ref-type="bibr" rid="bib88">Smith et al., 2019</xref>), tracking each individual bacterium throughout the initial 2 hr period of growth and the following 4 hr period treatment with each fluorescent antibiotic derivative. Briefly, during the initial 2 hr growth in LB, a rectangle was drawn around each bacterium in each bright-field image at every time point, obtaining its width, length, and relative position in the hosting microfluidic channel. Each bacterium’s average elongation rate was calculated as the average of the ratios of the differences in bacterial length over the lapse of time between two consecutive time points. During the following 4 hr incubation in the presence of the fluorescent antibiotic derivative, a rectangle was drawn around each bacterium in each bright-field image at every time point, obtaining its width, length, and relative position in the hosting microfluidic channel. The same rectangle was then used in the corresponding fluorescence image to measure the mean fluorescence intensity for each bacterium that is the total fluorescence of the bacterium normalised by cell size (i.e. the area covered by each bacterium in our 2D images), to account for variations in antibiotic accumulation due to the cell cycle (<xref ref-type="bibr" rid="bib95">Taniguchi et al., 2010</xref>). The same rectangle was then moved to the closest microfluidic channel that did not host any bacteria in order to measure the background fluorescence due to the presence of extracellular fluorescent antibiotic derivative in the media. This mean background fluorescence value was subtracted from the bacterium’s fluorescence value. Background subtracted values smaller than 20 a.u. were set to zero since this was the typical noise value in our background measurements. All data were then analysed and plotted using GraphPad Prism 8. Statistical significance was tested using either paired or unpaired, two-tailed, Welch’s <italic>t</italic>-test. Pearson correlation, means, SD, coefficients of variation, and medians were also calculated using GraphPad Prism 8.</p></sec><sec id="s4-7"><title>Inferring single-cell kinetic parameters of antibiotic accumulation via mathematical modelling</title><p>We constructed a minimal model of antibiotic accumulation in order to infer key kinetic parameters quantifying the accumulation of each antibiotic. We modelled antibiotic accumulation using the following set of ordinary differential equations (ODEs):<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>c</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi>U</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf1"><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula> represents the dimensionless step function:<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mi>U</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left left" columnspacing="1em" rowspacing="4pt"><mml:mtr><mml:mtd><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi>t</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>≥</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable><mml:mo fence="true" stretchy="true" symmetric="true"/></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Variable <inline-formula><mml:math id="inf2"><mml:mi>c</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> represents the intracellular antibiotic concentration (in arbitrary units [a.u.] of fluorescence levels), and <inline-formula><mml:math id="inf3"><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> (a.u. s<sup>–1</sup>) describes the antibiotic uptake rate. With the first equation we described how antibiotic accumulation, <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>c</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, changes over time as a result of two processes: (i) drug-uptake, which proceeds at a time-varying rate, <inline-formula><mml:math id="inf5"><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>; and (ii) drug loss (efflux or antibiotic transformation), which we modelled as a first order reaction with rate constant <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (s<sup>–1</sup>). With the second equation we described the dynamics of time-varying antibiotic uptake rate, <inline-formula><mml:math id="inf7"><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>. The uptake rate starts increasing with a characteristic time-delay (parameter <inline-formula><mml:math id="inf8"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>), parameter <inline-formula><mml:math id="inf9"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> (a.u. s<sup>–2</sup>) is the associated rate constant of this increase. We also assumed a linear dampening effect (with associated rate constant <inline-formula><mml:math id="inf10"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> [s<sup>–1</sup>]) to constrain the increase in uptake rate, which allowed us to recapitulate the measured saturation in antibiotic accumulation. In this model the maximum saturation is given by <inline-formula><mml:math id="inf11"><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula>. Finally, we introduced an adaptive inhibitory term (rate constant <inline-formula><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> [a.u. s<sup>–2</sup>]) to describe the dip observed in some single-cell trajectories in Figure 1-figure supplement 2 and Figure 1-figure supplement 3, which we assumed due to the fact that the presence of drugs intracellularly inhibits further drug uptake. We note that in this model we did not make any a priori assumptions about the mechanisms underlying antibiotic accumulation but rather aimed to capture the dynamics of the measured accumulation data.</p><p>Model parameters were inferred from single-cell fluorescence time-traces (see Image and data analysis section) using the probabilistic programming language Stan through its python interface pystan (<xref ref-type="bibr" rid="bib22">Carpenter et al., 2017</xref>). Stan provides full Bayesian parameter inference for continuous-variable models using the No-U-Turn sampler, a variant of the Hamiltonian Monte Carlo method. All No-U-Turn parameters were set to default values except parameter adapt_delta, which was set to 0.999 to avoid divergent runs of the algorithm. For each single-cell fluorescence time-trace the algorithm produced four chains, each one consisting of 3000 warm-up iterations followed by 1000 sampling iterations, giving in total 4000 samples from the parameters’ posterior distribution. For each parameter, the median of the sampled posterior is used for subsequent analysis. For parameter inference, model time was rescaled by the length of the time-trace T, i.e., <inline-formula><mml:math id="inf13"><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> so that time runs between 0 and 1, and model parameters were reparameterised (and made dimensionless) according to the rules (<inline-formula><mml:math id="inf14"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>T</mml:mi></mml:math></inline-formula>). The following diffuse priors were used for the dimensionless parameters, where <inline-formula><mml:math id="inf15"><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>b</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> denotes the uniform distribution in the range <inline-formula><mml:math id="inf16"><mml:mo>[</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>b</mml:mi><mml:mo>]</mml:mo></mml:math></inline-formula>: <inline-formula><mml:math id="inf17"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mi>U</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:math></inline-formula> so that uptake rate dynamics are always faster than drug-accumulation dynamics, i.e., <inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> ; <inline-formula><mml:math id="inf19"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mrow><mml:mo>~</mml:mo><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mn>3</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula> constraining the timescale associated with <inline-formula><mml:math id="inf20"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> to be shorter than the timescale of the experiment, i.e., 1/ <inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mi>T</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>; <inline-formula><mml:math id="inf22"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal"> log</mml:mi></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mrow><mml:mo>~</mml:mo><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mn>3</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula> and <inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>log</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo>⁡</mml:mo><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:mi>U</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>, so that the parameter controlling adaptive inhibition is small enough and there is no oscillatory behaviour in the model, i.e., <inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>; <inline-formula><mml:math id="inf25"><mml:msubsup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>~</mml:mo><mml:mi>U</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mn>1</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula>, since the transformed time <inline-formula><mml:math id="inf26"><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> runs from 0 to 1.</p></sec><sec id="s4-8"><title>Statistical classification of the accumulation of antibiotics</title><p>For each cell, the marginal posterior distributions of all model parameters (<italic>t<sub>0</sub></italic>, <italic>k<sub>1,</sub> k<sub>2</sub></italic>, <italic>d<sub>r</sub></italic>, <italic>d<sub>c</sub></italic>) were summarised using the corresponding first (Q<sub>1</sub>), second (Q<sub>2</sub>), and third (Q<sub>3</sub>) quantiles. For each classification task, a statistical model (classification decision tree) was developed for predicting the drug class for each cell using the summarised parameter posterior distributions as input. Depending on the classification task, either all 5 parameters were considered (5 × 3 = 15 predictors) or just parameters <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic> (2 × 3 = 6 predictors). Statistical classification was performed using Matlab (method <italic>fitctree</italic>) and the results presented were obtained using 10-fold cross-validation.</p></sec><sec id="s4-9"><title>Numerical simulations of antibiotic diffusion in microfluidic channels</title><p>Using COMSOL (version 5.5) with the Chemical Reaction Engineering module, we created a physical 2D model of the bacterial hosting microfluidic channel (with a length and width of 20 μm and 1 μm, respectively) with five bacteria (each with a length and width of 2 μm and 0.8 μm, respectively) arranged in the centre of the channel. We kept constant at 7×10<sup>4</sup> mol m<sup>–3</sup> (i.e. 46 µg mL<sup>–1</sup>) the extracellular antibiotic concentration at the open end of the channel because in our experiments we continuously supplied antibiotics via the main channel of the device. We used a diffusion coefficient of 2.5×10<sup>–10</sup> m<sup>2</sup> s<sup>–1</sup> (i.e. the average of the diffusion coefficients estimated for polymyxin B-NBD and roxithromycin-NBD by using the Stokes-Einstein equation and the molecular weights reported in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). Antibiotic binding to the bacterial surface was modelled with an absorption rate of 0.2 or 0.002 mol m<sup>–2</sup> s<sup>–1</sup> (i.e. this simple model does not intend to recapitulate the complex molecular transport across the bacterial double membrane), that linearly decreased to zero if the antibiotic concentration in the proximity of the bacterial surface was below 10% of the extracellular antibiotic concentration at the open end of the channel. Absorption at the surface of each bacterium stopped when the level of antibiotic concentration at the bacterial surface reached a value of 100 mol m<sup>–2</sup>. After performing these simulations with a range of maximal concentrations from 10 to 1000 mol m<sup>–2</sup>, the value 100 mol m<sup>–2</sup> was chosen empirically since it best matched the experimental observation that bacteria without screens reached saturation levels of intracellular polymyxin B fluorescence within minutes. Finally, when we run our simulations with an absorption rate value of 0.02 mol m<sup>–2</sup> s<sup>–1</sup> (i.e. intermediate between 0.2 and 0.002 mol m<sup>–2</sup> s<sup>–1</sup> values above), we obtained that only the simulated intracellular concentration of the most screened bacterium was affected by the presence of other bacteria.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Supervision, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Methodology, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Formal analysis, Funding acquisition, Project administration, Supervision, Writing - original draft, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-74062-transrepform1-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data acquired for this study are presented within the manuscript, the supplementary information and the source data files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>U.L. was supported through a BBSRC responsive mode grant (BB/V008021/1), an MRC Proximity to Discovery EXCITEME2 grant (MCPC17189) and an award from the Gordon and Betty Moore Foundation Marine Microbiology Initiative (GBMF5514). M.V. and K.T.A. gratefully acknowledge financial support from the EPSRC via grant EP/T017856/1. K.K.L was supported via a Living Systems Institute PhD studentship. A.C. and B.T. were supported via an EPSRC DTP PhD studentship (EP/M506527/1). M.R.L.S. was supported by an Australian Postgraduate Award and an Institute for Molecular Biosciences Research Advancement Award. B.Z was supported by a CSC scholarship. M.A.T.B. was supported in part by Wellcome Trust Strategic Grant WT1104797/Z/14/Z and NHMRC Development grant APP1113719. This work was further supported by a Royal Society Research Grant (RG180007) awarded to S.P., a QUEX Initiator grant awarded to S.P., K.T.A. and M.A.T.B., an NHMRC Ideas grant (2004367) awarded to M.A.T.B, and a GW4 Initiator award to M.V., K.T.A and S.P. S.P.’s work in this area is also supported by a Marie Skłodowska-Curie project SINGEK (H2020-MSCA-ITN-2015–675752).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackermann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A functional perspective on phenotypic heterogeneity in microorganisms</article-title><source>Nature Reviews. Microbiology</source><volume>13</volume><fpage>497</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3491</pub-id><pub-id pub-id-type="pmid">26145732</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta-Gutiérrez</surname><given-names>S</given-names></name><name><surname>Ferrara</surname><given-names>L</given-names></name><name><surname>Pathania</surname><given-names>M</given-names></name><name><surname>Masi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Bodrenko</surname><given-names>I</given-names></name><name><surname>Zahn</surname><given-names>M</given-names></name><name><surname>Winterhalter</surname><given-names>M</given-names></name><name><surname>Stavenger</surname><given-names>RA</given-names></name><name><surname>Pagès</surname><given-names>J-M</given-names></name><name><surname>Naismith</surname><given-names>JH</given-names></name><name><surname>van den Berg</surname><given-names>B</given-names></name><name><surname>Page</surname><given-names>MGP</given-names></name><name><surname>Ceccarelli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Getting Drugs into Gram-Negative Bacteria: Rational Rules for Permeation through General Porins</article-title><source>ACS Infectious Diseases</source><volume>4</volume><fpage>1487</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.8b00108</pub-id><pub-id pub-id-type="pmid">29962203</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asuquo</surname><given-names>AE</given-names></name><name><surname>Piddock</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Accumulation and killing kinetics of fifteen quinolones for <italic>Escherichia coli</italic>, <italic>Staphylococcus aureus</italic> and <italic>Pseudomonas aeruginosa</italic></article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>31</volume><fpage>865</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1093/jac/31.6.865</pub-id><pub-id pub-id-type="pmid">8360125</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attrill</surname><given-names>EL</given-names></name><name><surname>Claydon</surname><given-names>R</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Recker</surname><given-names>M</given-names></name><name><surname>Meaden</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>AT</given-names></name><name><surname>Westra</surname><given-names>ER</given-names></name><name><surname>Harding</surname><given-names>SV</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Individual bacteria in structured environments rely on phenotypic resistance to phage</article-title><source>PLOS Biology</source><volume>19</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001406</pub-id><pub-id pub-id-type="pmid">34637438</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakshi</surname><given-names>S</given-names></name><name><surname>Leoncini</surname><given-names>E</given-names></name><name><surname>Baker</surname><given-names>C</given-names></name><name><surname>Cañas-Duarte</surname><given-names>SJ</given-names></name><name><surname>Okumus</surname><given-names>B</given-names></name><name><surname>Paulsson</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tracking bacterial lineages in complex and dynamic environments with applications for growth control and persistence</article-title><source>Nature Microbiology</source><volume>6</volume><fpage>783</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1038/s41564-021-00900-4</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balaban</surname><given-names>NQ</given-names></name><name><surname>Merrin</surname><given-names>J</given-names></name><name><surname>Chait</surname><given-names>R</given-names></name><name><surname>Kowalik</surname><given-names>L</given-names></name><name><surname>Leibler</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Bacterial persistence as a phenotypic switch</article-title><source>Science (New York, N.Y.)</source><volume>305</volume><fpage>1622</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1126/science.1099390</pub-id><pub-id pub-id-type="pmid">15308767</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balaban</surname><given-names>NQ</given-names></name><name><surname>Gerdes</surname><given-names>K</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>McKinney</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A problem of persistence: still more questions than answers?</article-title><source>Nature Reviews. Microbiology</source><volume>11</volume><fpage>587</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3076</pub-id><pub-id pub-id-type="pmid">24020075</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balaban</surname><given-names>NQ</given-names></name><name><surname>Helaine</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Ackermann</surname><given-names>M</given-names></name><name><surname>Aldridge</surname><given-names>B</given-names></name><name><surname>Andersson</surname><given-names>DI</given-names></name><name><surname>Brynildsen</surname><given-names>MP</given-names></name><name><surname>Bumann</surname><given-names>D</given-names></name><name><surname>Camilli</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name><name><surname>Dehio</surname><given-names>C</given-names></name><name><surname>Fortune</surname><given-names>S</given-names></name><name><surname>Ghigo</surname><given-names>J-M</given-names></name><name><surname>Hardt</surname><given-names>W-D</given-names></name><name><surname>Harms</surname><given-names>A</given-names></name><name><surname>Heinemann</surname><given-names>M</given-names></name><name><surname>Hung</surname><given-names>DT</given-names></name><name><surname>Jenal</surname><given-names>U</given-names></name><name><surname>Levin</surname><given-names>BR</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name><name><surname>Storz</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>M-W</given-names></name><name><surname>Tenson</surname><given-names>T</given-names></name><name><surname>Van Melderen</surname><given-names>L</given-names></name><name><surname>Zinkernagel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Definitions and guidelines for research on antibiotic persistence</article-title><source>Nature Reviews. Microbiology</source><volume>17</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0196-3</pub-id><pub-id pub-id-type="pmid">30980069</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltekin</surname><given-names>Ö</given-names></name><name><surname>Boucharin</surname><given-names>A</given-names></name><name><surname>Tano</surname><given-names>E</given-names></name><name><surname>Andersson</surname><given-names>DI</given-names></name><name><surname>Elf</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antibiotic susceptibility testing in less than 30 min using direct single-cell imaging</article-title><source>PNAS</source><volume>114</volume><fpage>9170</fpage><lpage>9175</lpage><pub-id pub-id-type="doi">10.1073/pnas.1708558114</pub-id><pub-id pub-id-type="pmid">28790187</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamford</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Titball</surname><given-names>RW</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Investigating the physiology of viable but non-culturable bacteria by microfluidics and time-lapse microscopy</article-title><source>BMC Biology</source><volume>15</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-017-0465-4</pub-id><pub-id pub-id-type="pmid">29262826</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergmiller</surname><given-names>T</given-names></name><name><surname>Andersson</surname><given-names>AMC</given-names></name><name><surname>Tomasek</surname><given-names>K</given-names></name><name><surname>Balleza</surname><given-names>E</given-names></name><name><surname>Kiviet</surname><given-names>DJ</given-names></name><name><surname>Hauschild</surname><given-names>R</given-names></name><name><surname>Tkačik</surname><given-names>G</given-names></name><name><surname>Guet</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Biased partitioning of the multidrug efflux pump AcrAB-TolC underlies long-lived phenotypic heterogeneity</article-title><source>Science (New York, N.Y.)</source><volume>356</volume><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1126/science.aaf4762</pub-id><pub-id pub-id-type="pmid">28428424</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>JMA</given-names></name><name><surname>Webber</surname><given-names>MA</given-names></name><name><surname>Baylay</surname><given-names>AJ</given-names></name><name><surname>Ogbolu</surname><given-names>DO</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular mechanisms of antibiotic resistance</article-title><source>Nature Reviews Microbiology</source><volume>13</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3380</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>JMA</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name><name><surname>Wright</surname><given-names>GD</given-names></name><name><surname>Collier</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>How to Measure Export via Bacterial Multidrug Resistance Efflux Pumps</article-title><source>MBio</source><volume>7</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00840-16</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Hansford</surname><given-names>KA</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Muldoon</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Ramu</surname><given-names>S</given-names></name><name><surname>Silva</surname><given-names>AB</given-names></name><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Kavanagh</surname><given-names>AM</given-names></name><name><surname>Ziora</surname><given-names>Z</given-names></name><name><surname>Premraj</surname><given-names>R</given-names></name><name><surname>Lindahl</surname><given-names>F</given-names></name><name><surname>Bradford</surname><given-names>TA</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Karoli</surname><given-names>T</given-names></name><name><surname>Pelingon</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>DJ</given-names></name><name><surname>Amado</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Daud</surname><given-names>NH</given-names></name><name><surname>Deecke</surname><given-names>JE</given-names></name><name><surname>Sidjabat</surname><given-names>HE</given-names></name><name><surname>Ramaologa</surname><given-names>S</given-names></name><name><surname>Zuegg</surname><given-names>J</given-names></name><name><surname>Betley</surname><given-names>JR</given-names></name><name><surname>Beevers</surname><given-names>APG</given-names></name><name><surname>Smith</surname><given-names>RAG</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02123-w</pub-id><pub-id pub-id-type="pmid">29295973</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Blaskovich</surname><given-names>MA</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Stone</surname><given-names>MR</given-names></name><name><surname>Lapinska</surname><given-names>U</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Bhalla</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Dai</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>MX</given-names></name><name><surname>Popp</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antibiotic-derived molecular probes for bacterial imaging</article-title><conf-name>Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2019</conf-name><conf-loc>San Francisco, United States</conf-loc><elocation-id>1086303</elocation-id><pub-id pub-id-type="doi">10.1117/12.2507329</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brauner</surname><given-names>A</given-names></name><name><surname>Fridman</surname><given-names>O</given-names></name><name><surname>Gefen</surname><given-names>O</given-names></name><name><surname>Balaban</surname><given-names>NQ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Distinguishing between resistance, tolerance and persistence to antibiotic treatment</article-title><source>Nature Reviews. Microbiology</source><volume>14</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.34</pub-id><pub-id pub-id-type="pmid">27080241</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brochado</surname><given-names>AR</given-names></name><name><surname>Telzerow</surname><given-names>A</given-names></name><name><surname>Bobonis</surname><given-names>J</given-names></name><name><surname>Banzhaf</surname><given-names>M</given-names></name><name><surname>Mateus</surname><given-names>A</given-names></name><name><surname>Selkrig</surname><given-names>J</given-names></name><name><surname>Huth</surname><given-names>E</given-names></name><name><surname>Bassler</surname><given-names>S</given-names></name><name><surname>Zamarreño Beas</surname><given-names>J</given-names></name><name><surname>Zietek</surname><given-names>M</given-names></name><name><surname>Ng</surname><given-names>N</given-names></name><name><surname>Foerster</surname><given-names>S</given-names></name><name><surname>Ezraty</surname><given-names>B</given-names></name><name><surname>Py</surname><given-names>B</given-names></name><name><surname>Barras</surname><given-names>F</given-names></name><name><surname>Savitski</surname><given-names>MM</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Göttig</surname><given-names>S</given-names></name><name><surname>Typas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Species-specific activity of antibacterial drug combinations</article-title><source>Nature</source><volume>559</volume><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0278-9</pub-id><pub-id pub-id-type="pmid">29973719</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Henney</surname><given-names>AM</given-names></name><name><surname>Winterhalter</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Breaching the Barrier: Quantifying Antibiotic Permeability across Gram-negative Bacterial Membranes</article-title><source>Journal of Molecular Biology</source><volume>431</volume><fpage>3531</fpage><lpage>3546</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.03.031</pub-id><pub-id pub-id-type="pmid">30959052</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Voliotis</surname><given-names>M</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Iannucci</surname><given-names>J</given-names></name><name><surname>Keyser</surname><given-names>UF</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell microfluidics facilitates the rapid quantification of antibiotic accumulation in Gram-negative bacteria</article-title><source>Lab on a Chip</source><volume>20</volume><fpage>2765</fpage><lpage>2775</lpage><pub-id pub-id-type="doi">10.1039/d0lc00242a</pub-id><pub-id pub-id-type="pmid">32613221</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Microfluidic Single-Cell Phenotyping of the Activity of Peptide-Based Antimicrobials</article-title><source>Methods in Molecular Biology (Clifton, N.J.)</source><volume>2208</volume><fpage>237</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-0928-6_16</pub-id><pub-id pub-id-type="pmid">32856267</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Al Nahas</surname><given-names>K</given-names></name><name><surname>Fletcher</surname><given-names>M</given-names></name><name><surname>Hammond</surname><given-names>K</given-names></name><name><surname>Ryadnov</surname><given-names>MG</given-names></name><name><surname>Keyser</surname><given-names>UF</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>An ultrasensitive microfluidic approach reveals correlations between the physico-chemical and biological activity of experimental peptide antibiotics</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>4005</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-07973-z</pub-id><pub-id pub-id-type="pmid">35256720</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>B</given-names></name><name><surname>Gelman</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>MD</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Goodrich</surname><given-names>B</given-names></name><name><surname>Betancourt</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Stan: A probabilistic programming language</article-title><source>Journal of Statistical Software</source><volume>76</volume><fpage>1</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.18637/jss.v076.i01</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Novel antibiotic hypersensitive mutants of <italic>Escherichia coli</italic> genetic mapping and chemical characterization</article-title><source>FEMS Microbiology Letters</source><volume>21</volume><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.1984.tb00209.x</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Warren</surname><given-names>M</given-names></name><name><surname>Balakrishnan</surname><given-names>R</given-names></name><name><surname>Patsalo</surname><given-names>V</given-names></name><name><surname>Okano</surname><given-names>H</given-names></name><name><surname>Williamson</surname><given-names>JR</given-names></name><name><surname>Fredrick</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>YP</given-names></name><name><surname>Hwa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reduction of translating ribosomes enables <italic>Escherichia coli</italic> to maintain elongation rates during slow growth</article-title><source>Nature Microbiology</source><volume>2</volume><elocation-id>16231</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.231</pub-id><pub-id pub-id-type="pmid">27941827</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>TD</given-names></name><name><surname>Gerry</surname><given-names>CJ</given-names></name><name><surname>Tan</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>General platform for systematic quantitative evaluation of small-molecule permeability in bacteria</article-title><source>ACS Chemical Biology</source><volume>9</volume><fpage>2535</fpage><lpage>2544</lpage><pub-id pub-id-type="doi">10.1021/cb5003015</pub-id><pub-id pub-id-type="pmid">25198656</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defraine</surname><given-names>V</given-names></name><name><surname>Fauvart</surname><given-names>M</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics</article-title><source>Drug Resistance Updates</source><volume>38</volume><fpage>12</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.drup.2018.03.002</pub-id><pub-id pub-id-type="pmid">29857815</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delcour</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Outer membrane permeability and antibiotic resistance</article-title><source>Biochimica et Biophysica Acta</source><volume>1794</volume><fpage>808</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2008.11.005</pub-id><pub-id pub-id-type="pmid">19100346</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delcour</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Electrophysiology of bacteria</article-title><source>Annual Review of Microbiology</source><volume>67</volume><fpage>179</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-092412-155637</pub-id><pub-id pub-id-type="pmid">24024633</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinos</surname><given-names>GP</given-names></name><name><surname>Connell</surname><given-names>SR</given-names></name><name><surname>Nierhaus</surname><given-names>KH</given-names></name><name><surname>Kalpaxis</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Erythromycin, roxithromycin, and clarithromycin: use of slow-binding kinetics to compare their in vitro interaction with a bacterial ribosomal complex active in peptide bond formation</article-title><source>Molecular Pharmacology</source><volume>63</volume><fpage>617</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1124/mol.63.3.617</pub-id><pub-id pub-id-type="pmid">12606769</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>James</surname><given-names>NR</given-names></name><name><surname>Voss</surname><given-names>JE</given-names></name><name><surname>Klimont</surname><given-names>E</given-names></name><name><surname>Ohene-Agyei</surname><given-names>T</given-names></name><name><surname>Venter</surname><given-names>H</given-names></name><name><surname>Chiu</surname><given-names>W</given-names></name><name><surname>Luisi</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structure of the AcrAB–TolC multidrug efflux pump</article-title><source>Nature</source><volume>509</volume><fpage>512</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1038/nature13205</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>IA</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Kavanagh</surname><given-names>AM</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure-Activity and -Toxicity Relationships of the Antimicrobial Peptide Tachyplesin-1</article-title><source>ACS Infectious Diseases</source><volume>3</volume><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00123</pub-id><pub-id pub-id-type="pmid">28960954</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>ZS</given-names></name><name><surname>Hancock</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Influence of outer membrane mutations on susceptibility of <italic>Escherichia coli</italic> to the dibasic macrolide azithromycin</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>29</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1093/jac/29.1.27</pub-id><pub-id pub-id-type="pmid">1310670</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzpatrick</surname><given-names>AWP</given-names></name><name><surname>Llabrés</surname><given-names>S</given-names></name><name><surname>Neuberger</surname><given-names>A</given-names></name><name><surname>Blaza</surname><given-names>JN</given-names></name><name><surname>Bai</surname><given-names>XC</given-names></name><name><surname>Okada</surname><given-names>U</given-names></name><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>van Veen</surname><given-names>HW</given-names></name><name><surname>Zachariae</surname><given-names>U</given-names></name><name><surname>Scheres</surname><given-names>SHW</given-names></name><name><surname>Luisi</surname><given-names>BF</given-names></name><name><surname>Du</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure of the MacAB-TolC ABC-type tripartite multidrug efflux pump</article-title><source>Nature Microbiology</source><volume>2</volume><elocation-id>17070</elocation-id><pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.70</pub-id><pub-id pub-id-type="pmid">28504659</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallardo-Godoy</surname><given-names>A</given-names></name><name><surname>Muldoon</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>B</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Lash</surname><given-names>LH</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Pelingon</surname><given-names>R</given-names></name><name><surname>Kavanagh</surname><given-names>AM</given-names></name><name><surname>Ramu</surname><given-names>S</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B</article-title><source>Journal of Medicinal Chemistry</source><volume>59</volume><fpage>1068</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01593</pub-id><pub-id pub-id-type="pmid">26734854</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Voliotis</surname><given-names>M</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Invergo</surname><given-names>BM</given-names></name><name><surname>Soanes</surname><given-names>D</given-names></name><name><surname>O’Neill</surname><given-names>P</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Nikolic</surname><given-names>N</given-names></name><name><surname>Petrov</surname><given-names>PG</given-names></name><name><surname>Milner</surname><given-names>DS</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Heesom</surname><given-names>K</given-names></name><name><surname>Richards</surname><given-names>TA</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Nutrient and salt depletion synergistically boosts glucose metabolism in individual <italic>Escherichia coli</italic> cells</article-title><source>Communications Biology</source><volume>5</volume><elocation-id>385</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-022-03336-6</pub-id><pub-id pub-id-type="pmid">35444215</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golding</surname><given-names>I</given-names></name><name><surname>Paulsson</surname><given-names>J</given-names></name><name><surname>Zawilski</surname><given-names>SM</given-names></name><name><surname>Cox</surname><given-names>EC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Real-time kinetics of gene activity in individual bacteria</article-title><source>Cell</source><volume>123</volume><fpage>1025</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.09.031</pub-id><pub-id pub-id-type="pmid">16360033</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gollan</surname><given-names>B</given-names></name><name><surname>Grabe</surname><given-names>G</given-names></name><name><surname>Michaux</surname><given-names>C</given-names></name><name><surname>Helaine</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bacterial Persisters and Infection: Past, Present, and Progressing</article-title><source>Annual Review of Microbiology</source><volume>73</volume><fpage>359</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115650</pub-id><pub-id pub-id-type="pmid">31500532</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Bamford</surname><given-names>R</given-names></name><name><surname>Kahveci</surname><given-names>Z</given-names></name><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Attrill</surname><given-names>E</given-names></name><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Heterologous Protein Expression Favors the Formation of Protein Aggregates in Persister and Viable but Nonculturable Bacteria</article-title><source>ACS Infectious Diseases</source><volume>7</volume><fpage>1848</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00154</pub-id><pub-id pub-id-type="pmid">34000805</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Zarkan</surname><given-names>A</given-names></name><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Invergo</surname><given-names>BM</given-names></name><name><surname>Belgami</surname><given-names>D</given-names></name><name><surname>Caño-Muñiz</surname><given-names>S</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>O’Neill</surname><given-names>P</given-names></name><name><surname>Jeffries</surname><given-names>A</given-names></name><name><surname>Norville</surname><given-names>IH</given-names></name><name><surname>David</surname><given-names>J</given-names></name><name><surname>Summers</surname><given-names>D</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Persister <italic>Escherichia coli</italic> Cells Have a Lower Intracellular pH than Susceptible Cells but Maintain Their pH in Response to Antibiotic Treatment</article-title><source>MBio</source><volume>12</volume><elocation-id>e00909-e21</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00909-21</pub-id><pub-id pub-id-type="pmid">34281389</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goormaghtigh</surname><given-names>F</given-names></name><name><surname>Van Melderen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-cell imaging and characterization of <italic>Escherichia coli</italic> persister cells to ofloxacin in exponential cultures</article-title><source>Science Advances</source><volume>5</volume><elocation-id>eaav9462</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aav9462</pub-id><pub-id pub-id-type="pmid">31223653</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greulich</surname><given-names>P</given-names></name><name><surname>Scott</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>MR</given-names></name><name><surname>Allen</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Growth-dependent bacterial susceptibility to ribosome-targeting antibiotics</article-title><source>Molecular Systems Biology</source><volume>11</volume><elocation-id>796</elocation-id><pub-id pub-id-type="doi">10.15252/msb.20145949</pub-id><pub-id pub-id-type="pmid">26146675</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>K</given-names></name><name><surname>Cipcigan</surname><given-names>F</given-names></name><name><surname>Al Nahas</surname><given-names>K</given-names></name><name><surname>Losasso</surname><given-names>V</given-names></name><name><surname>Lewis</surname><given-names>H</given-names></name><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Martelli</surname><given-names>F</given-names></name><name><surname>Simcock</surname><given-names>PW</given-names></name><name><surname>Fletcher</surname><given-names>M</given-names></name><name><surname>Ravi</surname><given-names>J</given-names></name><name><surname>Stansfeld</surname><given-names>PJ</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Hoogenboom</surname><given-names>BW</given-names></name><name><surname>Keyser</surname><given-names>UF</given-names></name><name><surname>Sansom</surname><given-names>MSP</given-names></name><name><surname>Crain</surname><given-names>J</given-names></name><name><surname>Ryadnov</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Switching Cytolytic Nanopores into Antimicrobial Fractal Ruptures by a Single Side Chain Mutation</article-title><source>ACS Nano</source><volume>15</volume><fpage>9679</fpage><lpage>9689</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c00218</pub-id><pub-id pub-id-type="pmid">33885289</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidari-Torkabadi</surname><given-names>H</given-names></name><name><surname>Che</surname><given-names>T</given-names></name><name><surname>Lombardo</surname><given-names>MN</given-names></name><name><surname>Wright</surname><given-names>DL</given-names></name><name><surname>Anderson</surname><given-names>AC</given-names></name><name><surname>Carey</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Measuring propargyl-linked drug populations inside bacterial cells, and their interaction with a dihydrofolate reductase target, by Raman microscopy</article-title><source>Biochemistry</source><volume>54</volume><fpage>2719</fpage><lpage>2726</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.5b00202</pub-id><pub-id pub-id-type="pmid">25871808</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helaine</surname><given-names>S</given-names></name><name><surname>Cheverton</surname><given-names>AM</given-names></name><name><surname>Watson</surname><given-names>KG</given-names></name><name><surname>Faure</surname><given-names>LM</given-names></name><name><surname>Matthews</surname><given-names>SA</given-names></name><name><surname>Holden</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Internalization of Salmonella by macrophages induces formation of nonreplicating persisters</article-title><source>Science (New York, N.Y.)</source><volume>343</volume><fpage>204</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1126/science.1244705</pub-id><pub-id pub-id-type="pmid">24408438</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>TC</given-names></name><name><surname>Brynildsen</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Development of Persister-FACSeq: a method to massively parallelize quantification of persister physiology and its heterogeneity</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>25100</elocation-id><pub-id pub-id-type="doi">10.1038/srep25100</pub-id><pub-id pub-id-type="pmid">27142337</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>R</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Duncan</surname><given-names>L</given-names></name><name><surname>Tanudra</surname><given-names>MA</given-names></name><name><surname>Tsao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Brummel</surname><given-names>CL</given-names></name><name><surname>Erwin</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluating LC-MS/MS To Measure Accumulation of Compounds within Bacteria</article-title><source>ACS Infectious Diseases</source><volume>4</volume><fpage>1336</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.8b00083</pub-id><pub-id pub-id-type="pmid">29961312</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jõers</surname><given-names>A</given-names></name><name><surname>Tenson</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Growth resumption from stationary phase reveals memory in <italic>Escherichia coli</italic> cultures</article-title><source>Scientific Reports</source><volume>6</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/srep24055</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kepiro</surname><given-names>IE</given-names></name><name><surname>Marzuoli</surname><given-names>I</given-names></name><name><surname>Hammond</surname><given-names>K</given-names></name><name><surname>Ba</surname><given-names>X</given-names></name><name><surname>Lewis</surname><given-names>H</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Gunnoo</surname><given-names>SB</given-names></name><name><surname>De Santis</surname><given-names>E</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>MA</given-names></name><name><surname>Lorenz</surname><given-names>CD</given-names></name><name><surname>Hoogenboom</surname><given-names>BW</given-names></name><name><surname>Fraternali</surname><given-names>F</given-names></name><name><surname>Ryadnov</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Engineering Chirally Blind Protein Pseudocapsids into Antibacterial Persisters</article-title><source>ACS Nano</source><volume>14</volume><fpage>1609</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b06814</pub-id><pub-id pub-id-type="pmid">31794180</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Nikaido</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Permeation rates of penicillins indicate that <italic>Escherichia coli</italic> porins function principally as nonspecific channels</article-title><source>PNAS</source><volume>110</volume><fpage>E2629</fpage><lpage>E2634</lpage><pub-id pub-id-type="doi">10.1073/pnas.1310333110</pub-id><pub-id pub-id-type="pmid">23798411</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortright</surname><given-names>KE</given-names></name><name><surname>Chan</surname><given-names>BK</given-names></name><name><surname>Turner</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High-throughput discovery of phage receptors using transposon insertion sequencing of bacteria</article-title><source>PNAS</source><volume>117</volume><fpage>18670</fpage><lpage>18679</lpage><pub-id pub-id-type="doi">10.1073/pnas.2001888117</pub-id><pub-id pub-id-type="pmid">32675236</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Capilla-Lasheras</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>AJ</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bacterial ageing in the absence of external stressors</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>374</volume><elocation-id>20180442</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2018.0442</pub-id><pub-id pub-id-type="pmid">31587633</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>D</given-names></name><name><surname>Krasnopeeva</surname><given-names>E</given-names></name><name><surname>Sinjab</surname><given-names>F</given-names></name><name><surname>Pilizota</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>VS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Active Efflux Leads to Heterogeneous Dissipation of Proton Motive Force by Protonophores in Bacteria</article-title><source>MBio</source><volume>12</volume><elocation-id>e00676</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00676-21</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin-Reisman</surname><given-names>I</given-names></name><name><surname>Gefen</surname><given-names>O</given-names></name><name><surname>Fridman</surname><given-names>O</given-names></name><name><surname>Ronin</surname><given-names>I</given-names></name><name><surname>Shwa</surname><given-names>D</given-names></name><name><surname>Sheftel</surname><given-names>H</given-names></name><name><surname>Balaban</surname><given-names>NQ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Automated imaging with ScanLag reveals previously undetectable bacterial growth phenotypes</article-title><source>Nature Methods</source><volume>7</volume><fpage>737</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1485</pub-id><pub-id pub-id-type="pmid">20676109</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin-Reisman</surname><given-names>I</given-names></name><name><surname>Brauner</surname><given-names>A</given-names></name><name><surname>Ronin</surname><given-names>I</given-names></name><name><surname>Balaban</surname><given-names>NQ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epistasis between antibiotic tolerance, persistence, and resistance mutations</article-title><source>PNAS</source><volume>116</volume><fpage>14734</fpage><lpage>14739</lpage><pub-id pub-id-type="doi">10.1073/pnas.1906169116</pub-id><pub-id pub-id-type="pmid">31262806</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Persister cells, dormancy and infectious disease</article-title><source>Nature Reviews. Microbiology</source><volume>5</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1557</pub-id><pub-id pub-id-type="pmid">17143318</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lidstrom</surname><given-names>ME</given-names></name><name><surname>Konopka</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The role of physiological heterogeneity in microbial population behavior</article-title><source>Nature Chemical Biology</source><volume>6</volume><fpage>705</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/nchembio.436</pub-id><pub-id pub-id-type="pmid">20852608</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Imaging Commensal Microbiota and Pathogenic Bacteria in the Gut</article-title><source>Accounts of Chemical Research</source><volume>54</volume><fpage>2076</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.1c00068</pub-id><pub-id pub-id-type="pmid">33856204</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>E</given-names></name><name><surname>Pierno</surname><given-names>M</given-names></name><name><surname>Baldovin</surname><given-names>F</given-names></name><name><surname>Orlandini</surname><given-names>E</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Single-File Escape of Colloidal Particles from Microfluidic Channels</article-title><source>Physical Review Letters</source><volume>117</volume><elocation-id>038001</elocation-id><pub-id pub-id-type="doi">10.1103/PhysRevLett.117.038001</pub-id><pub-id pub-id-type="pmid">27472142</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Ishihama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Strength and Regulation of Seven rRNA Promoters in <italic>Escherichia coli</italic></article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>0144697</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0144697</pub-id><pub-id pub-id-type="pmid">26717514</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulcahy</surname><given-names>LR</given-names></name><name><surname>Burns</surname><given-names>JL</given-names></name><name><surname>Lory</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Emergence of <italic>Pseudomonas aeruginosa</italic> strains producing high levels of persister cells in patients with cystic fibrosis</article-title><source>Journal of Bacteriology</source><volume>192</volume><fpage>6191</fpage><lpage>6199</lpage><pub-id pub-id-type="doi">10.1128/JB.01651-09</pub-id><pub-id pub-id-type="pmid">20935098</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="1995">1995</year><source>Manual of Clinical Microbiology</source><publisher-name>American Society for Microbiology</publisher-name></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestorovich</surname><given-names>EM</given-names></name><name><surname>Danelon</surname><given-names>C</given-names></name><name><surname>Winterhalter</surname><given-names>M</given-names></name><name><surname>Bezrukov</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Designed to penetrate: time-resolved interaction of single antibiotic molecules with bacterial pores</article-title><source>PNAS</source><volume>99</volume><fpage>9789</fpage><lpage>9794</lpage><pub-id pub-id-type="doi">10.1073/pnas.152206799</pub-id><pub-id pub-id-type="pmid">12119404</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikaido</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Molecular basis of bacterial outer membrane permeability revisited</article-title><source>Microbiology and Molecular Biology Reviews</source><volume>67</volume><fpage>593</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1128/MMBR.67.4.593-656.2003</pub-id><pub-id pub-id-type="pmid">14665678</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonejuie</surname><given-names>P</given-names></name><name><surname>Burkart</surname><given-names>M</given-names></name><name><surname>Pogliano</surname><given-names>K</given-names></name><name><surname>Pogliano</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules</article-title><source>PNAS</source><volume>110</volume><fpage>16169</fpage><lpage>16174</lpage><pub-id pub-id-type="doi">10.1073/pnas.1311066110</pub-id><pub-id pub-id-type="pmid">24046367</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orman</surname><given-names>MA</given-names></name><name><surname>Brynildsen</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dormancy is not necessary or sufficient for bacterial persistence</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>57</volume><fpage>3230</fpage><lpage>3239</lpage><pub-id pub-id-type="doi">10.1128/AAC.00243-13</pub-id><pub-id pub-id-type="pmid">23629720</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An arresting antitoxin</article-title><source>Nature Reviews. Microbiology</source><volume>19</volume><fpage>138</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00512-z</pub-id><pub-id pub-id-type="pmid">33442065</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagès</surname><given-names>JM</given-names></name><name><surname>James</surname><given-names>CE</given-names></name><name><surname>Winterhalter</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria</article-title><source>Nature Reviews. Microbiology</source><volume>6</volume><fpage>893</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1994</pub-id><pub-id pub-id-type="pmid">18997824</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Persano</surname><given-names>L</given-names></name><name><surname>Camposeo</surname><given-names>A</given-names></name><name><surname>Cingolani</surname><given-names>R</given-names></name><name><surname>Pisignano</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Registration accuracy in multilevel soft lithography</article-title><source>Nanotechnology</source><volume>18</volume><elocation-id>175302</elocation-id><pub-id pub-id-type="doi">10.1088/0957-4484/18/17/175302</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panlilio</surname><given-names>M</given-names></name><name><surname>Grilli</surname><given-names>J</given-names></name><name><surname>Tallarico</surname><given-names>G</given-names></name><name><surname>Iuliani</surname><given-names>I</given-names></name><name><surname>Sclavi</surname><given-names>B</given-names></name><name><surname>Cicuta</surname><given-names>P</given-names></name><name><surname>Cosentino Lagomarsino</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Threshold accumulation of a constitutive protein explains <italic>E. coli</italic> cell-division behavior in nutrient upshifts</article-title><source>PNAS</source><volume>118</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2016391118</pub-id><pub-id pub-id-type="pmid">33931503</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>AA</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>McGroarty</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Decreased binding of antibiotics to lipopolysaccharides from polymyxin-resistant strains of <italic>Escherichia coli</italic> and Salmonella typhimurium</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>31</volume><fpage>230</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1128/AAC.31.2.230</pub-id><pub-id pub-id-type="pmid">3032093</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyrusson</surname><given-names>F</given-names></name><name><surname>Varet</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>TK</given-names></name><name><surname>Legendre</surname><given-names>R</given-names></name><name><surname>Sismeiro</surname><given-names>O</given-names></name><name><surname>Coppée</surname><given-names>J-Y</given-names></name><name><surname>Wolz</surname><given-names>C</given-names></name><name><surname>Tenson</surname><given-names>T</given-names></name><name><surname>Van Bambeke</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Intracellular <italic>Staphylococcus aureus</italic> persisters upon antibiotic exposure</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2200</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15966-7</pub-id><pub-id pub-id-type="pmid">32366839</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Zuegg</surname><given-names>J</given-names></name><name><surname>Mamidyala</surname><given-names>SK</given-names></name><name><surname>Ramu</surname><given-names>S</given-names></name><name><surname>Kavanagh</surname><given-names>AM</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>22</volume><fpage>4490</fpage><lpage>4498</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2014.05.054</pub-id><pub-id pub-id-type="pmid">25023540</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Pelingon</surname><given-names>R</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Kc</surname><given-names>S</given-names></name><name><surname>Pitt</surname><given-names>ME</given-names></name><name><surname>Kaeslin</surname><given-names>G</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fluorescent Trimethoprim Conjugate Probes To Assess Drug Accumulation in Wild Type and Mutant <italic>Escherichia coli</italic></article-title><source>ACS Infectious Diseases</source><volume>2</volume><fpage>688</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.6b00080</pub-id><pub-id pub-id-type="pmid">27737551</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piddock</surname><given-names>LJ</given-names></name><name><surname>Jin</surname><given-names>YF</given-names></name><name><surname>Ricci</surname><given-names>V</given-names></name><name><surname>Asuquo</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and <italic>Escherichia coli</italic></article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>43</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/jac/43.1.61</pub-id><pub-id pub-id-type="pmid">10381102</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pontes</surname><given-names>MH</given-names></name><name><surname>Groisman</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Physiological Basis for Nonheritable Antibiotic Resistance</article-title><source>MBio</source><volume>11</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00817-20</pub-id><pub-id pub-id-type="pmid">32546621</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prochnow</surname><given-names>H</given-names></name><name><surname>Fetz</surname><given-names>V</given-names></name><name><surname>Hotop</surname><given-names>S-K</given-names></name><name><surname>García-Rivera</surname><given-names>MA</given-names></name><name><surname>Heumann</surname><given-names>A</given-names></name><name><surname>Brönstrup</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Subcellular Quantification of Uptake in Gram-Negative Bacteria</article-title><source>Analytical Chemistry</source><volume>91</volume><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.8b03586</pub-id><pub-id pub-id-type="pmid">30485749</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Ke</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Baker</surname><given-names>MAB</given-names></name><name><surname>Ge</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>XS</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enhanced Efflux Activity Facilitates Drug Tolerance in Dormant Bacterial Cells</article-title><source>Molecular Cell</source><volume>62</volume><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.03.035</pub-id><pub-id pub-id-type="pmid">27105118</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>A</given-names></name><name><surname>Virolle</surname><given-names>C</given-names></name><name><surname>Goldlust</surname><given-names>K</given-names></name><name><surname>Berne-Dedieu</surname><given-names>A</given-names></name><name><surname>Nolivos</surname><given-names>S</given-names></name><name><surname>Lesterlin</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Direct visualisation of drug-efflux in live <italic>Escherichia coli</italic> cells</article-title><source>FEMS Microbiology Reviews</source><volume>44</volume><fpage>782</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1093/femsre/fuaa031</pub-id><pub-id pub-id-type="pmid">32761242</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>TA</given-names></name><name><surname>Massana</surname><given-names>R</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single cell ecology</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>374</volume><elocation-id>20190076</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2019.0076</pub-id><pub-id pub-id-type="pmid">31587644</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>MF</given-names></name><name><surname>Drown</surname><given-names>BS</given-names></name><name><surname>Riley</surname><given-names>AP</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Shirai</surname><given-names>T</given-names></name><name><surname>Svec</surname><given-names>RL</given-names></name><name><surname>Hergenrother</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Predictive compound accumulation rules yield a broad-spectrum antibiotic</article-title><source>Nature</source><volume>545</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/nature22308</pub-id><pub-id pub-id-type="pmid">28489819</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybenkov</surname><given-names>VV</given-names></name><name><surname>Zgurskaya</surname><given-names>HI</given-names></name><name><surname>Ganguly</surname><given-names>C</given-names></name><name><surname>Leus</surname><given-names>IV</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Moniruzzaman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Whole Is Bigger than the Sum of Its Parts: Drug Transport in the Context of Two Membranes with Active Efflux</article-title><source>Chemical Reviews</source><volume>121</volume><fpage>5597</fpage><lpage>5631</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c01137</pub-id><pub-id pub-id-type="pmid">33596653</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>M</given-names></name><name><surname>Gunderson</surname><given-names>CW</given-names></name><name><surname>Mateescu</surname><given-names>EM</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Hwa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Interdependence of cell growth and gene expression: origins and consequences</article-title><source>Science (New York, N.Y.)</source><volume>330</volume><fpage>1099</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1126/science.1192588</pub-id><pub-id pub-id-type="pmid">21097934</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shatalin</surname><given-names>K</given-names></name><name><surname>Nuthanakanti</surname><given-names>A</given-names></name><name><surname>Kaushik</surname><given-names>A</given-names></name><name><surname>Shishov</surname><given-names>D</given-names></name><name><surname>Peselis</surname><given-names>A</given-names></name><name><surname>Shamovsky</surname><given-names>I</given-names></name><name><surname>Pani</surname><given-names>B</given-names></name><name><surname>Lechpammer</surname><given-names>M</given-names></name><name><surname>Vasilyev</surname><given-names>N</given-names></name><name><surname>Shatalina</surname><given-names>E</given-names></name><name><surname>Rebatchouk</surname><given-names>D</given-names></name><name><surname>Mironov</surname><given-names>A</given-names></name><name><surname>Fedichev</surname><given-names>P</given-names></name><name><surname>Serganov</surname><given-names>A</given-names></name><name><surname>Nudler</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inhibitors of bacterial H<sub>2</sub>S biogenesis targeting antibiotic resistance and tolerance</article-title><source>Science (New York, N.Y.)</source><volume>372</volume><fpage>1169</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1126/science.abd8377</pub-id><pub-id pub-id-type="pmid">34112687</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silander</surname><given-names>OK</given-names></name><name><surname>Nikolic</surname><given-names>N</given-names></name><name><surname>Zaslaver</surname><given-names>A</given-names></name><name><surname>Bren</surname><given-names>A</given-names></name><name><surname>Kikoin</surname><given-names>I</given-names></name><name><surname>Alon</surname><given-names>U</given-names></name><name><surname>Ackermann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A genome-wide analysis of promoter-mediated phenotypic noise in <italic>Escherichia coli</italic></article-title><source>PLOS Genetics</source><volume>8</volume><elocation-id>e1002443</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002443</pub-id><pub-id pub-id-type="pmid">22275871</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Bioorganic &amp; Medicinal Chemistry A Gestalt approach to Gram-negative entry</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>24</volume><fpage>6379</fpage><lpage>6389</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2016.06.044</pub-id><pub-id pub-id-type="pmid">27381365</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Six</surname><given-names>DA</given-names></name><name><surname>Krucker</surname><given-names>T</given-names></name><name><surname>Leeds</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Advances and challenges in bacterial compound accumulation assays for drug discovery</article-title><source>Current Opinion in Chemical Biology</source><volume>44</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2018.05.005</pub-id><pub-id pub-id-type="pmid">29803973</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Kaczmar</surname><given-names>A</given-names></name><name><surname>Bamford</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Frustaci</surname><given-names>S</given-names></name><name><surname>Kovacs-Simon</surname><given-names>A</given-names></name><name><surname>O’Neill</surname><given-names>P</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Paszkiewicz</surname><given-names>K</given-names></name><name><surname>Titball</surname><given-names>RW</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Culture Environment Influences Both Gene Regulation and Phenotypic Heterogeneity in <italic>Escherichia coli</italic></article-title><source>Frontiers in Microbiology</source><volume>9</volume><elocation-id>1739</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.01739</pub-id><pub-id pub-id-type="pmid">30158905</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MMHelper: An automated framework for the analysis of microscopy images acquired with the mother machine</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>10123</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-46567-0</pub-id><pub-id pub-id-type="pmid">31300741</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapels</surname><given-names>DAC</given-names></name><name><surname>Hill</surname><given-names>PWS</given-names></name><name><surname>Westermann</surname><given-names>AJ</given-names></name><name><surname>Fisher</surname><given-names>RA</given-names></name><name><surname>Thurston</surname><given-names>TL</given-names></name><name><surname>Saliba</surname><given-names>A-E</given-names></name><name><surname>Blommestein</surname><given-names>I</given-names></name><name><surname>Vogel</surname><given-names>J</given-names></name><name><surname>Helaine</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>Salmonella</italic> persisters undermine host immune defenses during antibiotic treatment</article-title><source>Science (New York, N.Y.)</source><volume>362</volume><fpage>1156</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1126/science.aat7148</pub-id><pub-id pub-id-type="pmid">30523110</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>JM</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Swanson</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Cubillos-Ruiz</surname><given-names>A</given-names></name><name><surname>Donghia</surname><given-names>NM</given-names></name><name><surname>MacNair</surname><given-names>CR</given-names></name><name><surname>French</surname><given-names>S</given-names></name><name><surname>Carfrae</surname><given-names>LA</given-names></name><name><surname>Bloom-Ackermann</surname><given-names>Z</given-names></name><name><surname>Tran</surname><given-names>VM</given-names></name><name><surname>Chiappino-Pepe</surname><given-names>A</given-names></name><name><surname>Badran</surname><given-names>AH</given-names></name><name><surname>Andrews</surname><given-names>IW</given-names></name><name><surname>Chory</surname><given-names>EJ</given-names></name><name><surname>Church</surname><given-names>GM</given-names></name><name><surname>Brown</surname><given-names>ED</given-names></name><name><surname>Jaakkola</surname><given-names>TS</given-names></name><name><surname>Barzilay</surname><given-names>R</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Deep Learning Approach to Antibiotic Discovery</article-title><source>Cell</source><volume>180</volume><fpage>688</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.01.021</pub-id><pub-id pub-id-type="pmid">32084340</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>MRL</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fluorescent Antibiotics: New Research Tools to Fight Antibiotic Resistance</article-title><source>Trends in Biotechnology</source><volume>36</volume><fpage>523</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2018.01.004</pub-id><pub-id pub-id-type="pmid">29478675</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>MRL</given-names></name><name><surname>Masi</surname><given-names>M</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Pagès</surname><given-names>J-M</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fluoroquinolone-derived fluorescent probes for studies of bacterial penetration and efflux</article-title><source>MedChemComm</source><volume>10</volume><fpage>901</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1039/c9md00124g</pub-id><pub-id pub-id-type="pmid">31303987</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>MRL</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Masi</surname><given-names>M</given-names></name><name><surname>Blanchfield</surname><given-names>JT</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fluorescent macrolide probes - synthesis and use in evaluation of bacterial resistance</article-title><source>RSC Chemical Biology</source><volume>1</volume><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1039/d0cb00118j</pub-id><pub-id pub-id-type="pmid">34458770</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>E</given-names></name><name><surname>Nikaido</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Pore-forming activity of OmpA protein of <italic>Escherichia coli</italic></article-title><source>The Journal of Biological Chemistry</source><volume>267</volume><fpage>2507</fpage><lpage>2511</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)45908-X</pub-id><pub-id pub-id-type="pmid">1370823</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>Y</given-names></name><name><surname>Choi</surname><given-names>PJ</given-names></name><name><surname>Li</surname><given-names>G-W</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Babu</surname><given-names>M</given-names></name><name><surname>Hearn</surname><given-names>J</given-names></name><name><surname>Emili</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quantifying <italic>E. coli</italic> proteome and transcriptome with single-molecule sensitivity in single cells</article-title><source>Science (New York, N.Y.)</source><volume>329</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1126/science.1188308</pub-id><pub-id pub-id-type="pmid">20671182</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Six</surname><given-names>DA</given-names></name><name><surname>Krucker</surname><given-names>T</given-names></name><name><surname>Leeds</surname><given-names>JA</given-names></name><name><surname>Winograd</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Subcellular Chemical Imaging of Antibiotics in Single Bacteria Using C<sub>60</sub>-Secondary Ion Mass Spectrometry</article-title><source>Analytical Chemistry</source><volume>89</volume><fpage>5050</fpage><lpage>5057</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.7b00466</pub-id><pub-id pub-id-type="pmid">28332827</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tommasi</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>DG</given-names></name><name><surname>Walkup</surname><given-names>GK</given-names></name><name><surname>Manchester</surname><given-names>JI</given-names></name><name><surname>Miller</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ESKAPEing the labyrinth of antibacterial discovery</article-title><source>Nature Reviews. Drug Discovery</source><volume>14</volume><fpage>529</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/nrd4572</pub-id><pub-id pub-id-type="pmid">26139286</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ude</surname><given-names>J</given-names></name><name><surname>Tripathi</surname><given-names>V</given-names></name><name><surname>Buyck</surname><given-names>JM</given-names></name><name><surname>Söderholm</surname><given-names>S</given-names></name><name><surname>Cunrath</surname><given-names>O</given-names></name><name><surname>Fanous</surname><given-names>J</given-names></name><name><surname>Claudi</surname><given-names>B</given-names></name><name><surname>Egli</surname><given-names>A</given-names></name><name><surname>Schleberger</surname><given-names>C</given-names></name><name><surname>Hiller</surname><given-names>S</given-names></name><name><surname>Bumann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Outer membrane permeability: Antimicrobials and diverse nutrients bypass porins in <italic>Pseudomonas aeruginosa</italic></article-title><source>PNAS</source><volume>118</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1073/pnas.2107644118</pub-id><pub-id pub-id-type="pmid">34326266</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaara</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Agents that increase the permeability of the outer membrane</article-title><source>Microbiological Reviews</source><volume>56</volume><fpage>395</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1128/mr.56.3.395-411.1992</pub-id><pub-id pub-id-type="pmid">1406489</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaara</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>37</volume><fpage>354</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.2.354</pub-id><pub-id pub-id-type="pmid">8383945</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Bambeke</surname><given-names>F</given-names></name><name><surname>Barcia-Macay</surname><given-names>M</given-names></name><name><surname>Lemaire</surname><given-names>S</given-names></name><name><surname>Tulkens</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Cellular pharmacodynamics and pharmacokinetics of antibiotics: Current views and perspectives</article-title><source>Curr Opin Drug Discov Dev</source><volume>9</volume><fpage>218</fpage><lpage>230</lpage></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velkov</surname><given-names>T</given-names></name><name><surname>Gallardo-Godoy</surname><given-names>A</given-names></name><name><surname>Swarbrick</surname><given-names>JD</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>PE</given-names></name><name><surname>Roberts</surname><given-names>KD</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Becker</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Lash</surname><given-names>LH</given-names></name><name><surname>Henriques</surname><given-names>ST</given-names></name><name><surname>Nation</surname><given-names>RL</given-names></name><name><surname>Sivanesan</surname><given-names>S</given-names></name><name><surname>Sani</surname><given-names>MA</given-names></name><name><surname>Separovic</surname><given-names>F</given-names></name><name><surname>Mertens</surname><given-names>H</given-names></name><name><surname>Bulach</surname><given-names>D</given-names></name><name><surname>Seemann</surname><given-names>T</given-names></name><name><surname>Owen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria</article-title><source>Cell Chemical Biology</source><volume>25</volume><fpage>380</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.01.005</pub-id><pub-id pub-id-type="pmid">29396290</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergalli</surname><given-names>J</given-names></name><name><surname>Dumont</surname><given-names>E</given-names></name><name><surname>Cinquin</surname><given-names>B</given-names></name><name><surname>Maigre</surname><given-names>L</given-names></name><name><surname>Pajovic</surname><given-names>J</given-names></name><name><surname>Bacqué</surname><given-names>E</given-names></name><name><surname>Mourez</surname><given-names>M</given-names></name><name><surname>Réfrégiers</surname><given-names>M</given-names></name><name><surname>Pagès</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fluoroquinolone structure and translocation flux across bacterial membrane</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>9821</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-08775-4</pub-id><pub-id pub-id-type="pmid">28851902</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergalli</surname><given-names>J</given-names></name><name><surname>Dumont</surname><given-names>E</given-names></name><name><surname>Pajović</surname><given-names>J</given-names></name><name><surname>Cinquin</surname><given-names>B</given-names></name><name><surname>Maigre</surname><given-names>L</given-names></name><name><surname>Masi</surname><given-names>M</given-names></name><name><surname>Réfrégiers</surname><given-names>M</given-names></name><name><surname>Pagés</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spectrofluorimetric quantification of antibiotic drug concentration in bacterial cells for the characterization of translocation across bacterial membranes</article-title><source>Nature Protocols</source><volume>13</volume><fpage>1348</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1038/nprot.2018.036</pub-id><pub-id pub-id-type="pmid">29773906</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergalli</surname><given-names>J</given-names></name><name><surname>Atzori</surname><given-names>A</given-names></name><name><surname>Pajovic</surname><given-names>J</given-names></name><name><surname>Dumont</surname><given-names>E</given-names></name><name><surname>Malloci</surname><given-names>G</given-names></name><name><surname>Masi</surname><given-names>M</given-names></name><name><surname>Vargiu</surname><given-names>AV</given-names></name><name><surname>Winterhalter</surname><given-names>M</given-names></name><name><surname>Réfrégiers</surname><given-names>M</given-names></name><name><surname>Ruggerone</surname><given-names>P</given-names></name><name><surname>Pagès</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The challenge of intracellular antibiotic accumulation, a function of fluoroquinolone influx versus bacterial efflux</article-title><source>Communications Biology</source><volume>3</volume><elocation-id>198</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-020-0929-x</pub-id><pub-id pub-id-type="pmid">32346058</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters III</surname><given-names>MC</given-names></name><name><surname>Roe</surname><given-names>F</given-names></name><name><surname>Bugnicourt</surname><given-names>A</given-names></name><name><surname>Franklin</surname><given-names>MJ</given-names></name><name><surname>Stewart PS</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Contributions of Antibiotic Penetration, Oxygen Limitation</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>47</volume><fpage>317</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.1.317-323.2003</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Pelletier</surname><given-names>J</given-names></name><name><surname>Dang</surname><given-names>WL</given-names></name><name><surname>Taddei</surname><given-names>F</given-names></name><name><surname>Wright</surname><given-names>A</given-names></name><name><surname>Jun</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Robust Growth of <italic>Escherichia coli</italic></article-title><source>Current Biology</source><volume>20</volume><fpage>1099</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2010.04.045</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilmaerts</surname><given-names>D</given-names></name><name><surname>Windels</surname><given-names>EM</given-names></name><name><surname>Verstraeten</surname><given-names>N</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>General Mechanisms Leading to Persister Formation and Awakening</article-title><source>Trends in Genetics</source><volume>35</volume><fpage>401</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2019.03.007</pub-id><pub-id pub-id-type="pmid">31036343</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windels</surname><given-names>EM</given-names></name><name><surname>Michiels</surname><given-names>JE</given-names></name><name><surname>Fauvart</surname><given-names>M</given-names></name><name><surname>Wenseleers</surname><given-names>T</given-names></name><name><surname>Van den Bergh</surname><given-names>B</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates</article-title><source>The ISME Journal</source><volume>13</volume><fpage>1239</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1038/s41396-019-0344-9</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windels</surname><given-names>EM</given-names></name><name><surname>Michiels</surname><given-names>JE</given-names></name><name><surname>Van den Bergh</surname><given-names>B</given-names></name><name><surname>Fauvart</surname><given-names>M</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Antibiotics: Combatting Tolerance To Stop Resistance</article-title><source>MBio</source><volume>10</volume><elocation-id>e02095-19</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02095-19</pub-id><pub-id pub-id-type="pmid">31506315</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Moser</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>HZ</given-names></name><name><surname>Høiby</surname><given-names>N</given-names></name><name><surname>Song</surname><given-names>ZJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Strategies for combating bacterial biofilm infections</article-title><source>International Journal of Oral Science</source><volume>7</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/ijos.2014.65</pub-id><pub-id pub-id-type="pmid">25504208</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaslaver</surname><given-names>A</given-names></name><name><surname>Bren</surname><given-names>A</given-names></name><name><surname>Ronen</surname><given-names>M</given-names></name><name><surname>Itzkovitz</surname><given-names>S</given-names></name><name><surname>Kikoin</surname><given-names>I</given-names></name><name><surname>Shavit</surname><given-names>S</given-names></name><name><surname>Liebermeister</surname><given-names>W</given-names></name><name><surname>Surette</surname><given-names>MG</given-names></name><name><surname>Alon</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A comprehensive library of fluorescent transcriptional reporters for <italic>Escherichia coli</italic></article-title><source>Nature Methods</source><volume>3</volume><fpage>623</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1038/nmeth895</pub-id><pub-id pub-id-type="pmid">16862137</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zgurskaya</surname><given-names>HI</given-names></name><name><surname>Rybenkov</surname><given-names>VV</given-names></name><name><surname>Krishnamoorthy</surname><given-names>G</given-names></name><name><surname>Leus</surname><given-names>IV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Trans-envelope multidrug efflux pumps of Gram-negative bacteria and their synergism with the outer membrane barrier</article-title><source>Research in Microbiology</source><volume>169</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.resmic.2018.02.002</pub-id><pub-id pub-id-type="pmid">29454787</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Joubran</surname><given-names>C</given-names></name><name><surname>Miller-Vedam</surname><given-names>L</given-names></name><name><surname>Isabella</surname><given-names>V</given-names></name><name><surname>Nayar</surname><given-names>A</given-names></name><name><surname>Tentarelli</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Thinking outside the “bug”: A unique assay to measure intracellular drug penetration in gram-negative bacteria</article-title><source>Analytical Chemistry</source><volume>87</volume><fpage>3579</fpage><lpage>3584</lpage><pub-id pub-id-type="doi">10.1021/ac504880r</pub-id><pub-id pub-id-type="pmid">25753586</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>List of fluorescent antibiotic derivatives (obtained by linking the parental antibiotic to nitrobenzoxadiazole, NBD, see Methods), the bacterial compartment where their target is located, their molecular weight (MW) after linkage to NBD, their partition coefficient (logP), their measured minimum inhibitory concentration (MIC) against <italic>E. coli</italic> BW25113, and the fold-change compared to the MIC measured for each corresponding parental antibiotic (see Methods).</title><p>MIC data were collated from biological triplicate.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="6" valign="bottom"><inline-graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-74062-inf001-v1.tif"/></th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Antibiotic probe</bold></td><td align="left" valign="bottom"><bold>Compartment</bold></td><td align="left" valign="bottom"><bold>MW (g/mol)</bold></td><td align="left" valign="bottom"><bold>logP</bold></td><td align="left" valign="bottom"><bold>MIC</bold><break/><bold>(μg/mL)</bold></td><td align="left" valign="bottom"><bold>Fold change</bold></td></tr><tr><td align="left" valign="bottom">Polymyxin B-NBD</td><td align="left" valign="bottom">Membrane</td><td align="char" char="." valign="bottom">1,449</td><td align="char" char="." valign="bottom">–2.5</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Octapeptin-NBD</td><td align="left" valign="bottom">Membrane</td><td align="char" char="." valign="bottom">1,304</td><td align="char" char="." valign="bottom">–0.4</td><td align="char" char="." valign="bottom">4</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Tachyplesin-NBD</td><td align="left" valign="bottom">Membrane</td><td align="char" char="." valign="bottom">2,523</td><td align="char" char="." valign="bottom">–2.7</td><td align="char" char="." valign="bottom">1</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Vancomycin-NBD</td><td align="left" valign="bottom">Cell wall</td><td align="char" char="." valign="bottom">1,650</td><td align="char" char="." valign="bottom">–2.6</td><td align="char" char="." valign="bottom">&gt;192</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Linezolid-NBD</td><td align="left" valign="bottom">Cytoplasm</td><td align="char" char="." valign="bottom">638</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">134</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Roxithromycin-NBD</td><td align="left" valign="bottom">Cytoplasm</td><td align="char" char="." valign="bottom">1,064</td><td align="char" char="." valign="bottom">3.1</td><td align="char" char="." valign="bottom">192</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom">Ciprofloxacin-NBD</td><td align="left" valign="bottom">Cytoplasm</td><td align="char" char="." valign="bottom">633</td><td align="char" char="." valign="bottom">–1.1</td><td align="char" char="." valign="bottom">8</td><td align="char" char="." valign="bottom">256</td></tr><tr><td align="left" valign="bottom">Trimethoprim-NBD</td><td align="left" valign="bottom">Cytoplasm</td><td align="char" char="." valign="bottom">577</td><td align="char" char="." valign="bottom">0.9</td><td align="char" char="." valign="bottom">64</td><td align="char" char="." valign="bottom">64</td></tr></tbody></table></table-wrap><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Pearson correlation coefficients and significance of the correlation between <italic>t<sub>0</sub></italic> and <italic>k<sub>1</sub></italic>, <italic>t<sub>0</sub></italic> and <italic>F<sub>max</sub></italic> and <italic>k<sub>1</sub></italic> and <italic>F<sub>max</sub></italic> for the accumulation in single <italic>E. coli</italic> of all the fluorescent antibiotic derivatives investigated (apart from vancomycin) in individual <italic>E. coli</italic>.</title><p>Data from <xref ref-type="fig" rid="fig1s13">Figure 1—figure supplement 13</xref> were used for these statistical comparisons. ****: p-value&lt;0.0001, ***: p-value &lt;0.001, **: p-value&lt;0.01, *: p-value&lt;0.05, ns: not significant, p-value&gt;0.05.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" colspan="3" valign="bottom">Pearson correlation coefficients and significance</th></tr><tr><th align="left" valign="bottom">Antibiotics</th><th align="left" valign="bottom"><italic>t0</italic> vs <italic>k1</italic></th><th align="left" valign="bottom"><italic>t0</italic> vs <italic>Fmax</italic></th><th align="left" valign="bottom"><italic>k1</italic> vs <italic>Fmax</italic></th></tr></thead><tbody><tr><td align="left" valign="bottom">Polymyxin B</td><td align="left" valign="bottom">–0,51, ****</td><td align="left" valign="bottom">–0,54, ****</td><td align="left" valign="bottom">0,56, ****</td></tr><tr><td align="left" valign="bottom">Octapeptin</td><td align="left" valign="bottom">–0,46, ****</td><td align="left" valign="bottom">–0,61, ****</td><td align="left" valign="bottom">0,20, ns</td></tr><tr><td align="left" valign="bottom">Tachyplesin</td><td align="left" valign="bottom">–0,13, ns</td><td align="left" valign="bottom">–0,10, ns</td><td align="left" valign="bottom">–0,01, ns</td></tr><tr><td align="left" valign="bottom">Linezolid</td><td align="left" valign="bottom">0.03, ns</td><td align="left" valign="bottom">–0,21, **</td><td align="left" valign="bottom">0,05, ns</td></tr><tr><td align="left" valign="bottom">Ciprofloxacin</td><td align="left" valign="bottom">–0,12, ns</td><td align="left" valign="bottom">–0,11, ns</td><td align="left" valign="bottom">0,29, ***</td></tr><tr><td align="left" valign="bottom">Trimethoprim</td><td align="left" valign="bottom">0,06, ns</td><td align="left" valign="bottom">–0,32, ****</td><td align="left" valign="bottom">0,11, ns</td></tr><tr><td align="left" valign="bottom">Roxithromycin</td><td align="left" valign="bottom">–0,22, ***</td><td align="left" valign="bottom">–0,10, ns</td><td align="left" valign="bottom">0,41, ****</td></tr><tr><td align="left" valign="bottom">All antibiotics</td><td align="left" valign="bottom">–0,40, ****</td><td align="left" valign="bottom">–0,27, ****</td><td align="left" valign="bottom">0,65, ****</td></tr></tbody></table></table-wrap><table-wrap id="app1table3" position="float"><label>Appendix 1—table 3.</label><caption><title>List of genes encoding outer membrane proteins (i.e. porins) and efflux pumps compiled using EcoCyc as previously reported (<xref ref-type="bibr" rid="bib50">Kortright et al., 2020</xref>), alongside their transcript reads after a 2 hr growth period in lysogeny broth (LB) (i.e. the time point at which antibiotic treatment starts in our microfluidic experiments) measured via RNA-sequencing as previously reported (<xref ref-type="bibr" rid="bib87">Smith et al., 2018</xref>). Note that it has been reported that permeability of solutes through OmpA (with the most highly expressed transcripts) is a 100-fold lower compared to that through OmpC (<xref ref-type="bibr" rid="bib94">Sugawara and Nikaido, 1992</xref>) (with the second most highly expressed transcripts), hence we decided to investigate the role played by OmpC in the heterogeneity in the intracellular accumulation of roxithromycin (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Membrane genes</th><th align="left" valign="bottom">Transcript reads</th><th align="left" valign="bottom">Membrane genes</th><th align="left" valign="bottom">Transcript reads</th><th align="left" valign="bottom">Membrane genes</th><th align="left" valign="bottom">Transcript reads</th><th align="left" valign="bottom">Membrane genes</th><th align="left" valign="bottom">Transcript reads</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>ompA</italic></td><td align="char" char="." valign="bottom">60,955</td><td align="left" valign="bottom"><italic>mltA</italic></td><td align="char" char="." valign="bottom">398</td><td align="left" valign="bottom"><italic>acrZ</italic></td><td align="char" char="." valign="bottom">47</td><td align="left" valign="bottom"><italic>yaiO</italic></td><td align="char" char="." valign="bottom">6</td></tr><tr><td align="left" valign="bottom"><italic>ompC</italic></td><td align="char" char="." valign="bottom">57,458</td><td align="left" valign="bottom"><italic>yncD</italic></td><td align="char" char="." valign="bottom">388</td><td align="left" valign="bottom"><italic>yfiB</italic></td><td align="char" char="." valign="bottom">39</td><td align="left" valign="bottom"><italic>cusB</italic></td><td align="char" char="." valign="bottom">6</td></tr><tr><td align="left" valign="bottom"><italic>ompX</italic></td><td align="char" char="." valign="bottom">19,210</td><td align="left" valign="bottom"><italic>lolB</italic></td><td align="char" char="." valign="bottom">345</td><td align="left" valign="bottom"><italic>cusA</italic></td><td align="char" char="." valign="bottom">39</td><td align="left" valign="bottom"><italic>yehB</italic></td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom"><italic>lptD</italic></td><td align="char" char="." valign="bottom">10,977</td><td align="left" valign="bottom"><italic>nlpD</italic></td><td align="char" char="." valign="bottom">326</td><td align="left" valign="bottom"><italic>macb</italic></td><td align="char" char="." valign="bottom">36</td><td align="left" valign="bottom"><italic>bglH</italic></td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom"><italic>tolC</italic></td><td align="char" char="." valign="bottom">4722</td><td align="left" valign="bottom"><italic>mdtK</italic></td><td align="char" char="." valign="bottom">312</td><td align="left" valign="bottom"><italic>yhcD</italic></td><td align="char" char="." valign="bottom">33</td><td align="left" valign="bottom"><italic>wza</italic></td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom"><italic>fhuA</italic></td><td align="char" char="." valign="bottom">4360</td><td align="left" valign="bottom"><italic>yiaD</italic></td><td align="char" char="." valign="bottom">292</td><td align="left" valign="bottom"><italic>fimD</italic></td><td align="char" char="." valign="bottom">31</td><td align="left" valign="bottom"><italic>blc</italic></td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom"><italic>bamA</italic></td><td align="char" char="." valign="bottom">4237</td><td align="left" valign="bottom"><italic>nplE</italic></td><td align="char" char="." valign="bottom">291</td><td align="left" valign="bottom"><italic>acrF</italic></td><td align="char" char="." valign="bottom">30</td><td align="left" valign="bottom"><italic>acrE</italic></td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom"><italic>acrB</italic></td><td align="char" char="." valign="bottom">4044</td><td align="left" valign="bottom"><italic>fepA</italic></td><td align="char" char="." valign="bottom">289</td><td align="left" valign="bottom"><italic>pgaA</italic></td><td align="char" char="." valign="bottom">29</td><td align="left" valign="bottom"><italic>yfgH</italic></td><td align="char" char="." valign="bottom">4</td></tr><tr><td align="left" valign="bottom"><italic>bamB</italic></td><td align="char" char="." valign="bottom">3796</td><td align="left" valign="bottom"><italic>yraP</italic></td><td align="char" char="." valign="bottom">256</td><td align="left" valign="bottom"><italic>mdtL</italic></td><td align="char" char="." valign="bottom">28</td><td align="left" valign="bottom"><italic>nanC</italic></td><td align="char" char="." valign="bottom">4</td></tr><tr><td align="left" valign="bottom"><italic>ompF</italic></td><td align="char" char="." valign="bottom">3650</td><td align="left" valign="bottom"><italic>emtA</italic></td><td align="char" char="." valign="bottom">252</td><td align="left" valign="bottom"><italic>mdtG</italic></td><td align="char" char="." valign="bottom">28</td><td align="left" valign="bottom"><italic>yqhH</italic></td><td align="char" char="." valign="bottom">4</td></tr><tr><td align="left" valign="bottom"><italic>slyB</italic></td><td align="char" char="." valign="bottom">3516</td><td align="left" valign="bottom"><italic>ydiY</italic></td><td align="char" char="." valign="bottom">241</td><td align="left" valign="bottom"><italic>mdtF</italic></td><td align="char" char="." valign="bottom">27</td><td align="left" valign="bottom"><italic>phoE</italic></td><td align="char" char="." valign="bottom">4</td></tr><tr><td align="left" valign="bottom"><italic>nlpI</italic></td><td align="char" char="." valign="bottom">3367</td><td align="left" valign="bottom"><italic>tamA</italic></td><td align="char" char="." valign="bottom">236</td><td align="left" valign="bottom"><italic>yfaL</italic></td><td align="char" char="." valign="bottom">25</td><td align="left" valign="bottom"><italic>mdtQ</italic></td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"><italic>fadL</italic></td><td align="char" char="." valign="bottom">2612</td><td align="left" valign="bottom"><italic>yjgL</italic></td><td align="char" char="." valign="bottom">222</td><td align="left" valign="bottom"><italic>gfcD</italic></td><td align="char" char="." valign="bottom">24</td><td align="left" valign="bottom"><italic>yliI</italic></td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"><italic>ompT</italic></td><td align="char" char="." valign="bottom">2601</td><td align="left" valign="bottom"><italic>mdfA</italic></td><td align="char" char="." valign="bottom">220</td><td align="left" valign="bottom"><italic>gspD</italic></td><td align="char" char="." valign="bottom">23</td><td align="left" valign="bottom"><italic>ompN</italic></td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"><italic>mipA</italic></td><td align="char" char="." valign="bottom">2289</td><td align="left" valign="bottom"><italic>ynfB</italic></td><td align="char" char="." valign="bottom">220</td><td align="left" valign="bottom"><italic>yraJ</italic></td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom"><italic>mdtO</italic></td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"><italic>mltD</italic></td><td align="char" char="." valign="bottom">2045</td><td align="left" valign="bottom"><italic>ypjA</italic></td><td align="char" char="." valign="bottom">220</td><td align="left" valign="bottom"><italic>gfcE</italic></td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom"><italic>cusC</italic></td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom"><italic>fecA</italic></td><td align="char" char="." valign="bottom">2009</td><td align="left" valign="bottom"><italic>pgpB</italic></td><td align="char" char="." valign="bottom">193</td><td align="left" valign="bottom"><italic>flgG</italic></td><td align="char" char="." valign="bottom">22</td><td align="left" valign="bottom"><italic>cusF</italic></td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom"><italic>tsx</italic></td><td align="char" char="." valign="bottom">1971</td><td align="left" valign="bottom"><italic>mltC</italic></td><td align="char" char="." valign="bottom">187</td><td align="left" valign="bottom"><italic>mdtJ</italic></td><td align="char" char="." valign="bottom">21</td><td align="left" valign="bottom"><italic>mdtP</italic></td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom"><italic>pal</italic></td><td align="char" char="." valign="bottom">1945</td><td align="left" valign="bottom"><italic>mdtC</italic></td><td align="char" char="." valign="bottom">166</td><td align="left" valign="bottom"><italic>mdtD</italic></td><td align="char" char="." valign="bottom">19</td><td align="left" valign="bottom"><italic>yfeN</italic></td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom"><italic>skp</italic></td><td align="char" char="." valign="bottom">1553</td><td align="left" valign="bottom"><italic>lpoB</italic></td><td align="char" char="." valign="bottom">155</td><td align="left" valign="bottom"><italic>ydeT</italic></td><td align="char" char="." valign="bottom">17</td><td align="left" valign="bottom"><italic>mdtN</italic></td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom"><italic>bamD</italic></td><td align="char" char="." valign="bottom">1544</td><td align="left" valign="bottom"><italic>macA</italic></td><td align="char" char="." valign="bottom">153</td><td align="left" valign="bottom"><italic>slp</italic></td><td align="char" char="." valign="bottom">16</td><td align="left" valign="bottom"><italic>csgF</italic></td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom"><italic>acrA</italic></td><td align="char" char="." valign="bottom">1505</td><td align="left" valign="bottom"><italic>loiP</italic></td><td align="char" char="." valign="bottom">137</td><td align="left" valign="bottom"><italic>yceK</italic></td><td align="char" char="." valign="bottom">16</td><td align="left" valign="bottom"><italic>yjbF</italic></td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><italic>mepS</italic></td><td align="char" char="." valign="bottom">1303</td><td align="left" valign="bottom"><italic>mltF</italic></td><td align="char" char="." valign="bottom">134</td><td align="left" valign="bottom"><italic>mdtI</italic></td><td align="char" char="." valign="bottom">13</td><td align="left" valign="bottom"><italic>csgB</italic></td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><italic>lpp</italic></td><td align="char" char="." valign="bottom">1168</td><td align="left" valign="bottom"><italic>yaiW</italic></td><td align="char" char="." valign="bottom">131</td><td align="left" valign="bottom"><italic>chiP</italic></td><td align="char" char="." valign="bottom">12</td><td align="left" valign="bottom"><italic>envY</italic></td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><italic>borD</italic></td><td align="char" char="." valign="bottom">1167</td><td align="left" valign="bottom"><italic>bhsA</italic></td><td align="char" char="." valign="bottom">119</td><td align="left" valign="bottom"><italic>pagP</italic></td><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom"><italic>ybgQ</italic></td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><italic>nmpC</italic></td><td align="char" char="." valign="bottom">1146</td><td align="left" valign="bottom"><italic>pqiC</italic></td><td align="char" char="." valign="bottom">114</td><td align="left" valign="bottom"><italic>yedS</italic></td><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom"><italic>acrS</italic></td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><italic>cirA</italic></td><td align="char" char="." valign="bottom">1127</td><td align="left" valign="bottom"><italic>rsxG</italic></td><td align="char" char="." valign="bottom">107</td><td align="left" valign="bottom"><italic>yjbH</italic></td><td align="char" char="." valign="bottom">10</td><td align="left" valign="bottom"><italic>uidC</italic></td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><italic>bamC</italic></td><td align="char" char="." valign="bottom">1123</td><td align="left" valign="bottom"><italic>rcsF</italic></td><td align="char" char="." valign="bottom">105</td><td align="left" valign="bottom"><italic>rhsD</italic></td><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom"><italic>csgE</italic></td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>ygiB</italic></td><td align="char" char="." valign="bottom">1115</td><td align="left" valign="bottom"><italic>yfaZ</italic></td><td align="char" char="." valign="bottom">101</td><td align="left" valign="bottom"><italic>elfC</italic></td><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom"><italic>ompL</italic></td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>flu</italic></td><td align="char" char="." valign="bottom">1064</td><td align="left" valign="bottom"><italic>cusR</italic></td><td align="char" char="." valign="bottom">99</td><td align="left" valign="bottom"><italic>rhsB</italic></td><td align="char" char="." valign="bottom">9</td><td align="left" valign="bottom"><italic>ompG</italic></td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>lptA</italic></td><td align="char" char="." valign="bottom">1052</td><td align="left" valign="bottom"><italic>nfrA</italic></td><td align="char" char="." valign="bottom">98</td><td align="left" valign="bottom"><italic>yfcU</italic></td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom"><italic>rzoD</italic></td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>mlaA</italic></td><td align="char" char="." valign="bottom">1042</td><td align="left" valign="bottom"><italic>cusS</italic></td><td align="char" char="." valign="bottom">92</td><td align="left" valign="bottom"><italic>lamB</italic></td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom"><italic>rzoR</italic></td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>ybhC</italic></td><td align="char" char="." valign="bottom">1021</td><td align="left" valign="bottom"><italic>acrR</italic></td><td align="char" char="." valign="bottom">85</td><td align="left" valign="bottom"><italic>pgaB</italic></td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom"><italic>yddL</italic></td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom"><italic>lptE</italic></td><td align="char" char="." valign="bottom">924</td><td align="left" valign="bottom"><italic>yghG</italic></td><td align="char" char="." valign="bottom">83</td><td align="left" valign="bottom"><italic>sfmD</italic></td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom"><italic>appX</italic></td><td align="left" valign="bottom">ND</td></tr><tr><td align="left" valign="bottom"><italic>bamE</italic></td><td align="char" char="." valign="bottom">732</td><td align="left" valign="bottom"><italic>fhuE</italic></td><td align="char" char="." valign="bottom">81</td><td align="left" valign="bottom"><italic>htrE</italic></td><td align="char" char="." valign="bottom">8</td><td align="left" valign="bottom"><italic>bcsC</italic></td><td align="left" valign="bottom">ND</td></tr><tr><td align="left" valign="bottom"><italic>rlpA</italic></td><td align="char" char="." valign="bottom">637</td><td align="left" valign="bottom"><italic>amiD</italic></td><td align="char" char="." valign="bottom">80</td><td align="left" valign="bottom"><italic>mdtH</italic></td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom"><italic>epcC</italic></td><td align="left" valign="bottom">ND</td></tr><tr><td align="left" valign="bottom"><italic>lpoA</italic></td><td align="char" char="." valign="bottom">620</td><td align="left" valign="bottom"><italic>yddB</italic></td><td align="char" char="." valign="bottom">76</td><td align="left" valign="bottom"><italic>yiaT</italic></td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom"><italic>qseG</italic></td><td align="left" valign="bottom">ND</td></tr><tr><td align="left" valign="bottom"><italic>fiu</italic></td><td align="char" char="." valign="bottom">607</td><td align="left" valign="bottom"><italic>acrD</italic></td><td align="char" char="." valign="bottom">72</td><td align="left" valign="bottom"><italic>mliC</italic></td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom"><italic>ychO</italic></td><td align="left" valign="bottom">ND</td></tr><tr><td align="left" valign="bottom"><italic>btuB</italic></td><td align="char" char="." valign="bottom">489</td><td align="left" valign="bottom"><italic>ecnB</italic></td><td align="char" char="." valign="bottom">69</td><td align="left" valign="bottom"><italic>mdtE</italic></td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom"><italic>ypjB</italic></td><td align="left" valign="bottom">ND</td></tr><tr><td align="left" valign="bottom"><italic>tamB</italic></td><td align="char" char="." valign="bottom">408</td><td align="left" valign="bottom"><italic>mdtB</italic></td><td align="char" char="." valign="bottom">64</td><td align="left" valign="bottom"><italic>flgH</italic></td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom"><italic>yzcX</italic></td><td align="left" valign="bottom">ND</td></tr><tr><td align="left" valign="bottom"><italic>mltB</italic></td><td align="char" char="." valign="bottom">406</td><td align="left" valign="bottom"><italic>mdtA</italic></td><td align="char" char="." valign="bottom">54</td><td align="left" valign="bottom"><italic>csgG</italic></td><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>pldA</italic></td><td align="char" char="." valign="bottom">404</td><td align="left" valign="bottom"><italic>ecnA</italic></td><td align="char" char="." valign="bottom">51</td><td align="left" valign="bottom"><italic>hofQ</italic></td><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><italic>ppk</italic></td><td align="char" char="." valign="bottom">404</td><td align="left" valign="bottom"><italic>mdtM</italic></td><td align="char" char="." valign="bottom">49</td><td align="left" valign="bottom"><italic>ompW</italic></td><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><media id="app1video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-74062-video1.mp4"><label>Appendix 1—video 1.</label><caption><title>Comparison of roxithromycin accumulation in gram-negative and gram-positive bacteria.</title><p>Time-lapse microscopy displaying the accumulation of roxithromycin-NDB in individual <italic>E. coli</italic> (top) and <italic>S. aureus</italic> bacteria (bottom). Roxithromycin-NDB was added to the microfluidic device at t=0 at an extracellular concentration of 46 µg mL<sup>–1</sup>.</p></caption></media><media id="app1video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-74062-video2.mp4"><label>Appendix 1—video 2.</label><caption><title>Comparison of vancomycin and roxithromycin accumulation in gram-positive bacteria.</title><p>Time-lapse microscopy displaying the accumulation of vancomycin-NDB (top) and roxithromycin-NDB (bottom) in individual <italic>S. aureus</italic> bacteria. Both fluorescent antibiotic derivatives were added to the microfluidic device at t=0 at an extracellular concentration of 46 µg mL<sup>–1</sup>.</p></caption></media></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74062.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cooper</surname><given-names>Vaughn S</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>University of Pittsburgh</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.10.18.464851" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.18.464851"/></front-stub><body><p>This study addresses mechanisms by which bacteria are able to survive and evade killing by antibiotics. Using fluorescent versions of antibiotics it studies whether entry/efflux of the drug itself is a significant contributor to the observed variability of antibiotic activity. This study will be of interest to microbiologists and clinicians for the design of better antibiotic therapies and improves our understanding of the relationships between drug uptake, bacterial growth, and drug efficacy.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74062.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cooper</surname><given-names>Vaughn S</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>University of Pittsburgh</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.18.464851">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.10.18.464851v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review</bold></p><p>Thank you for submitting your article ‘Fast bacterial growth reduces antibiotic accumulation and efficacy’ for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Gisela Storz as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions</p><p>1) The authors report a predrug growth rate variability of more than an order of magnitude (Figure 5A-C), which also seems to vary drastically between experiments (compare x-axis range in Figure 5A-C with Figure 5E-F). This variation is considerably larger than what has been reported by other groups using very similar methods and conditions (e.g. Figure 2 in https://doi.org/10.1016/j.cub.2010.04.045 shows a spread of only a few percent in division time). This large spread possibly occurs because the cells have not yet reached steady state growth conditions before antibiotic addition. The 2 h growth period in LB before antibiotic addition indeed seems insufficient for reaching a new steady state of exponential growth; at the end of this period, large parts of the population are likely still in lag phase or stressed from loading into the microfluidic device. In any case, the state of the cells at drug addition and its reproducibility is not clear.</p><p>2) The authors claim that growth-dependent drug sensitivity for roxithromycin is because of growth-dependent transport rates. This conclusion seems insufficiently supported by data.</p><p>– Roxithromycin is the only drug that shows a negative correlation between growth rate and drug increase rate—and it is also the drug with the slowest net drug increase. Indeed, the changes in drug concentration are slow compared to the division time. Therefore, dilution via growth might be sufficient to explain the correlation without the need for any more detailed molecular mechanism. Importantly, does a TolC knockout reduce the growth rate in the presence of roxithromycin? If so, (how) can one distinguish a general growth rate effect from a specific TolC effect?</p><p>– If the authors can indeed clearly show that the effect is TolC-specific, it would be interesting to also measure the difference in drug uptake kinetics of an ompC mutant. OmpC can still play a role in drug uptake kinetics, even if its expression does not correlate with growth rate.</p><p>3) It is not clear why correlations of tolC and ompC expression with the growth before drug addition are analyzed (Figure 5). Since these proteins can affect drug uptake and efflux, it seems more relevant to directly test their correlation with the parameters quantifying these phenomena. To rule out various well-known non-specific effects of GFP reporters observed at different growth rates (e.g. copy number variation of the reporter gene, dependence of maturation time and other properties of GFP on the cytosolic milieu etc.), it would be important to perform controls using several unrelated promoters to corroborate the relevance of the correlations in Figure 5D-F.</p><p><italic>Reviewer #1 (Recommendations for the authors)</italic></p><p>There have been several studies that have visualised drug accumulation in bacteria at the single-cell level (Cinquin et al., – PMID26656111; Reuter et al., PMID32761242). However, in this study, the authors have done a more thorough job by looking at different classes of antibiotics, against both gram-negative and gram-positive bacteria. They also directly address the functional consequences of decreased accumulation and show that at least for one of the compounds survival was not linked with slower growth rates.</p><p>Overall, the study is well designed and the authors have carried out exhaustive characterisation of the different compounds. However, based on their results, what strongly comes across is that there are no unifying principles. Accumulation properties and correlations are unique to each antibiotic and behaviors cannot be generalised even across antibiotics targeting the same sub-cellular space or target. Therefore, some of the conclusions needs to be toned down accordingly.</p><p>Specific comments</p><p>– Ln 103-104. Table S1, the effect of the fluorescent tag was not neutral across different compounds, some of them exhibited a fold-shift in MIC of 3-256 fold, which are not-insignificant.</p><p>– It is clear that for the results to be comparable across different compounds, the authors used the same concentration of compound (46 ug/ml). However, this dose would represent 46x MIC for compounds such as polymyxin B and 0.23x MIC for roxithromycin. Considering that the different fold MICs have hugely differing impact on growth and cellular processes, this would probably translate to differences in accumulation properties depending upon the fold MIC for that particular compound. In Figure S9B, the authors are probably trying to address this issue by using 192 and 46 ug/ml of roxithromycin, but these would represent 1x and 0.23x MICs. It would be more relevant to use 20-40x MIC concentrations of roxithromycin or if solubility is an issue, to use Polymyxin at 1x and 46x concentrations.</p><p>– Ln 173-183. It could be useful to provide MIC values of roxithromycin-NBD and vancomycin-NBD for S. aureus and ciprofloxacin-NBD for <italic>P. aeruginosa</italic> and <italic>B. cenocepacia</italic>.</p><p>– Ln 213, – Linezolid despite being an intracellular targeting drug, seems to exhibit accumulation kinetics similar to membrane targeting compounds. Maybe the authors can discuss about this in more detail.</p><p>– Figure 2. I don’t see the value of this figure. The data shown in panels A and B are quite scattered and the correlations are not so obvious.</p><p>– Data in Figure 3C and 5A are plotting correlations of the same two parameters, but the values shown are different.</p><p>– Ln 448-451 – The authors generated a tolC reporter strain to address the link between kinetic parameter t0 and tolC expression. However, they do not show this correlation but based on positive correlations between t0 and elongation rate and between GFP and elongation rate, conclude that it is in line with their hypothesis. This is erroneous. This would need comparing of GFP levels with t0 and correlating directly. Similar logic was used for in subsequent paragraphs for panels 5E and 5F.</p><p><italic>Reviewer #2 (Recommendations for the authors)</italic></p><p>– To check whether the dye has an effect on the drug activity, it would be informative to compare single cell growth variability with labelled and unlabeled compounds.</p><p>– Background fluorescence is analyzed in empty channels. Another relevant control to rule out that autofluorescence affects the results is to measure fluorescence in cells that are treated with the non-fluorescent versions of the antibiotics.</p><p>– Quite a few claims and implications seem exaggerated</p><p>– Line 569: the authors claim to mechanistically understand why some drugs are more effective in biofilms than others. Whilst their Figure 4 is interesting, and seems in line with the cited references, it remains unclear why some drugs show a trend as a function of position whereas others don’t.</p><p>– Identifying the target of antibiotics via single cell drug uptake kinetic measurements seems a bit farfetched as an application. First, following the data provided by the authors, one could also classify the drugs using (more high throughput) bulk measurements. Second, the authors should compare their technique in the context of current approaches used to classify drugs to clarify its advantages and disadvantages. Lastly, in line 292 it says that this technique can help ‘phenotyping bacterial populations’. What do the authors mean here? Microfluidic techniques to rapidly phenotype drug sensitivity have already been proposed without using fluorescent antibiotics – it is not clear how much fluorescence would add here.</p><p>– Line 491 suggests that reducing heterogeneity is the main goal of any treatment. However, the more established goal is to inhibit the growth of as many cells as possible. This can be achieved by keeping the same heterogeneity but simply reducing the mean.</p><p>– In line 515 ‘needs to be’ seems exaggerated; similarly ‘major rethink’ in line 543.</p><p>– The term ‘phenotypically engineer’ is used both in the abstract and in line 581. This term is unclear for adding an extra compound.</p><p>– Figure 3a shows four exemplary curves out of a large data set. It would help to rigorously analyze the reduction in growth rate after the supposed lag time for the entire dataset.</p><p>– Line 587: The ‘biases’ mentioned here need to be explained. As is, this claim is unclear without digging into literature.</p><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled ‘Fast bacterial growth reduces antibiotic accumulation and efficacy’ for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Gisela Storz (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>Specifically, the extent of heterogeneity in elongation rates disagrees significantly from prior work, and the current version still does not address prior concerns from Reviewer 2. The robustness of the findings of this study appear to hinge on these concerns, so despite our enthusiasm for the principle, the distribution of growth rates must be well accounted for.</p><p><italic>Reviewer #1 (Recommendations for the authors)</italic></p><p>The authors have addressed and made modifications to the revised text and have incorporated these new data in the revised manuscript.</p><p>I am satisfied with the current version of the manuscript.</p><p>Only one important edit. Figure 4D-F needs to be updated and reflect the new content being described in the text and figure legend. The correct figure was shown in the response to the reviewers letter but the figure in the main file is still the previous version.</p><p><italic>Reviewer #2 (Recommendations for the authors)</italic></p><p>The manuscript has certainly improved, especially due to the inclusion of new control experiments and some simulations. However, some of my concerns remain.</p><p>1. I am not convinced that the intra-experiment heterogeneity in elongation rate is similar to that reported in literature as claimed in the response. For example, the elongation rates shown in Figure 2 in Wang et al., are approximately normally distributed with almost all data falling between 0.03/min and 0.06/min; no elongation rates are anywhere near zero. Similarly, in Baltekin et al., Figure 2F (left panel) virtually all (normalised) growth rates fall between 0.5 and 1.25 with a handful of lower values and no values near zero. In both papers, the numbers of cells analyzed are orders of magnitude larger, making outliers more likely. In the preset work, while fewer cells were analyzed, the elongation rates are spread from 0 to 15 μm/h with many values near zero (Figure 4). Therefore, I cannot follow the authors' reasoning here: the variability in elongation rates they observed is clearly much greater than what has been reported in literature. This is problematic for the reasons described in my first report.</p><p>2. The authors argue that dilution via growth is unlikely to play a role because they rarely observed cell division during their experiment. However, the two fundamental timescales here are the doubling time and the drug uptake time. The authors state that the doubling time is 75 min = 4500 seconds, while uptake of roxithromycin takes more than 5000 seconds (Figure 1). Therefore, regardless of whether the experiment was performed long enough to observe cell division, drug uptake is slow compared to dilution via growth of cell volume (which happens continuously irrespective of cell divisions). This effect therefore inevitably contributes to the net drug uptake kinetics. One could try to quantitatively correct for this effect; this would be important to rule out that it largely explains the observed correlation between growth rate and net uptake.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74062.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors report a pre-drug growth rate variability of more than an order of magnitude (Figure 5A-C), which also seems to vary drastically between experiments (compare x-axis range in Figure 5A-C with Figure 5E-F). This variation is considerably larger than what has been reported by other groups using very similar methods and conditions (e.g. Figure 2 in https://doi.org/10.1016/j.cub.2010.04.045 shows a spread of only a few percent in division time). This large spread possibly occurs because the cells have not yet reached steady state growth conditions before antibiotic addition. The 2 h growth period in LB before antibiotic addition indeed seems insufficient for reaching a new steady state of exponential growth; at the end of this period, large parts of the population are likely still in lag phase or stressed from loading into the microfluidic device. In any case, the state of the cells at drug addition and its reproducibility is not clear.</p></disp-quote><p>First, we would like to thank the reviewer for noticing the discrepancy between the elongation rates in Figures 5A-C and Figures 5D-F of the submitted manuscript (now Figures 4A-C and Figures 4DF). This was due to the use of an erroneous pixel to µm correction factor that we have now rectified as reported in the amended Figure 4 (please note that we have then further amended this figure according to essential revision 3 below). The elongation rates averaged over three independent experiments performed with the parental, <italic>tolC</italic>, <italic>ompC</italic> and <italic>rrnB</italic> strains were (5.3±1.2) µm hr<sup>-1</sup>, (4.9±0.4) µm hr<sup>-1</sup>, (5.4±0.5) µm hr<sup>-1</sup> and (4.2±0.7) µm hr<sup>-1</sup>, respectively. This inter-experimental variability is in agreement with the one reported in the landmark paper by Wang et al<italic>.,</italic> suggested by the reviewer and cited in our manuscript (https://doi.org/10.1016/j.cub.2010.04.045). In fact, Wang et al<italic>.,</italic> reported doubling times ranging between 0.04 and 0.05 divisions min<sup>-1</sup> across the different strains they examined. Moreover, we have now run new experiments to further verify that the elongation rate does not substantially vary after 2 h post-addition in the microfluidic device (new Figure 1—figure supplement 1). This data is in accordance with our previous bulk data showing that <italic>E. coli</italic> is in exponential phase between 2 and 5 h after passage in fresh medium (see for example Figure 3A in Smith et al<italic>., Front Microbiol</italic> 9, 1739, 2018). In terms of intra-experimental variability the coefficients of variations for the elongation rate of the parental, <italic>tolC</italic>, <italic>ompC</italic> and <italic>rrnB</italic> strains were 55, 41, 36, and 49%, respectively, in line with previously reported single-cell growth rate variabilities both in the absence and in the presence of antibiotics (see for example Figures 2 and 3 in Baltekin et al<italic>., PNAS</italic> 114, 9170, 2017).</p><p>These new data are discussed on lines 97-101 and 436-439 of our revised manuscript with track changes (please note that line numbers might be different in the clean copy of the manuscript because we noticed that some parts of the manuscript moved around during the pdf building process on <italic>eLife</italic> portal) and in the new Figures 4 and Figure 1—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>2) The authors claim that growth-dependent drug sensitivity for roxithromycin is because of growth-dependent transport rates. This conclusion seems insufficiently supported by data.</p><p>– Roxithromycin is the only drug that shows a negative correlation between growth rate and drug increase rate – and it is also the drug with the slowest net drug increase. Indeed, the changes in drug concentration are slow compared to the division time. Therefore, dilution via growth might be sufficient to explain the correlation without the need for any more detailed molecular mechanism. Importantly, does a TolC knockout reduce the growth rate in the presence of roxithromycin? If so, (how) can one distinguish a general growth rate effect from a specific TolC effect?</p><p>– If the authors can indeed clearly show that the effect is TolC-specific, it would be interesting to also measure the difference in drug uptake kinetics of an ompC mutant. OmpC can still play a role in drug uptake kinetics, even if its expression does not correlate with growth rate.</p></disp-quote><p>We thank the reviewer for giving us the opportunity to expand on this important point. Indeed in our submitted manuscript we had very briefly acknowledged the possibility that dilution of the intracellular concentration via bacterial doubling could account for reduced intracellular drug accumulation. To minimise this effect we investigated the accumulation of all our fluorescent antibiotic derivatives using minimal medium M9 as the drug milieu (please see lines 149-151 of the submitted manuscript). As a consequence, during drug treatment bacterial divisions were rare events and thus the changes in drug concentration were not slow compared to the division time. In fact, during treatment with roxithromycin dissolved in M9 (data in Figure 1B of the submitted paper) none of the analysed bacteria underwent a full cell cycle from birth to division. Moreover, 15% of the bacteria analysed underwent one division during treatment but were born before drug treatment. The average doubling time of these bacteria was (75±28) min (new Figure 1—figure supplement 5A). In comparison, during treatment with roxithromycin dissolved in LB (data in Figure S9A of the submitted paper, now Figure 1—figure supplement 11A) 41% of the analysed bacteria underwent a full cell cycle from birth to division. Furthermore, when including bacteria that underwent one division during treatment but were born before drug treatment, the average doubling time ((29±9) min) was significantly shorter compared to that measured for treatment in M9 (****, Figure 1figure supplement 5). However, we found higher roxithromycin-NBD accumulation (Figure 1—figure supplement 11A) when LB was used as drug milieu. We also found similarly large heterogeneities when roxithromycin-NBD was dissolved in M9 or LB (CV in range of 84-372% and 51-428%, respectively). Taken together these data demonstrate that heterogeneity in roxithromycin accumulation cannot be explained via dilution due to bacterial doubling.</p><p>Moreover, when using the D<italic>tolC</italic> knockout and M9 as the drug milieu we found again that none of the analysed bacteria underwent a full cell cycle from birth to division and 13% of the bacteria analysed underwent one division during treatment but were born before drug treatment. The average doubling time of these bacteria was (80±30) minutes and the distribution of doubling times was not significantly different compared to the distribution of doubling times measured when using the parental strain and M9 as the drug milieu (p-value=0.51, Figure 1—figure supplement 5A). Therefore, the measured impact of the absence of <italic>tolC</italic> on roxithromycin accumulation (i.e. significantly shorter <italic>t<sub>0</sub></italic> and larger <italic>k<sub>1</sub></italic>) can not be ascribed to dilution via cell doubling. Finally, we have now carried out new experiments that demonstrate that, under the experimental conditions investigated, the outer membrane porin OmpC does not play a significant role in roxithromycin accumulation (Figure 5—figure supplement 1), thus corroborating our previous data obtained using an <italic>ompC</italic> fluorescent reporter strain.</p><p>These new data are discussed in the revised manuscript on lines 142-150, 185-192, 523-526, and in the new Figure 1—figure supplement 5 and Figure 5—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>3) It is not clear why correlations of tolC and ompC expression with the growth before drug addition are analyzed (Figure 5). Since these proteins can affect drug uptake and efflux, it seems more relevant to directly test their correlation with the parameters quantifying these phenomena. To rule out various well-known non-specific effects of GFP reporters observed at different growth rates (e.g. copy number variation of the reporter gene, dependence of maturation time and other properties of GFP on the cytosolic milieu etc.), it would be important to perform controls using several unrelated promoters to corroborate the relevance of the correlations in Figure 5D-F.</p></disp-quote><p>We agree with the reviewer that it is more relevant to directly show the correlation between the expression of the investigated promoter and the kinetic parameters quantifying roxithromycin accumulation. Therefore, we have amended Figures 5D-F (now Figures 4D-F) accordingly. We also agree with the reviewer that it is important to perform independent experiments to further corroborate these findings. Indeed we have now shown that a deletion mutant lacking <italic>tolC</italic> displays shorter <italic>t<sub>0</sub></italic> and larger <italic>k<sub>1</sub></italic> compared to the parental strain (Figure 6 of the submitted paper, now Figure 5), whereas a deletion mutant lacking <italic>ompC</italic> accumulates roxithromycin in a similar fashion as the parental strain (please see new Figure 5—figure supplement 1). Moreover, following the reviewer suggestion we have further verified that there exist a significant negative correlation also between <italic>F<sub>max</sub></italic> and the expression of <italic>rrnH</italic> (new Figure 4—figure supplement 3), a different <italic>rrn</italic> operon that is expressed at lower levels compared to <italic>rrnB</italic> (Maeda et al<italic>., PLoS One</italic> 10, e0144697, 2015).</p><p>These new data are discussed in the revised manuscript on lines 473-474, 479-482, 487-489, 491495, and in the new Figures 4 and Figure 4—figure supplement 3.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>There have been several studies that have visualised drug accumulation in bacteria at the single-cell level (Cinquin et al., – PMID26656111; Reuter et al., PMID32761242). However, in this study, the authors have done a more thorough job by looking at different classes of antibiotics, against both gram-negative and gram-positive bacteria. They also directly address the functional consequences of decreased accumulation and show that at least for one of the compounds survival was not linked with slower growth rates.</p><p>Overall, the study is well designed and the authors have carried out exhaustive characterisation of the different compounds. However, based on their results, what strongly comes across is that there are no unifying principles. Accumulation properties and correlations are unique to each antibiotic and behaviors cannot be generalised even across antibiotics targeting the same sub-cellular space or target. Therefore, some of the conclusions needs to be toned down accordingly.</p></disp-quote><p>We would like to thank the reviewer for appreciating our novel approach to investigate bacterial heterogeneity in the response to antibiotics and for their constructive feedback. We had already cited the landmark work from the Pages' group using microspectroscopy to study drug accumulation at the single-cell level (references 44-46 in our revised manuscript) and we have now cited the work of Reuter et al., (reference 47 in our revised manuscript). Moreover, we have now toned down our conclusions following the comments of both reviewers, please see lines 75-77, 295-297, 346-347, 363, 416, 449, 470, 499-501, 548-551, 579-580, 604-606, 619-622 of our revised manuscript.</p><disp-quote content-type="editor-comment"><p>Specific comments:</p><p>– Ln 103-104. Table S1, the effect of the fluorescent tag was not neutral across different compounds, some of them exhibited a fold-shift in MIC of 3-256 fold, which are not-insignificant.</p></disp-quote><p>We have now explicitly acknowledged that the fluorescent derivatives of polymyxin B, octapeptin, tachyplesin, vancomycin and linezolid maintained the antibiotic activity of the parent drug, whereas the fluorescent derivatives of roxithromycin, trimethoprim and ciprofloxacin displayed a 3-, 64- and 256-fold increase compared to the parent drug, respectively.</p><p>This new information is discussed on lines 88-92 of our revised manuscript.</p><disp-quote content-type="editor-comment"><p>– It is clear that for the results to be comparable across different compounds, the authors used the same concentration of compound (46 ug/ml). However, this dose would represent 46x MIC for compounds such as polymyxin B and 0.23 X MIC for roxithromycin. Considering that the different fold MICs have hugely differing impact on growth and cellular processes, this would probably translate to differences in accumulation properties depending upon the fold MIC for that particular compound. In Figure S9B, the authors are probably trying to address this issue by using 192 and 46 ug/ml of roxithromycin, but these would represent 1x and 0.23x MICs. It would be more relevant to use 20-40X MIC concentrations of roxithromycin or if solubility is an issue, to use Polymyxin at 1x and 46x concentrations.</p></disp-quote><p>We have now carried out new experiments using polymyxin B-NBD at the MIC (i.e. 1 µg ml<sup>-1</sup>) as suggested by the reviewer. As expected, we found that at this lower extracellular concentration, polymyxin B-NBD accumulated in individual <italic>E. coli</italic> more slowly (compared to a 46 µg ml<sup>-1</sup> extracellular concentration). However, the heterogeneity in polymyxin B accumulation was similarly large at both concentrations with CVs in the range 9-250 and 11-212% in the case of 1 and 46 µg ml<sup>-1</sup> extracellular concentration, respectively.</p><p>These new data are discussed in the revised manuscript on lines 193-195 and in the new Figure 1 figure supplement 11C.</p><disp-quote content-type="editor-comment"><p>– Ln 173-183. It could be useful to provide MIC values of roxithromycin-NBD and vancomycin-NBD for S. aureus and ciprofloxacin-NBD for P. aeruginosa and B. cenocepacia.</p></disp-quote><p>MIC values of roxithromycin-NBD and vancomycin-NBD for <italic>S. aureus</italic> (1 and 0.5 µg ml<sup>-1</sup>, respectively) and ciprofloxacin-NBD for <italic>P. aeruginosa</italic> and <italic>B. cenocepacia</italic> (32 µg ml<sup>-1</sup> for both species) have now been provided in the captions of Figure 1—figure supplements 8, 9, and 10.</p><disp-quote content-type="editor-comment"><p>– Ln 213, – Linezolid despite being an intracellular targeting drug, seems to exhibit accumulation kinetics similar to membrane targeting compounds. Maybe the authors can discuss about this in more detail.</p></disp-quote><p>We agree with the reviewer that linezolid displayed a mean <italic>t<sub>0</sub></italic> value closer to the <italic>t<sub>0</sub></italic> values recorded for antibiotics with a membrane target compared to the <italic>t<sub>0</sub></italic> values measured for antibiotics with an intracellular target (e.g. <italic>t<sub>0</sub></italic> = 437, 6614, and 364 s for linezolid, roxithromycin and polymyxin B, respectively). However, when considering the other five accumulation parameters linezolid displayed averaged values closer to the values measured for antibiotics with an intracellular target (e.g. <italic>k<sub>1</sub></italic> = 1.6, 4.4, and 229 a.u. s<sup>-2</sup>, <italic>F<sub>max</sub></italic> = 512, 1034, and 2264 a.u., <italic>k<sub>2</sub></italic> = 0.0001, 0.0001, and 0.007 s, <italic>d<sub>r</sub></italic> = 0.0003, 0.001, and 0.09 s<sup>-1</sup>, <italic>d<sub>c</sub></italic> = 0.0006, 0.0003, and 0.01 s<sup>-1</sup> for linezolid, roxithromycin, and polymyxin B, respectively).</p><p>We have now explicitly acknowledged this in the revised manuscript on lines 233-237.</p><p>It is tempting to speculate that linezolid diffuses via <italic>E. coli</italic> outer membrane porins faster than larger or more hydrophobic antibiotics (such as roxithormyin and ciprofloxacin, respectively) while being pumped out more efficiently via efflux pumps. This hypothesis might explain the measured kinetic parameters reported above. In our opinion, we should not formally advance this hypothesis in this manuscript without further experimental support. We believe that this hypothesis should instead be further investigated in a follow up study.</p><disp-quote content-type="editor-comment"><p>– Figure 2. I don't see the value of this figure. The data shown in panels A and B are quite scattered and the correlations are not so obvious.</p></disp-quote><p>Following the reviewer's suggestion we have now moved this figure to the Supplementary Information (new Figure 1—figure supplement 15) and summarised the paragraph describing these correlations on lines 263-281 of our revised manuscript. We have also added further information to this paragraph in response to comment 5 of reviewer 2, please see below.</p><disp-quote content-type="editor-comment"><p>– Data in Figure 3C and 5A are plotting correlations of the same two parameters, but the values shown are different.</p></disp-quote><p>The data in Figure 3C (Figure 2C in our revised manuscript) report single-cell elongation rates <italic>during</italic> treatment with roxithromycin-NBD whereas the data in Figure 5A (Figure 4A in our revised manuscript) report single-cell elongation rates <italic>before</italic> treatment with roxithromycin-NBD as detailed in the caption of each figure and discussed in the manuscript. Therefore, the two figures report two different datasets. These two datasets are also reproduced in Figure 4—figure supplement 2A to allow for comparisons between the elongation rate before and during treatment with roxithromycin-NBD as discussed on lines 439-441 of our revised manuscript. We have now also explicitly acknowledged that the data in Figure 4—figure supplement 2A are reproduced from Figure 2C and Figure 4A to further clarify this point.</p><disp-quote content-type="editor-comment"><p>– Ln 448-451 – The authors generated a tolC reporter strain to address the link between kinetic parameter t0 and tolC expression. However, they do not show this correlation but based on positive correlations between t0 and elongation rate and between GFP and elongation rate, conclude that it is in line with their hypothesis. This is erroneous. This would need comparing of GFP levels with t0 and correlating directly. Similar logic was used for in subsequent paragraphs for panels 5E and 5F.</p></disp-quote><p>We agree with the reviewer, we have now amended Figure 4 accordingly, please see our essential revision 3 above.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>– To check whether the dye has an effect on the drug activity, it would be informative to compare single cell growth variability with labeled and unlabeled compounds.</p></disp-quote><p>We agree with the reviewer and for this reason we did compare single-cell elongation rate both before and during treatment with both labelled and unlabelled roxithromycin, please see Figure S14 of the submitted manuscript (now Figure 4—figure supplement 2). We have now explicitly acknowledged that we found large single cell growth variability in the presence of both labelled and unlabelled roxithromycin (CV of 59 and 44%, respectively) in accordance with previous data obtained with unlabelled antibiotics (see for example Figures 2 and 3 in Baltekin et al<italic>., PNAS</italic> 114, 9170, 2017).</p><p>This information has been added on lines 446-447 of our revised manuscript.</p><disp-quote content-type="editor-comment"><p>– Background fluorescence is analyzed in empty channels. Another relevant control to rule out that autofluorescence affects the results is to measure fluorescence in cells that are treated with the non-fluorescent versions of the antibiotics.</p></disp-quote><p>We agree with the reviewer and we did measure autofluorescence of unlabelled roxithromycin and ciprofloxacin using the same excitation conditions used for their fluorescent derivatives (0.03 s exposure to the blue excitation band of a broad-spectrum LED operated at 8 mW). Under these conditions the drug autofluorescence detected from the bacteria was not distinguishable from the background (i.e. from empty channels). We have now explicitly acknowledged this on lines 197200 and 442-444 of our revised manuscript. However, please note that unlabelled ciprofloxacin was distinguishable from the background upon 0.1 s exposure to the UV excitation band of a broadspectrum LED operated at 40 mW, please see data reported in Figure S10A of the submitted manuscript (now Figure 1—figure supplement 12A). We have now explicitly acknowledged this on lines 200201 of our revised manuscript.</p><disp-quote content-type="editor-comment"><p>– Quite a few claims and implications seem exaggerated:</p><p>– Line 569: the authors claim to mechanistically understand why some drugs are more effective in biofilms than others. Whilst their Figure 4 is interesting, and seems in line with the cited references, it remains unclear why some drugs show a trend as a function of position whereas others don't.</p></disp-quote><p>We agree with the reviewer that this statement might have been misleading. We have therefore, rephrased it as follows on lines 604-606:</p><p>&quot;Our data are in agreement with previous work in clinical settings suggesting that macrolides, quinolones, and oxazolidinones are more effective within infecting biofilms compared to glycopeptides and polymyxins.&quot;</p><disp-quote content-type="editor-comment"><p>– Identifying the target of antibiotics via single cell drug uptake kinetic measurements seems a bit farfetched as an application. First, following the data provided by the authors, one could also classify the drugs using (more high throughput) bulk measurements. Second, the authors should compare their technique in the context of current approaches used to classify drugs to clarify its advantages and disadvantages. Lastly, in line 292 it says that this technique can help 'phenotyping bacterial populations'. What do the authors mean here? Microfluidic techniques to rapidly phenotype drug sensitivity have already been proposed without using fluorescent antibiotics – it is not clear how much fluorescence would add here.</p></disp-quote><p>We agree with reviewer and we have now rephrased this sentence as follows on lines 295-297 of our revised manuscript:</p><p>&quot;Taken together, these data suggest the existence of a unique accumulation pattern for the specific antibiotic in use and could be used in combination with existing single-cell microfluidic platforms to rapidly phenotype drug sensitivity (Baltekin et al.<italic>, PNAS</italic> 114, 9170, 2017; Bakshi et al<italic>., Nat Microbiol</italic> 6, 783, 2021; Bergmiller et al.<italic>, Science</italic> 356, 311, 2017), ultimately in clinical antibiotic testing.”</p><disp-quote content-type="editor-comment"><p>– Line 491 suggests that reducing heterogeneity is the main goal of any treatment. However, the more established goal is to inhibit the growth of as many cells as possible. This can be achieved by keeping the same heterogeneity but simply reducing the mean.</p></disp-quote><p>We agree with the reviewer that this sentence might have been misleading and therefore we have removed it from our revised manuscript.</p><disp-quote content-type="editor-comment"><p>– In line 515 ‘needs to be’ seems exaggerated; similarly ‘major rethink’ in line 543.</p></disp-quote><p>We have now changed line 550-551 to ‘a finding that <italic>could inform the design of antibiotic therapy using macrolides’</italic> and line 579-580 to ‘This new knowledge <italic>deepens our understanding</italic> of phenotypic resistance to antibiotics.’</p><disp-quote content-type="editor-comment"><p>– The term ‘phenotypically engineer’ is used both in the abstract and in line 581. This term is unclear for adding an extra compound.</p></disp-quote><p>We have now changed the sentence in the abstract to ‘<italic>We used this new knowledge to eradicate</italic> variants that displayed low antibiotic accumulation’ and the sentence on line 616-617 to ‘We show that it is possible to eradicate phenotypic variants currently avoiding antibiotic accumulation clonal bacterial populations.’</p><disp-quote content-type="editor-comment"><p>– Figure 3a shows four exemplary curves out of a large data set. It would help to rigorously analyse the reduction in growth rate after the supposed lag time for the entire dataset.</p></disp-quote><p>We did compare the elongation rate before and after uptake for the entire dataset, please see Figure 3C and 3D (now Figure 2C and 2D) of the submitted manuscript. We have now explicitly stated on line 335 of our revised manuscript that the findings in Figure 2C and 2D were obtained by analysing the entire dataset.</p><disp-quote content-type="editor-comment"><p>– Line 587: The ‘biases’ mentioned here need to be explained. As is, this claim is unclear without digging into literature.</p></disp-quote><p>We agree with the reviewer that this last part of the sentence requires further explanations that go beyond the scope of the current manuscript. Therefore, we have rephrased the last sentence of the conclusions as follows on lines 619-622 of our revised manuscript: ‘Finally, our novel single-cell approach reveals that each antibiotic is characterised by a unique accumulation pattern and thus could in future be employed to simultaneously characterise the accumulation and efficacy of new leading antibiotic compounds.’</p><p>[Editors’ note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The authors have addressed and made modifications to the revised text and have incorporated these new data in the revised manuscript.</p><p>I am satisfied with the current version of the manuscript.</p><p>Only one important edit. Figure 4D-F needs to be updated and reflect the new content being described in the text and figure legend. The correct figure was shown in the response to the reviewers letter but the figure in the main file is still the previous version.</p></disp-quote><p>We thank the reviewer for recommending our manuscript for publication, we have now updated Figure 4 in the manuscript file.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The manuscript has certainly improved, especially due to the inclusion of new control experiments and some simulations. However, some of my concerns remain.</p><p>1. I am not convinced that the intra-experiment heterogeneity in elongation rate is similar to that reported in literature as claimed in the response. For example, the elongation rates shown in Figure 2 in Wang et al., are approximately normally distributed with almost all data falling between 0.03/min and 0.06/min; no elongation rates are anywhere near zero. Similarly, in Baltekin et al., Figure 2F (left panel) virtually all (normalised) growth rates fall between 0.5 and 1.25 with a handful of lower values and no values near zero. In both papers, the numbers of cells analyzed are orders of magnitude larger, making outliers more likely. In the preset work, while fewer cells were analyzed, the elongation rates are spread from 0 to 15 μm/h with many values near zero (Figure 4). Therefore, I cannot follow the authors' reasoning here: the variability in elongation rates they observed is clearly much greater than what has been reported in literature. This is problematic for the reasons described in my first report.</p></disp-quote><p>We agree with the reviewer that the variability in the elongation rate before antibiotic treatment measured in our study was larger compared to that measured in previous reports (Wang et al<italic>., Current Biology</italic> 20:1099, 2010; Baltekin et al<italic>., PNAS</italic> 114:9170, 2017). This discrepancy is due to the fact that we started to measure single-cell elongation rates immediately upon loading an aliquot of stationary phase <italic>E. coli</italic> in the mother machine (and then averaged over all values obtained for each cell during the 2 h growth period). In contrast, previous studies either did not measure single-cell elongation rates of the first ten generations upon loading <italic>E. coli</italic> in the mother machine (Wang et al<italic>., Current Biology</italic> 20:1099, 2010) or pre-cultured <italic>E. coli</italic> for 2 h before loading in the mother machine and thus did not measure single-cell elongation rates during the 2 h regrowth period from stationary phase (Baltekin et al<italic>., PNAS</italic> 114:9170, 2017). Therefore, our elongation rate measurements capture heterogeneous growth resumption from stationary phase (Levin-Reisman et al<italic>., Nature Methods</italic> 7:737, 2010; Joers et al<italic>., Scientific Reports</italic> 6:24055, 2016), with a minority of bacteria that did not divide in the 2 h growth prior to antibiotic exposure (i.e. 10%, non dividing Figure 4—figure supplement 2A-C), a few bacteria that divided once (i.e. 30%, slow dividing subgroup, Figure 4—figure supplement 2D-F), and the majority of bacteria that divided two times (i.e. 60%, fast dividing subgroup, Figure 4—figure supplement 2G-I). Elongation rates within bacteria that divided once fell within 1.5 and 5 µm hr<sup>-1</sup>, elongation rates within bacteria that divided twice fell within 4 and 12 µm hr<sup>-1</sup>, with a within subgroup variation of 3-4 folds in line with previous reports (Wang et al<italic>., Current Biology</italic> 20:1099, 2010; Baltekin et al<italic>., PNAS</italic> 114:9170, 2017). Importantly, cells within both the slow and fast dividing subgroups displayed a significant correlation between elongation rate (before treatment) and <italic>t<sub>0</sub></italic> or <italic>F<sub>max</sub></italic> (Figure 4—figure supplement 2).</p><p>These data are discussed on page 16, lines 447-461 of the revised manuscript and in the new Figure 4—figure supplement 2.</p><p>Finally, we had already performed separate experiments flowing LB for a longer period of time and found that the elongation rate (averaged over the whole bacterial population) did not further increase after the first 2 h exposure to LB (Figure 1—figure supplement 1), as detailed in our previous response to Essential revision 1 and on lines 98-101 of the current manuscript. In fact, by the 2 h time point over 90% of the bacteria had reached an elongation rate in range 4-12 µm hr<sup>-1</sup>.</p><disp-quote content-type="editor-comment"><p>2. The authors argue that dilution via growth is unlikely to play a role because they rarely observed cell division during their experiment. However, the two fundamental timescales here are the doubling time and the drug uptake time. The authors state that the doubling time is 75 min = 4500 seconds, while uptake of roxithromycin takes more than 5000 seconds (Figure 1). Therefore, regardless of whether the experiment was performed long enough to observe cell division, drug uptake is slow compared to dilution via growth of cell volume (which happens continuously irrespective of cell divisions). This effect therefore inevitably contributes to the net drug uptake kinetics. One could try to quantitatively correct for this effect; this would be important to rule out that it largely explains the observed correlation between growth rate and net uptake.</p></disp-quote><p>We agree with the reviewer that growth in cell volume during roxithromycin treatment helps bacteria in diluting the intracellular drug concentration. In fact, we measured a 3-fold variation in elongation rate (and thus in cell volume considering that the other two cell dimensions are physically constrained in all cells due to the device geometry), with the slowest and fastest bacterium displaying an elongation rate of 0.7 and 2.3 µm hr<sup>-1</sup>, respectively, during treatment with roxithromycin at a growth inhibitory concentration (i.e. 192 µg ml<sup>-1</sup>, Figure 4—figure supplement 3). Therefore, the measured variation in roxithromycin accumulation is due in part to dilution of intracellular drug concentration via differential cell growth. To account for this effect, we had already integrated the rate constant <italic>d<sub>c</sub></italic> in equation 1 of our phenomenological mathematical model. This parameter accounts for drug loss via efflux, degradation or dilution via growth (please see page 8, lines 213-216 and Methods, page 26). Moreover, other factors (including ribosome and efflux pump abundance) must also play a role in the measured cell-to-cell differences in roxithromycin accumulation. In fact, these differences include a 160-fold variation in <italic>t<sub>0</sub></italic> (30 s &lt; <italic>t<sub>0</sub></italic> &lt; 4900 s), a 60-fold variation in <italic>k<sub>1</sub></italic> (0.2 a.u. s<sup>-2</sup> &lt; <italic>k<sub>1</sub></italic> &lt; 12 a.u. s<sup>-2</sup>) and a 12-fold variation in <italic>F<sub>max</sub></italic> (250 a.u. &lt; <italic>F<sub>max</sub></italic> &lt; 3000 a.u.) far larger than the measured variation in elongation rate.</p><p>These data are discussed on page 17, lines 482-494 of the revised manuscript and in the new Figure 4—figure supplement 3.</p></body></sub-article></article>